<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-832-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FLUDARA 10MG F.C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUDARABINE PHOSPHATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1986.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Lille S.A.S," />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Lille S.A.S,
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENZYME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fludara oral contains the active substance fludarabine phosphate which stops the growth of new cancer cells. All cells of the body produce new cells like themselves by dividing. Fludara oral is taken up by the cancer cells and stops them dividing.<br />In cancers of the white blood cells (such as chronic lymphocytic leukaemia) , the body produces many abnormal white blood cells (lymphocytes) and lymph nodes start to grow in various parts of the body. The abnormal white blood cells cannot carry out the normal disease fighting functions and may push aside healthy blood cells. This can result in infections, a decrease in number of red blood cells (anaemia), bruising, severe bleeding or even organ failure.<br />Fludara is used in the treatment of B-cell chronic lymphocytic leukaemia (B-CLL) in patients with sufficient healthy blood cell production.<br />First treatment for chronic lymphocytic leukaemia with Fludara oral should only be started in patients with advanced disease having disease-related symptoms or evidence of disease progression.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Fludara oral:</strong></p><p>if you are allergic to fludarabine phosphate or any of the other ingredients of this medicine (listed in section 6).<br />- if you have an intolerance to lactose monohydrate (see sub-section &ldquo;Fludara oral contains lactose monohydrate&rdquo;).<br />- if you are breast-feeding.<br />- if you have severe kidney problems.<br />- if your red blood cell count is low, because of a type of anaemia (decompensated haemolytic anaemia). Your doctor will have told you if you have this condition.<br />Tell your doctor, before taking Fludara oral if you think any of these may apply to you.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Fludara oral.<br />Take special care with Fludara oral:<br />&bull;<strong> if your bone marrow</strong> is not working properly or if you have a poorly functioning or depressed immune system or a history of serious infections.<br />- Your doctor may decide to not give you this medicine, or may take precautions.<br />&bull;<strong> if you feel very unwell,</strong> notice any unusual bruising, more bleeding than usual after injury, or if you seem to be catching a lot of infections.<br />&bull; <strong>if during treatment you have a red to brownish urine, or have a rash or any blisters on your skin.</strong><br />- Tell your doctor immediately.<br />These may be signs of a reduction in the number of your blood cells, which may be caused either by the disease itself or the treatment. It can last for up to a year, independent of whether or not you had treatment with Fludara oral before. During treatment with Fludara oral also your immune system may attack different parts of your body, or your red blood cells (called &lsquo;autoimmune disorders&rsquo;). These conditions can be life-threatening.<br />If this occurs your doctor will stop your treatment and you may receive further medication such as transfusion of irradiated blood (see below) and adrenocorticoids.<br />You will have regular blood tests during treatment and you will be closely monitored while you are being treated with Fludara oral.<br />&bull;<strong> if you notice any unusual symptoms of your nervous system such as disturbed vision, headache, confusion, seizures.</strong><br />If Fludara oral is used for a long time, its effects on the central nervous system are not known. However, patients treated with the recommended dose for up to 26 courses of treatment were able to tolerate it.<br />When Fludara is used at the recommended dose, following the treatment with some other medications or at the same time as some other medications, the following adverse events have been reported:</p><p>neurological disorders manifested by headache, feeling sick (nausea) and vomiting, seizures, visual disturbances including vision loss, changes in mental status (thinking abnormal, confusion, altered consciousness) and occasionally neuromuscular disorders manifested by muscle weakness in your limbs (including irreversible partial or complete paralysis) (symptoms of leukoencephalopathy, acute toxic leukoencephalopathy or posterior reversible leukoencephalopathy syndrome (RPLS)).<br />In patients on doses four times greater than recommended blindness, coma and death have been reported. Some of these symptoms appeared delayed around 60 days or more after treatment had been stopped. In some patients receiving Fludara doses higher than the recommended dose, leukoencephalopathy (LE), acute toxic leukoencephalopathy (ATL) or posterior reversible leukoencephalopathy syndrome (RPLS) have also been reported. Same symptoms of LE, ATL or RPLS as above described could occur. LE, ATL, and RPLS may be irreversible, life-threatening, or fatal.<br />Whenever LE, ATL or RPLS is suspected, your treatment will Fludara will be stopped for further investigations. If the diagnosis of LE, ATL, or RPLS is confirmed, you doctor will permanently discontinue your treatment with Fludara.<br />&bull; if you notice any pain in your side, blood in your urine or reduced amount of urine.<br />When your disease is very severe, your body may not be able to clear all the waste products from the cells destroyed by Fludara oral. This is called tumour lysis syndrome and can cause kidney failure and heart problems from the first week of treatment. Your doctor will be aware of this and may give you other medicines to help prevent it. He/she may decide that you should start your treatment in hospital.<br />&bull; if you need to have stem cells collected and you are being treated with Fludara oral (or have been).<br />&bull; if you need a blood transfusion and you are being treated with Fludara oral (or have been).<br />In case you need a blood transfusion your doctor will ensure that you only receive blood that has been treated by irradiation. There have been severe complications and even death, from transfusions of non-irradiated blood.<br />&bull; if you notice any changes to your skin either while you are receiving this medicine or after you have finished the treatment.<br />&bull; if you have or have had skin cancer it may worsen or flare up again while you take Fludara oral or afterwards. You may develop skin cancer during or after Fludara oral treatment.<br />Other things to consider, when taking Fludara oral:<br />- Men and women, who are fertile, must use effective contraception during treatment and for at least 6 months afterwards. It cannot be ruled out that Fludara oral may harm an unborn baby. Your doctor will carefully weigh the benefit of your treatment against</p><p>a possible risk for an unborn child and, if you are pregnant, will only treat you with Fludara if clearly necessary.<br />&bull; if you consider or are breastfeeding you should not start it or continue while on treatment with Fludara.<br />&bull; if you need a vaccination, check with your doctor, because live vaccinations should be avoided during and after treatment with Fludara oral.<br />&bull; if you have kidney problems or if you are over 65, you will have regular blood and/or laboratory tests to check your kidney function. If your kidney problems are severe, you will not be prescribed this medicine at all (see sections 2 and 3).<br />&bull; Fludara oral tablets may cause more vomiting and nausea (being or feeling sick) than Fludara given intravenously. If this is a problem, your doctor will consider switching your treatment to the intravenous Fludara.<br /><strong>Children and adolescents</strong><br />The safety and effectiveness of Fludara oral in children below the age of 18 years has not been established. Therefore, Fludara oral is not recommended for use in children.<br /><strong>Older patients and Fludara:</strong><br />People over 65 will have regular tests for kidney function (see section 3. How to take Fludara oral).<br />People over 75 will be monitored especially closely.<br /><strong>Other medicines and Fludara oral</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.<br />It is especially important to tell your doctor about:<br />&bull; pentostatin (deoxycoformycin), also used to treat B-CLL. Taking these two drugs together can lead to severe lung problems.<br />&bull; dipyridamole, used to prevent excessive blood clotting or other similar drugs. They may reduce the effectiveness of Fludara oral.<br />&bull; cytarabine (Ara-C) used to treat chronic lymphatic leukaemia. If Fludara oral is combined with cytarabine, levels of the active form of Fludara in leukaemic cells may rise. However, the overall levels in the blood and its elimination from the blood were not shown to have changed.<br /><strong>Pregnancy, breast-feeding and fertility </strong></p><p><em><u>Pregnancy</u></em><br />Fludara oral should not be given to women who are pregnant because animal studies and very limited experience in humans have shown a possible risk of abnormalities in the unborn baby as well as early pregnancy loss or premature delivery.<br />If you are pregnant or you think you may be pregnant, tell your doctor immediately. Your doctor will carefully weigh the benefit of your treatment against a possible risk for an unborn child and, if you are pregnant, will only prescribe Fludara if clearly necessary.</p><p><em><u>Breast-feeding:</u></em><br />You must not start or continue breast feeding during your treatment with Fludara, as this medicine may interfere with the growth and development of your baby.<br /><em><u>Fertility</u></em><br />Men and women, who are fertile, must use effective contraception during treatment and for at least 6 months afterwards.<br /><strong>Driving and using machines</strong><br />Some people get tired, feel weak, have disturbed vision, become confused, or agitated or have seizures while they are treated with Fludara oral. Do not try to drive or operate machines until you are sure that you are not affected.<br /><strong>Fludara oral contains lactose monohydrate</strong><br />This medicine contains lactose monohydrate (a type of sugar). If you have been told by your doctor that you cannot tolerate certain sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>How many tablets to take</strong><br />The dose you should take depends on your body surface area. This is measured in square metres (m2) and is worked out by the doctor from your height and weight.<br />The recommended dose is 40 mg fludarabine phosphate/m2 body surface area, once a day. The usual dose is between 3 to 10 tablets once a day. The exact number of tablets you should take is calculated by your doctor.<br /><strong>How to take Fludara oral tablets</strong><br />Swallow the tablet whole with water. Do not break or chew the tablets. You can take Fludara oral either on an empty stomach or together with food.<br /><strong>How long you should take Fludara oral</strong><br />Take the dose worked out by your doctor once a day for 5 consecutive days.<br />This 5-day-course of treatment will be repeated every 28 days until your doctor has decided that the best effect has been achieved (usually after 6 courses).<br />How long the treatment lasts depends on how successful your treatment is and how well you tolerate Fludara oral. The repeat course may be delayed if side effects are a problem.<br />You will have blood tests after every treatment. Your individual dose will be carefully adjusted according to the number of your blood cells and your response to the treatment. If the number of your blood cells is too low, your next treatment cycle may be postponed for up to two weeks or your dose may be decreased. The dosage may also be decreased if side effects are a problem.</p><p><strong>If you have been treated for two courses and you did not respond to the treatment</strong> but you also showed few symptoms of a reduced blood cell count, your doctor may decide to increase your dose.<br /><strong>If you have kidney problems or if you are over the age of 65</strong>, you will have regular tests to check your kidney function. If your kidneys do not work properly your doctor may prescribe a lower dose. If your kidney function is severely reduced you will not be prescribed this medicine at all (see section 2).<br /><strong>If you take more Fludara oral than you should</strong><br />Tell your doctor immediately if you took too many Fludara oral tablets<br />High doses can lead to a severely reduced number of blood cells.<br />For Fludara given intravenously it has been reported, that overdose can cause delayed blindness, coma and even death.<br /><strong>If you forget to take Fludara oral</strong><br />Talk to your doctor as soon as possible if you think you may have missed a dose or vomit after tablet taking.<br />Do not take a double dose to make up for the forgotten tablets.<br /><strong>If you stop taking Fludara oral</strong><br />Do not stop taking Fludara oral without advice from your doctor.<br />You and your doctor may decide to stop your treatment with Fludara oral, if the side effects are becoming too severe.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you are not sure what the side effects below are, ask your doctor to explain them to you.<br />Some side effects can be life-threatening. Tell your doctor immediately:<br />&bull; if you have difficulty breathing, have a cough, or have chest pain with or without fever. These may be signs of an infection of the lungs.<br />&bull; if you notice any unusual bruising, more bleeding than usual after injury or if you seem to be catching a lot of infections. These may be caused by a reduced number of blood cells. This may also lead to an increased risk of (serious) infections, caused by organisms, that usually do not cause disease in healthy persons (opportunistic infections) including a late reactivation of viruses, for example herpes zoster.<br />&bull; if you notice any pain in your side, blood in your urine, or reduced amount of urine. These may be signs of tumour lysis syndrome (see section 2).<br />&bull; if you notice any skin and / or mucous coat reaction with redness, inflammation, blistering and tissue break down. These may be signs of a severe allergic reaction (Lyell&rsquo;s syndrome, Stevens-Johnson syndrome).</p><p>&bull; if you have palpitations (if you suddenly become aware of your heart beat) or chest pain. These may be signs of heart problems.<br />Below are possible side effects by how common they are, as known from Fludara for intravenous use.<br /><strong>Very common side effects (may affect more than 1 in 10 people)</strong><br />&bull; infections (some serious)<br />&bull; infections due to depressed immune system (opportunistic infections)<br />&bull; infection of the lungs (pneumonia) with possible symptoms like breathing difficulties and / or cough with or without fever<br />&bull; reduction in the number of blood platelets (thrombocytopenia) with the possibility of bruising and bleeding<br />&bull; lowered white blood cell count (neutropenia)<br />&bull; lowered red blood cell count (anaemia)<br />&bull; cough<br />&bull; vomiting, diarrhea, feeling sick (nausea)<br />&bull; fever<br />&bull; feeling tired (fatigue)<br />&bull; weakness<br /><strong>Common side effects (may affect up to 1 in 10 people)</strong><br />&bull; other blood related cancers (myelodysplastic syndrome, acute myeloid leukaemia). Most patients with these conditions were previously, or at the same time or later treated with other cancer drugs (alkylating agents, topoisomerase inhibitors) or radiation therapy<br />&bull; bone marrow depression (myelosuppression)<br />&bull; severe loss of appetite leading to weight loss (anorexia)<br />&bull; numbness or weakness in limbs (peripheral neuropathy)<br />&bull; disturbed vision<br />&bull; inflammation of the inside of the mouth (stomatitis)<br />&bull; skin rash<br />&bull; swelling due to excessive fluid retention (oedema)<br />&bull; inflammation of the mucous coat of the digestive system from the mouth to the anus (mucositis)<br />&bull; chills<br />&bull; generally feeling unwell<br /><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong><br />&bull; autoimmune disorder (see section 2)<br />&bull; tumour lysis syndrome (see section 2)<br />&bull; confusion<br />&bull; lung toxicity, scarring throughout the lungs (pulmonary fibrosis), inflammation of the lungs (pneumonitis), shortness of breath (dyspnoea)<br />&bull; bleeding in the stomach or intestines<br />&bull; abnormal levels of the liver or pancreas enzymes<br />Rare side effects (may affect up to 1 in 1,000 people)<br />&bull; disorders of the lymph system due to a viral infection (EBV-associated lymphoproliferative disorder)</p><p>&bull; coma<br />&bull; seizures<br />&bull; agitation<br />&bull; blindness<br />&bull; inflammation or damage of the nerve of the eyes (optic neuritis; optic neuropathy)<br />&bull; heart failure<br />&bull; irregular heart beat (arrhythmia)<br />&bull; skin cancer<br />&bull; skin and/or mucous coat reaction with redness, inflammation, blistering and tissue break down (Lyell&#39;s syndrome, Stevens-Johnson syndrome)<br /><strong>Not known (frequency cannot be estimated from available data)</strong><br />&bull; bleeding in the brain<br />&bull; neurological disorders manifested by headache, feeling sick (nausea) and vomiting, seizures, visual disturbances including vision loss, changes in mental status (thinking abnormal, confusion, altered consciousness), and occasionally neuromuscular disorders manifested by muscle weakness in your limbs (including irreversible partial or complete paralysis) (symptoms of leukoencephalopathy, acute toxic leukoencephalopathy or posterior reversible leukoencephalopathy syndrome (RPLS)).<br />&bull; bleeding in the lungs<br />&bull; inflammation of the bladder, which can cause pain when passing urine, and can lead to blood in the urine (haemorrhagic cystitis)<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o SFDA call center : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the bottle label and blister foil after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Fludara oral is a cytotoxic drug. It should always be stored in the original, child resistant container.<br />This medicine does not require any special temperature storage conditions. Store in the original package to protect from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>Return any unused or waste tablets to your doctor or pharmacist. They will take care that Fludara oral is disposed of according to local requirements for cytotoxic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is fludarabine phosphate. Each film-coated tablet of Fludara oral contains 10 mg fludarabine phosphate.<br />- The other ingredients are<br />- in the tablet core: cellulose (microcrystalline), lactose (monohydrate), silica (colloidal anhydrous), croscarmellose sodium, magnesium stearate;<br />- in the film-coat: hypromellose, talc, titanium dioxide (E171), ferric oxide pigment (yellow (E172)), ferric oxide pigment (red (E172)).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fludara oral are salmon-pink, capsule-shaped film-coated tablets, marked with ‘LN’ in a regular hexagon on one side.
The tablets are provided in blisters of 5 tablets each. The blisters are of polyamide/aluminium/poly-propylene thermoformable foil with a lidding foil of aluminium. The blisters are packed in a polyethylene tablet container with a child-resistent polypropylene screw cap.
Fludara oral is available in packs containing:
• 15 tablets in 3 blisters in a child-resistant bottle.
• 20 tablets in 4 blisters in a child-resistant bottle.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong><br />GENZYME LTD.<br />37 Hollands Road<br />Haverhill, Suffolk<br />CB9 8PU, UK<br />SANOFI WINTHROP INDUSTRIE, 30-36,<br />avenue Gustave Eiffel<br />37100 Tours, France.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2010
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>􀇽حتوي فلودا ا ر الفموي على المادة الفعالة فلودا ا ربین فوسفات التي توقف نمو خلا 􀇽ا السرطان الجدیدة.<br />تنقسم جمیع خلا 􀇽ا الجسم لتنتج خلا 􀇽ا جدیدة مشابهه لها. وعند استخدام فلودا ا ر الفموي 􀇽صل إلى الخلا 􀇽ا<br />السرطانیة و 􀈄وقف انقسامه.</p><p>عند الإصا 􀇼ة 􀇼سرطانات خلا 􀇽ا الدم البیضاء (مثل سرطان الدم اللیمفاوي المزمن)، یبدأ الجسم 􀇼إنتاج العدید<br />من خلا 􀇽ا الدم البیضاء غیر الطبیعیة (الخلا 􀇽ا اللمفاو 􀈄ة) وتبدأ الغدد اللیمفاو 􀈄ة في أج ا زء مختلفة من الجسم<br />􀇼التضخم نتیجة لذلك. لا 􀇽مكن لخلا 􀇽ا الدم البیضاء غیر الطبیعیة أن تقوم 􀇼المهام الطبیعیة في مكافحة<br />العدوى وقد تؤُثر أ 􀇽ضًا على فاعلیة خلا 􀇽ا الدم البیضاء السلیمة. 􀇽مكن أن یؤدي ذلك إلى حدوث العدوى ،<br />وانخفاض في عدد خلا 􀇽ا الدم الحم ا رء (فقر الدم)، والتكدُّم، والنز􀈄ف الحاد أو حتى فشل الأعضاء .<br />􀇽 سُتخدم فلودا ا ر في علاج ابیضا ض الدم اللیمفاوي المزمن للمفاو 􀈄ات البائیة ( B-CLL ) للمرضى ممن ل دیهم<br />عد 􀘗افٍ من خلا 􀇽ا الدم السلیمة.<br />􀇽جب أن 􀇽قتصر الاستخدام الأول لفلودا ا ر في علاج سرطان الدم اللیمفاوي المزمن فقط على المرضى الذین<br />􀇽عانون من مرض متقدم مع وجود أع ا رض مرتبطة 􀇼المرض أو دلیل على تفاقم المر ض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول فلودا ا ر الفموي إذا:<br />- 􀘗نت تعاني من حساسیة نحو فلودا ا ربین فوسفات أو أي من المكونات الأخرى لهذا الدواء (المذ 􀘗ورة في<br />الفقرة ٦.)<br />- 􀘗نت تعاني من عدم تحمّل لمونوهید ا رت اللاكتوز (انظر الفقرة الفرعیة 􀇼عنوان &quot; فلودا ا ر الفموي 􀇽حتوي على<br />مونوهید ا رت اللاكتوز&quot; تحت الفقرة ٢.)<br />- 􀘗ن ت ترضعین طفلك.<br />- 􀘗ان لد 􀇽ك مشاكل شدیدة في الكلى.<br />- 􀘗ان عدد خلا 􀇽ا الدم الحم ا رء لد 􀇽ك منخفضًا، 􀇼سبب نوع من أنواع فقر الدم (فقر الدم الانحلالي غیر المُعاوض<br />&quot;غیر منضبط&quot;). سیخبرك طبیبك إذا 􀘗نت تعاني من هذه الحالة.</p><p>أخبر طبیبك قبل استخدام فلودا ا ر الفموي إذا 􀘗نت تعتقد أن أ 􀄎 􀇽ا من هذه الحالات ینطبق علیك .<br />التحذی ا رت والاحتیاطات<br />تحدث إلى طبیبك قبل تناو ل فلودا ا ر الفموي .<br />توخ الحرص الشدید عند استخدم فلودا ا ر الفموي :<br />&bull; إذا 􀘕ان النخاع العظمي لد 􀇽ك لا 􀇽عمل 􀇼شكل صحیح أو إذا 􀘗ان لد 􀇽ك جهاز المناعة ضعیف الأداء أو<br />مثبط أو لد 􀇽ك تار􀈄خ من الإصا 􀇼ة 􀇺عدوى خطیرة .<br />- قد 􀇽قرر طبیبك عدم إعطائك هذا الدواء، أو قد یتخذ الاحتیاطات اللازمة.<br />&bull; إذا شعرت بتوعك شدید، لاحظت ظهور 􀘕دمات 􀇼شكل غیر عادي، أو نز 􀈂ف أكثر من المعتاد 􀇼عد الإصا 􀇼ة،<br />أو إذا 􀘗نت تعاني من عدوى 􀘕ثیرة.<br />&bull; إذا تغیّر لد 􀇻ك لون البول إلى اللون الأحمر المائل إلى الب ني، أو ظهر لد 􀇻ك ط فح جلدي أو أي بثور على<br />جلدك.<br />أخبر طبیبك على الفور. قد تكون هذه علامات على انخفاض عدد خلا 􀇽ا الدم لد 􀇽ك، والذي قد 􀇽حدث إما<br />􀇼سبب المرض نفسه أو العلاج. 􀇽مكن أن 􀇽ستمر هذا التأثیر لمدة تصل إلى عام ولا ی رتبط 􀇼كونك تلقیت<br />العلاج 􀇼فلودا ا ر الفموي في السابق أم لم تتلقاه. قد یهاجم جهاز المناعة لد 􀇽ك أ 􀇽ضًا أثناء العلاج 􀇼فلودا ا ر<br />الفموي أج ا زء مختلفة من الجسم، أو خلا 􀇽ا الدم الحم ا رء (تسمى &quot;اضط ا ر 􀇼ات المناعة الذاتیة&quot;). 􀇽مكن لهذ ه<br />الحالات أن تهدد الحیاة .<br />إذا حدث ذلك، فسوف یوقف طبیبك علاجك 􀇼فلودا ا ر الفموي وقد تتلقى أدو 􀈄ة أخرى مثل نقل الدم المشعّ ع<br />(انظر أدناه) والستیرو 􀈄دات ال قشر􀈄ة.</p><p>ستخضع أثناء علاجك 􀇼فلودا ا ر الفموي لفحوصات دم منتظمة 􀘗ما ست تم م ا رقبتك عن 􀘗ث ب.<br />&bull; إذا واجهت أي أع ا رض غیر عاد 􀇻ة مرتبطة 􀇺الجهاز العصبي لد 􀇻ك مثل اضط ا رب الرؤ 􀈂ة والصداع والارتباك<br />والتشنّجات.<br />إن تأثیر فلودا ا ر الفموي على الجهاز العصبي عند استخدامه لفت ا رت طو 􀈄لة غیر معروف. ومع ذلك، فإن<br />المرضى الذین عولجوا 􀇼الجرعة الموصى بها لما 􀇽صل إلى ٢٦ دورة علاجیة 􀘗انوا قادر􀈄ن على تحمله .<br />تم الإبلاغ عن حدوث الأع ا رض الجانبیة التالیة عند استخدام فلودا ا ر الفموي 􀇼الجرعة الموصى بها، 􀇼عد<br />العلاج ببعض الأدو 􀈄ة الأخرى أو أثناء العلاج مع 􀇼عض الأدو 􀈄ة الأخرى :<br />الاضط ا ر 􀇼ات العصبیة التي تتجلى في الصداع، والغثیان والقيء، والنو 􀈃ات، والاضط ا ر 􀇼ات البصر􀈄ة 􀇼ما في<br />ذلك فقدان البصر، والتغی ا رت في الحالة العقلیة (التفكیر غیر الطبیعي، والارتباك، والتغیّر في الوعي)<br />وأحیا نا الاضط ا ر 􀇼ات العصبیة العضلیة التي تظهر على شكل ضعف العضلات في أط ا رفك ( 􀇼ما في ذلك<br />الشّلل الجزئي أو التام غیر القابل للعكس) (أع ا رض اعتلال بیضاء الدماغ &quot; LE &quot;، اعتلال بیضاء الدماغ<br />السميّ الحدا &quot; ATL &quot; أو متلازمة اعتلال بیضاء الدماغ الخلفي القابل للعكس &quot; RPLS .(&quot;<br />تم الإبلاغ عن تعرّض 􀇼عض المرضى للعمى والغیبو 􀈃ة وحتى الموت عند تناولهم لجرعات أكبر أر􀈃ع م ا رت<br />من الجرعات الموصى بها. ظه رت 􀇼عض هذه الأع ا رض متأخرة 􀇼حوالي ٦٠ یومًا أو أكثر 􀇼عد توقف<br />العلاج. 􀘗ما تم الإبلاغ أ 􀇽ضًا عن تعرض 􀇼عض المرضى الذین تلق وا ج رعا ت من فلودا ا ر أعلى من الجرعة<br />الموصى بها لا عتلال بیضاء الدماغ ( LE )، اعتلال بیضاء الدماغ السميّ الحدا ( ATL ) أو متلازمة اعتلال<br />بیضاء الدماغ الخلفي القابل للعكس ( RPLS ). قد تحدث أع ا رض ل ATL ،LE و RPLS 􀘗ما هو موضح<br />أعلاه.</p><p>قد 􀇽كون أي من LE و ATL و RPLS غیر قابل للعكس أو مُهه دا للحیاة أو قد یؤدي إلى الوفاة.<br />عندما 􀇽شتبه الطبیب في وجود ATL ،LE أو RPLS ، سیتم إ 􀇽قاف علاجك 􀇼فلودا ا ر لإج ا رء مز􀈄د من<br />الفحوصا ت . إذا تأكد تشخیص LE أو ATL أو RPLS ، فسوف یوقف طبیبك علاجك 􀇼فلودا ا ر 􀇼شكل دائم.<br />&bull; إذا عانیت من أي ألم في أحد جانبیك، أو من وجود دم في البول أو من انخفاض 􀘕میة البول .<br />عندم ا تشتدّ حدة مرضك، قد لا یتمكن جسمك من إ ا زلة جمیع 􀇼قا 􀇽ا الخلا 􀇽ا التي دمرها فلودا ا ر الفموي. وهذا ما<br />􀇽سمى 􀇼متلازمة انحلال الورم و 􀈄مكن أن 􀇽سبب الفشل الكلوي ومشاكل في القلب بدءًا من الأسبوع الأول من<br />العلاج. سوف 􀇽كون طبیبك مُتأهبًا لذلك، وقد 􀇽صف لك أدو 􀈄ة أخرى للمساعدة في الوقا 􀇽ة من حدوثها. قد<br />􀇽قرر/ تُقرّر أنه 􀇽جب أن تبدأ علاجك في المستشفى .<br />&bull; إذا 􀘕نت 􀇺حاجة إلى جمع خلا 􀇻ا جذعیّة أثناء علاجك 􀇺فلودا ا ر الفموي (أو سبق لك العلاج 􀇺ه).<br />&bull; إذا 􀘕نت 􀇺حاجة إلى نقل دم أثناء علاجك 􀇺فلودا ا ر الفموي (أو سبق لك العلاج 􀇺ه).<br />إذا 􀘗نت 􀇼حاجة إلى نقل دم، سیتأكد طبیبك من تلقیك الدم المُشعّع فقط. إذ حدثت هناك مضاعفات خطیرة<br />لدى 􀇼عض المرضى وحتى الموت، 􀇼سبب عملیات نقل الدم غیر المش عع.<br />&bull; إذا لاحظت أي تغیی ا رت على جلدك إما أثناء استخدام هذا الدواء أو 􀇺عد الانتهاء من العلاج.<br />&bull; إذا 􀘕نت مصاً􀇺ا أو أُصبت في السابق 􀇺سرطان الجلد، فقد یتفاقم أو یهیج مرة أخرى أثناء تناول فلودا ا ر<br />الفموي أو 􀇼ع د الانتهاء من العلاج 􀇼ه. قد تصاب 􀇼سرطان الجلد أثناء أو 􀇼عد العلاج 􀇼فلودا ا ر الفموي.</p><p>أمور أخرى 􀇻جب م ا رعاتها، عند تناول فلودا ا ر الفموي :<br />- 􀇽جب على الرجال والنسا ء القادر􀈄ن على الإنجاب استخدام وسائل منع الحمل الفعالة أثناء العلاج ولمدة ٦<br />أشهر على الأقل 􀇼عد الانتهاء. إذ لا 􀇽مكن استبعاد حدوث الضرر للجنین 􀇼سبب استخدام فلودا ا ر. سیقوم<br />الطبیب 􀇼الموازنة بین الفائدة المرجوة من علاجكِ مقابل الخطر المحتمل للجنین، و􀈂ذا 􀘗ن ت حاملاً، فسوف<br />􀇽عالجك 􀇼فلودا ا ر إذا لزم الأمر 􀇼شكل واضح فقط.<br />&bull; إذا 􀘕نتِ تفكر 􀈂ن 􀇺إرضاع طفلك أو 􀘕نت ترضعینه، فینبغي ألّا تبدئي أو تُواصلي الرضاعة أثناء علاج ك<br />􀇼فلودا ا ر.<br />&bull; إذا 􀘕نت 􀇺حاجة إلى التطعیم، فاستشر طبیبك، لأنه 􀇽جب تجنب اللقاحات الحیة أثناء و 􀈃عد العلاج 􀇼فلودا ا ر<br />الفموي .<br />&bull; إذا 􀘕نت تعاني من مشاكل في الكلى أو إذا 􀘕ان عمرك یتجاوز ٦٥ عامًا، فستخضع لفحوصات دم و /<br />أو مخبر􀈄ة منتظمة لفحص وظائف الكلى لد 􀇽ك. إذا 􀘗انت لد 􀇽ك مشاكل 􀘗لى شدیدة، فلن یتم وصف هذا<br />الدواء على الإطلاق (انظر الفقرتین ٢ و ٣.)<br />&bull; قد تسبب أق ا رص فلودا ا ر الفمو 􀈂ة القيء والغثیان أكثر من فلودا ا ر الذي 􀇽ُعطى عن طر􀈄ق الور􀈄د. إذا 􀘗انت<br />هذه مشكلة 􀇼النسبة لك، فسوف ینظر طبیبك في تحو 􀈄ل علاجك إلى حُقن فلودا ا ر التي تُعطى عن طر􀈄 ق<br />الور􀈄د.<br />الأطفال والم ا رهقو ن</p><p>لم تثبت سلامة وفعالیة فلودا ا ر الفموي في الأطفال دون سن ١٨ عامًا. لذلك، لا یُنصح 􀇼استخدام فلودا ا ر<br />الفموي في هذه الفئة العمر􀈄ة.<br />المرضى من 􀘕بار السن وفلودا ا ر:<br />الأشخاص الذین تز􀈄د أعمارهم عن ٦٥ عامًا: سیخضعون لفحوصا ت منتظمة لوظائف الكلى (انظر الفقر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائما حسب ارشادات طبیبك تماما. استشر طبیبك أو الصیدلي إذا 􀘗نت غیر متأكد .<br />الجرعة الموصى بها<br />تعتمد الجرعة التي 􀇽جب أن تتناولها على مساحة سطح جسمك التي تُقاس 􀇼المتر المر􀈃ع (م ٢)، و 􀈄قوم الطبی ب<br />􀇼حسابها بناءً على طولك ووزنك.<br />الجرعة الموصى بها هي ٤٠ مجم من فلودا ا ربین فوسفات / م ٢ من مساحة سطح الجسم، مرة واحدة في<br />الیوم. تت ا روح الجرعة المعتادة بین ٣ إلى ١٠ أق ا رص مرة واحدة یومیًا. یتم حساب العدد الدقیق للأق ا رص التي<br />􀇽جب أن تتناولها من قبل الطبیب .<br />كیفیة تناول أق ا رص فلودا ا ر الفمو 􀈂ة<br />ابتلع القرص 􀇼أكمله مع الماء. لا تكسر أو تمضغ الأق ا رص. 􀇽مكنك تناول أق ا رص فلودا ا ر الفمو 􀈄ة قبل الأكل<br />(على معدة فارغة) أو مع الأكل.<br />مدة العلاج 􀇺استخدام فلودا ا ر الفموي<br />خذ الجرعة التي وصفها لك طبیبك مرة واحدة في الیوم لمدة ٥ أ 􀇽ام متتالیة .<br />سیتم تك ا رر دورة العلاج هذه التي تستمر ٥ أ 􀇽ام 􀘗ل ٢٨ یومًا حتى 􀇽قرر طبیبك أنك قد حصلت على أفضل<br />تأثیر للدواء (عادة 􀇼عد ٦ دورا ت علاجیة).<br />􀇽عتمد طول المدة التي 􀇽ستغرقها العلاج على مدى استجابتك للعلاج ومدى تحمّلك لفلودا ا ر الفموي . قد یتأخر<br />مسار الدو ا رت العلاجیة إذا 􀘗انت الأعراض الجانبیة التي تواجهها تمثل مشكلة.<br />ستخضع لفحوصات الدم 􀇼عد 􀘗ل دورة علاجیة. و سیتم ضبط الجرعة الفرد 􀇽ة الخاصة 􀇼ك 􀇼عنا 􀇽ة وفقًا لعدد<br />خلا 􀇽ا الدم لد 􀇽ك واستجابتك للعلاج. إذا 􀘗ان عدد خلا 􀇽ا الدم لد 􀇽ك منخفضًا للغا 􀇽ة، فقد تُؤجّل دورة العلاج<br />التالیة لمدة تصل إلى أسبوعین أو ق د تُخفّض لك الجرعة. 􀇽مكن أ 􀇽ضًا تقلیل الجرعة إذا 􀘗انت الأع ا ر ض<br />الجانبیة التي تواجهها تمثل مشكلة.<br />إذا عولجت بدورتین علاجیتین ولم تستجب للعلاج لكنك أظهرت أ 􀇽ضًا أع ا رضًا قلیلة لانخفاض عدد خلا 􀇽ا<br />الدم، فقد 􀇽قرر الطبیب ز􀈄ادة الجرعة .<br />إذا 􀘕نت تعاني من مشاكل في الكلى أو إذا 􀘕ان عمرك یتجاوز ٦٥ عامًا، فستخضع لفحوصا ت منتظمة<br />للتحقق من وظائف الكلى. إذا 􀘗ان لد 􀇽ك اضط ا رب في وظائف الكلى، فقد 􀇽صف لك الطبیب جرعة أقل. إذا<br />أصبحت وظائف الكلى لد 􀇽ك متدنیة 􀇼شدة، فلن یتم وصف هذا الدواء لك على الإطلاق (انظر الفقرة ٢).<br />إذا تناولت من فلودا ا ر الفموي أكثر مما 􀇻ج ب<br />أخبر طبیبك على الفور إذا تناولت من أقراص فلودا ا ر الفمو 􀈄ة أكثر مما 􀇽ج ب. 􀇽مكن أن تُؤدي الجرعا ت<br />العالیة إلى انخفاض شدید في عدد خلا 􀇽ا الدم .<br />􀇼النسبة إلى فلودا ا ر ال ذي ع􀇽ُطى عن طر􀈄ق الور􀈄د، تم الإبلاغ عن أن الجرعة ال ا زئدة 􀇽مكن أن تسبب العمى<br />المتأخر والغیبو 􀈃ة وحتى المو ت.<br />إذا نسیت تناول إحدى جرعات فلودا ا ر الفموي</p><p>تحدث إلى طبیبك في أقرب وقت ممكن إذا 􀘗نت تعتقد أنّ إحدى الجرعات قد فاتتك أو إذا تقیّأت 􀇼عد تناول<br />القر ص.<br />لا ت تناول جرعة مضاعفة لتعو 􀈄ض جرعة فائتة .<br />إذا توقفت عن تناول فلودا ا ر الفموي<br />لا تتوقف عن تناول فلودا ا ر الفموي دون استشارة طبیبك .<br />قد تقرر أنت وطبیبك إ 􀇽قاف علاجك 􀇼فلودا ا ر الفموي إذا أصبحت الأعراض الجانبیة شدیدة للغا 􀇽ة.<br />إذا 􀘗ان لد 􀇽ك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبیبك أو الصیدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع سائر الأدو 􀈄ة، 􀇽مكن أن 􀇽سبب هذا الدواء أع ا رضًا جانبیة، مع أنها لا تحدث لدى جمیع من<br />یتناوله. إذا استعصى علیك فهم أي من الأعراض الجانبیة الموضحة أدناه، فاطلب من طبیبك توضیحها لك.<br />􀇼عض الأع ا ر ض الجانبیة 􀇽مكن أن تهدد الحیاة. أخبر طبیبك على الفور إذا:<br />&bull; إذا 􀘗نت تعاني من صعو 􀈃ة في التنفس أو سعال أو ألم في الصدر مع أو بدون حمى. قد تكون هذه<br />علامات على عدوى الرئتین.<br />&bull; إذا لاحظت ظهور 􀘗دمات 􀇼شكل غیر اعتیادي، أو النز􀈄ف أكثر من المعتاد 􀇼عد الإصا 􀇼ة أو إذا 􀘗نت<br />تعاني من 􀘗ثرة الإصا 􀇼ة 􀇼العدوى . قد 􀇽كون سبب ه ذا هو انخفاض عدد خلا 􀇽ا الدم. وقد یؤدي ذلك بدوره<br />إلى ز􀈄ادة خطر الإصا 􀇼ة 􀇼العدوى (الخطیرة) التي تسببها الكائنات الحیة، والتي لا تسبب المرض عادةً<br />للأشخاص الأصحاء (العدوى الانتهاز􀈄ة) 􀇼ما في ذلك إعادة التنشیط المتأخر للفیروسات، مثل الهر􀈃س النطاقي .</p><p>&bull; إذا عانیت من أي ألم في أحد جان بیك، أو من وجود دم في البول أو من انخفاض 􀘗میة البول. قد تكون هذه<br />علامات على حدوث متلازمة انحلال الورم (انظر الفق رة ٢.)<br />&bull; إذا لاحظت أي رد فعل على الجلد و / أو الأغشیة المخاطیة مثل الاحم ا رر والالتها 􀇼ات والتقرحات و تقشّر<br />الأنسجة. قد تكون هذه علامات تدل على الحساسیة الشدیدة (متلازمة لایل، متلازمة ستیفنز جونسون )<br />&bull; إذا شعرت 􀇼الخفقان (إذا شعرت أو أحسست 􀇼ضر􀈃ات قلبك) أو ألم في الصدر. قد تكون هذه علامات على<br />حدوث مشاكل في القلب.<br />فیما یلي 􀇺عض الأع ا رض الجانبیة المحتملة مُدرجة ح سب شیوعها، و 􀘗ما تم الإبلاغ عنه مع استخدام<br />فلودا ا ر الذي 􀇽ُعطى 􀇼الحقن في الور􀈄د.<br /><strong>أع ا رض جانبیة شائعة جدًا (قد تؤثر على أكثر من شخص من 􀘗ل ١٠ أشخا ) ص</strong><br />&bull; العدوى ( 􀇼عضها خطیر )<br />&bull; العدوى الناجمة عن 􀘗بت الجهاز المناعي (العدوى الانتهاز􀈄ة )<br />&bull; عدوى الرئتین (الالتهاب الرئوي) مع أع ا رض محتملة مثل صعو 􀈃ات التنفس و / أو السعال مع أو بدون<br />حمى<br />&bull; انخفاض عدد الصفائح الدمو 􀈄ة (نقص الصفیحات) مع إمكانیة حدوث 􀘗دمات ونز􀈄ف<br />&bull; انخفاض عدد خلا 􀇽ا الدم البیضاء (قلة العدلات)<br />&bull; انخفاض عدد خلا 􀇽ا الدم الحم ا رء (فقر الدم)<br />&bull; السعال<br />&bull; القيء والإسهال والشعور 􀇼الغثیان<br />&bull; الحمى</p><p>&bull; الشعور 􀇼التع ب (الإجهاد)<br />&bull; الشعور 􀇼الضعف<br /><strong>الأع ا رض الجانبیة الشائعة (قد تؤثر على ما 􀇽صل إلى ١ من 􀘗ل ١٠ أشخاص)</strong><br />&bull; سرطانات الدم الأخرى (متلازمة خلل التنسج النخاعي، سرطان الدم النخاعي الحاد). خضع معظم<br />المرضى الذین 􀇽عانون من هذه الحالات من قبل، أو في نفس الوقت أو لاحقًا 􀇼ا لأدو 􀈄ة المضادة للسرطان<br />الأخرى (عوامل الألكلة، مثبطات تو 􀈃 و 􀈄زومی ا رز) أو العلاج الإشعاعي .<br />&bull; 􀘗بت النخاع العظمي (كبت النقي العظمي)<br />&bull; فقدان شدید للشهیة یؤدي إلى فقدان الوزن (فقدان الشهیة أو القَهَم)<br />&bull; خدر أو ضعف في الأط ا رف (الاعتلال العصبي المحیطي)<br />&bull; اضط ا رب الرؤ 􀈄 ة<br />&bull; التهاب داخل الفم (التهاب الفم)<br />&bull; طفح جلدي<br />&bull; تورم 􀇼سبب احتباس السوائل ال ا زئد (وذمة)<br />&bull; التهاب الطبقة المخاطیة في الجهاز الهضمي من الفم إلى فتحة الشرج (التهاب الغشاء المخاطي )<br />&bull; قشعر􀈄ر ة<br />&bull; الشعور العام 􀇼 التوعك<br /><strong>أع ا رض جانبیة غیر شائعة (قد تؤثر على ما 􀇽صل إلى شخص من 􀘗ل ١٠٠ شخص)</strong><br />&bull; اضط ا رب المناعة الذاتیة (انظر الفقرة ٢)<br />&bull; متلازمة تحلل الورم (انظر الفقرة ٢)<br />&bull; الارتبا ك<br />&bull; سمیة الرئة، تندب في جمیع أنحاء الرئتین (التلیف الرئوي)، التهاب الرئتین، ضیق التنفس</p><p>&bull; نز􀈄ف في المعدة أو الأمعاء<br />&bull; مستو 􀈄ات غیر طبیعیة من أنز􀈄مات الكبد أو البنكر􀈄ا س في الدم<br /><strong>أع ا رض جانبیة نادرة (قد تؤثر على ما 􀇽صل إلى ١ من 􀘗ل ١٠٠٠ شخص)</strong><br />&bull; اضط ا ر 􀇼ات في الجهاز اللیمفاوي 􀇼سبب عدوى فیروسیة (الاضط ا رب التكاثري اللمفاوي المرتبط بفیروس<br />إیبشتاین - 􀇼ار EBV (<br />&bull; غیبو 􀈃 ة<br />&bull; التشنجّا ت<br />&bull; الهیجا ن<br />&bull; العمى<br />&bull; التهاب أو تلف أعصاب العینین (التهاب العصب البصري، اعتلال الأعصاب البصري)<br />&bull; فشل القل ب<br />&bull; عدم انتظام ضر􀈃ات القلب (اضط ا رب نظم القلب )<br />&bull; سرطان الجل د<br />&bull; ردود فعل على الجلد و / أو الغشاء المخاطي تظهر على شكل احم ا رر، التهاب، تقرحات وتقشّر الأنسجة<br />(متلازمة لایل، متلازمة ستیفنز جونسون )<br />أع ا رض جانبیة ذات التك ا رر غیر المعروف (لا 􀇽مكن تقدیر التردد من البیانات المتاحة)<br />&bull; نز􀈄ف في الدماغ<br />&bull; الاضط ا ر 􀇼ات العصبیة التي تتجلى في الصداع، والغثیان والقيء، والتشّنجّا ت ، والاضط ا ر 􀇼ات البصر􀈄ة 􀇼ما<br />في ذلك فقدان البصر، والتغی ا رت في الحالة العقلیة (التفكیر غیر الطبیعي، والارتباك، والتغیّر في الوعي)،<br />و أحیانًا تحدث الاضط ا ر 􀇼ات العصبیة العضلیة التي تتجلى 􀇼ضعف العضلات في أط ا رفك ( 􀇼ما في ذلك شلل</p><p>جزئي أو 􀘗لي غیر قابل للعكس) (أع ا رض اعتلال بیضاء الدماغ &quot;<br />LE &quot;، اعتلال بیضاء الدماغ السميّ<br />الحدا &quot; ATL &quot; أو متلازمة اعتلال بیضاء الدماغ الخلف ي القابل للعكس &quot; . (&quot;RPLS<br />&bull; نز􀈄ف في الرئتی ن<br />&bull; التهاب المثانة، والذي 􀇽مكن أن 􀇽سبب الألم عند التبوّ ل، و 􀈄مكن أن یؤدي إلى ظهور دم في البول (التها ب<br />المثانة النزفي) .<br /><strong>للإبلاغ عن الأع ا رض الجانبی ة<br />&bull; المملكة العر􀈁یة السعود 􀇻 ة</strong><br />- المر 􀘗ز الوطني للتیقظ والسلامة الدوائیة<br />o فاكس: ٧٦٦٢ - ٢٠٥ - ١١ - ٩٦٦ +<br />o للاتصال 􀇼المر 􀘗ز الوطني للتیقظ والسلامة الدوائیة هاتف: ٨٢٢٢ - ٢٠٣ - ١١ - ٩٦٦ +<br />o تحو 􀈄لة: ٢٣١٧ - ٢٣٥٦ - ٢٣٥٣ - ٢٣٥٤ - ٢٣٣٤ - ٢٣٤٠<br />o مر 􀘗ز الاتصال المُوحّ د: ١٩٩٩٩<br />o البر􀈄د الإلكتروني: npc.drug@sfda.gov.sa<br />o الموقع الإلكتروني: www.sfda.gov.sa/npc<br />o سانوفي للتیقظ: KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحُفظ هذا الدواء 􀇼عیدا عن م أ رى ومتناول الأطفال.<br />لا تستخدم هذا الدواء 􀇼عد تار􀈄خ انتهاء الصلاحیة المذ 􀘗ور في ملصق القارورة ورقاقة البثرة 􀇼ع د 􀘗لمة .&quot;EXP<br />􀇽شیر تار􀈄خ انتهاء الصلاحیة إلى الیوم الأخیر من ذلك الشهر.<br />فلودا ا ر الفموي هو دواء سام للخلا 􀇽ا. 􀇽جب حفظه دائمًا في القارورة الأصلیة المقاومة للأطفال.<br />هذا ال دواء لا یتطلب أي شروط خاصة لدرجة الح ا ررة. احفظ القارورة داخل العلبة الأصلیة للحما 􀇽ة من<br />الرطو 􀈃ة.<br />لا تتخلص من أي أدو 􀈄ة عن طر􀈄ق میاه الصرف الصحي أو النفا 􀇽ات المنزلیة. اسأل الصیدلي عن 􀘗یفیة<br />التخلص من الأدو 􀈄ة التي لم تعد تستخدمها. هذه التدابیر سوف تساعد على حما 􀇽ة البیئة .<br />أعد أي أق ا رص غیر مستخدمة أو مُتبقیة إلى طبیبك أو الصیدلي. سیحرصا ن على التخلص من فلودا ا ر<br />الفموي وفقًا للمتطلبات المحلیة للأدو 􀈄ة السامة للخلا 􀇽ا .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتو 􀈂ات العبو ة</strong><br />- المادة الفعالة هي فلودا ا ربین فوسفات. 􀇽حتوي 􀘗ل قرص مغلف 􀇼غشاء رقیق من أق ا رص فلودا ا ر الفمو 􀈄ة<br />على ١٠ مجم من فلودا ا ربین فوسفات.<br />- المكونات الأخرى هي :<br />- لب القر ص: السلیلوز (دقیق التبلور)، اللاكتوز (أحادي الهید ا رت)، السیلیكا (اللامائیة الغرو 􀈄ة)، الصودیو م<br />􀘗روسكارمیلوز، ستی ا رت المغنیسیوم ؛<br />- طبقة الغشاء الرقیق: هی برومیلوز، التالك، ثاني أكسید التیتانیوم ( E171 )، صبغة أكسید الحدید 􀇽ك (أصفر<br />E172) ))، صبغة أكسید الحدید 􀇽ك (أحمر ( (E172 .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">فلودا ا ر الفموي عبارة عن أق ا ر ص على شكل 􀘗بسولا ت مغلفة 􀇼غشاء رقیق لونها برتقالي وردي، تحمل في أحد<br />جانبیها العلامة &quot; LN &quot; داخل شكل سداسي منتظم .<br />یتم توفیر الأق ا رص في ش ا رئط من البثور 􀇽حتوي 􀘗ل شر􀈄ط على ٥ أق ا رص. شر􀈄ط البثور مكوّن من رقائق<br />البولي أمید / الألومنیوم / بولي برو 􀈃یلین مُشكّلة 􀇼الح ا ررة والضغط مع رقائق ا لأغطیة المكونة من الألومنیوم.<br />ش ا رئط البثور مُ عبأة في قارورة أق ا رص مكونة من البولي ایثیلین مع غطاء حلزوني مكوّن من البولي برو 􀈃لین<br />مقاوم للطفل .<br />یتوفر فلودا ا ر الفموي في عبوات تحتوي على:<br />&bull; ١٥ قرص في ٣ شرائط ثب ر􀈄ة في قارورة مقاومة للطفل.<br />&bull; ٢٠ قرص في ٤ شرائط ثب ر􀈄ة في قارورة مقاومة للأطفال.<br />قد لا یتم تسو 􀈄ق جمیع أحجام العبوا ت</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشر 􀘕ة المصنع ة</strong><br />جین ا ز 􀇽م المحدودة.<br />٣٧ شارع هولاندز<br />هافرهیل، سوفولك<br />سي بي ٩ ٨ بّي یو، المملكة المتح دة</p><p>سانوفي و 􀈄نثروب إنداستري، ٣٠ - ٣٦ ،<br />شارع غوستاف إ 􀇽ف ل<br />٣٧١٠٠ تورز، فرنس ا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            October 2010
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fludara oral 10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10mg fludarabine phosphate.
Excipients: Lactose monohydrate 74.75 mg
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
Salmon-pink, capsule-shaped tablet marked with ‘LN’ in a regular hexagon on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of B-cell chronic lymphocytic leukaemia (CLL) in adult patients with sufficient bone marrow reserves.<br />First line treatment with Fludara oral should only be initiated in adult patients with advanced disease, Rai stages III/IV (Binet stage C) or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em><br />The recommended dose is 40 mg fludarabine phosphate/m&sup2; body surface given daily for 5 consecutive days every 28 days by oral route. This dose corresponds to 1.6 times the recommended intravenous dose of fludarabine phosphate (25 mg/m2 body surface per day).<br />The following table provides guidance for determining the number of tablets of Fludara oral to be administered:</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM2MwAAkpIAAgAAAAM2MwAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMjoyNjowNAAyMDIxOjA2OjI3IDEyOjI2OjA0AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTI6MjY6MDQuNjI1PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAPkC7gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiio2uYFuo7VpoxcSI0iRFxvZVKhmA6kAuoJ7bh6igCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKjubmCztZbq8mjgt4UMkssrhUjUDJZieAABkk1JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVHc3MFnay3V5NHBbwoZJZZXCpGoGSzE8AADJJqSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACio5bmCCSGOeaON7hzHCruAZG2ltqg9TtVjgdlJ7VJQAVxviPRdK174k6Ba65plnqVumk6jIsV5brMisJrIBgGBGcEjPua7Kubvv+Sp6F/wBgXUv/AEfY0AZHifwx4E8LeHbrWbj4f6Ve29ohkmS00u13qgGWbD7QQAOgOfQGufsLv4bXN9osGofDa10iPXUDadc3ukWRinJAKruiZ9rEHIDAV1fxYvbWx+E/iNr25htxLp80MZlcLvdkIVRnqSegrymwvbT7d8Of7A1d/Gl9biFJNOZ4pE0uIxqGlHkquxl6Zl3Hj15pw1lbzX43/wCB+op6Rv5P8LHsX/CuPBH/AEJvh/8A8FcH/wATWH4v0DwB4N8N3Gt33gDS7y1tsGZbTSrUuinjdh9oIzjoSeeledatLdacuuvcOqeNP+EsjGnO7f6Q1o8kewIfvGEqGBA+Xg55FHjCJLux+JsOuwmbxGZkTS49jNMbM7AghA+bYTndt+XPWp+zdf1s/wBfwZaS5+V/1q1+n4o9btfAPgW8s4bmLwZoISaNZFDaVBkAjIz8vvT5vh94Et4JJpvCHh5I41Lux0uDCgDJP3a4TWtA/s7xF4M8caJoouLm6ij0zUIZbba5WWLakjBwCpUjaTwdpx04r0uPTdO8N+EZLKxsI1sbS2f/AEWCMKHGCWAA4y3P4mqmrJtef9fdb7yIa2T6pf199zj9M0v4famtpMnw7sYbO/KCyvJdGtjHchhuDDblkGB/y0CZ6DJ4ro/+FceCP+hN8P8A/grg/wDia830nTz4R8VaRafD3xHPqGm3V0i3vha/JklsIW5MoVvnhC9cMBzjkniuI8Vppul+GfGumzx29tcw+MIrmC3ZArRRMVxIB/CpGRu4HOKas2l/W6X63+QPRN/1s3+h7/8A8K48Ef8AQm+H/wDwVwf/ABNczqll8OdO8TpoEPw+sdSvgkclwtjolvILaOR9iu+QDjPXaGwBk4FYcVn4d139o3XdNuPslzBfeHolngRwPPfcCc45LBNpznIGD2FR203hq0/aE8VSR/YxPDoasv2QIbgTAMZdmOfN29cc+tTtyt+b+6/+QXvdLyX32/zPRv8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrxrwJeBPiLolzoANumq+G53QSEb7qVXbYZ3AVZZuhJxkZ79Tt+Cktrr4Z6hf6VEyfEW2sLqC8wzC6NwdxBlXPzZwNjODjopHSiWib7X/Nr9PxQ1q0l1t+KT/X8D0r/hXHgj/oTfD/8A4K4P/iaq6l4J+H+k6XdahfeEfD8dtaxNNK50uD5VUZP8PtXJfBWx32sGr2+vWM3m2CwX+mWlk0UiXSkFpLhjKxM3JBJClhz2rrfE+uRXWsQeGNLfSL7U5B59xpt9f+RviAOB8schJzg429FJyO7nFx0W/wDX/DhFp6vb+v8AhiDQPCfw78SeH7LWdM8IaC9pewrNEW0uDIBHQ4U4I6EeorR/4Vx4I/6E3w//AOCuD/4mvJfhr4i0vQNL8XfDrxRf6WF083D20f2tZoXhZWZ4g7AbihzkEA9eODR4ZsJJf2YI9Y8Kq0viK302e1Se2cmaNDNukjAXvtGQOo7deSVrOS20f33/ACtZhG/MoPe7X3W/Pc9a/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mvKfM0/SfhVquuxa6l/pd7FaAWPh+2+yJbzBhnezPKAWJAk3DkA5BJrofg6y2njLx1pUJhhtre8gkt7S3j8qGNWjJJjj6BSe44PXvT5dWu3/A/wAyebRPudr/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE10lFSUc3/wrjwR/0Jvh/wD8FcH/AMTR/wAK48Ef9Cb4f/8ABXB/8TXSUUAed+PvAPg+z+G3iW6s/CehwXEOk3UkUsWmwq8bCFiGUhcggjIIroP+FceCP+hN8P8A/grg/wDiaPiP/wAks8V/9gW8/wDRD10lAHN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNdJRQByd/4H+Hul6fPfaj4V8N21rboZJZpNMgCoo6knbXOWlt8PrvTJNWX4ZwR6MkRmTUX0O22Sp1ysQzNj3MYGBnpWn8afD2qeJ/hVqmnaEjS3ZMcohQ8zKjhig9yB074q94b8ceHtS0O0tbe8iN+tsiy6TwLqIhQCjQn5hgnGSMe+KI63B6WLK/DrwOyhh4N8P4Iz/wAguD/4muf0/Svh3qHjjU/CqeAtLhvtNgSeSSXSbXypEfGChGT37gdK84+Kmo2r614jubBbmO/0fUNPzdXOGkg3HB+zkANFFgDdliGJ6Dvqa1qdzL8V/iEnhi6STV38NRLaLDIPMLgAnb/tAHP5Ur6c3r+Ebhrfl9Pxdj1T/hXHgj/oTfD/AP4K4P8A4mo5/h74Igt5JR4J0KUohbYml2+5sDoMqBn6kVwMWleFda+B2t3Phiwimv7rRSt7BCGZvtMaZ/eR8gTB+ckbzgHJxWB4R1XRz8TvBtxDeWgH/CGCKWYOoBkQHKlu7KFOR1GD6VUla67f5Sf6fiEdYqX9bpfr+B6H4M0b4c+OPDMOuaV4H0iC2md0VLrSbdXBVipyFDDqPWtHVfB/w60WzF1qXhTw7DG0iRJu0yDLu7BVUfLySTXjvgjUtHn+FXg7S7wtdtc63cQmAsrWmSWbFyhB3DawZU4JOCCOtVoIob/4EeHTqsS3Mem+KliuPtMe4WsAlYFW3fcTBAIOB0FU171l3X42/wAxtWv8/wD2635HvH/CuPBH/Qm+H/8AwVwf/E1meI/CngTw34dvNYn8BaRdw2URmlitdLtfM2DliN+0HAyeueOMniuA8RafNffFW60WTVdP8O2D6bbjw7LcWBcRbfvfZcSRrHLk9ACSMDGKXxXGJvE3j+LxUvn3i6Eg8P8AmRncymFhKYF6hi5+bbzjrxWb+G68/wAP62KilzWfl+Nv8z0HQ/CPw/1/w9Y6xZ+C9Djtr63S4jWbSrcMqsMjdhSAcH1NP0nwf8O9bsBe6Z4U8Oz2xkeNZV0uAqxRyhIO3kZU80ngKAXPwb0W0u7SQEaUkEtvc27I2VTaVKMAeo9MHqOK8h8N2Edt8EfC8lnaxQRw67H/AMJKY4gjGFZpARcEDlVBXIbovXitZRSqSitk0vvdjNXcE/60Vz1/V/B3w60PSbjUtU8KeHbe1t0LySNpkHA9B8vJPQDuauL8OvA7KGHg3w/gjP8AyC4P/ia8V8WRrqHw6+IcWmQw3OgWGr2p0wQIHigUeX53l4yFQZ/h4GWrX+Jn9gS7tG0exyIvDNxd2cawqbKMA5V4Iwv+uzkh1Iwpzzms3pHm/r4eYpau3r+djstR0z4daZ460rwtc+AtLN3q0UktvcLpNqYfkBLAn7wOAP4ccjnrjov+FceCP+hN8P8A/grg/wDia8l0zW4Lrx98HZbzUY5bh9Fl815JgWLvCFGSTnLMCPcg12/xXbGqeEl1fZ/wjDakRq3nf6k/IfKEuePL39d3GcVco8tl5tfi0Sndv0v+Fx3hfSfh74qn1WC3+H+mWU+k3X2S5iu9Ktc78Z4KbgRg9c1q6r4I8EaVpNzff8IFpN79njMn2ez0eCSaXH8KLtGSfSvLft9lonh34kyz22rRWT61G1u1qjwiVSVUASOhXy9y4YYI29sEVjam9jaeCfixpVybOG2t57aSxtEjEUMbMAQYYz0yehHXr3rNv3b+Sf5X/Mr7VvO35nqUFh8OpvHUfhR/h/p0N/Lp41BZJdHthH5ecY/vBgeCCvY10v8AwrjwR/0Jvh//AMFcH/xNeV6TPout/GnQbG6ns7y1vfBaWzRM6sspJyUx3O0E464FdF8MfCo0y6vfDmqaPCbfwvqckum3rwrmQSqGQg4yWVWIJ9dvJxxo42dvX8JNf5EX0T9Pxin+Z2LfDnwQFJHgzQGIHQaXBz/47XPeENK+HnjGDUXs/AGmWT6bevY3EN5pNqGWVAC2Nm4Ec9c1H8TiD4y8GR66Iz4Ve6mGoC4x9nMvl/uBLnjbuzjPGce1ee2lvfx+E/FEdla30ViPGi3N3uglRZbEuAxyR8y/L8wzwBzxUx13/rVL9b+mpbVl/XZ/5HtH/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNeZWllF4gn8daToup2lj4aiurJ9OZIxLZCQRiSRCg+XyWwNwGF5JrK1e8uJtL8GpPZaNonhg3t3FfEQG50l5f+WUu0MgMTMWK5YKCc84ot+n4r+kJ6f1/X9XPYH+HXghUZh4L0BiBkKNLgyfblawvBukfDrxtob6ppvgTSbaNLiS2aO70m2Dh0OG+7uGM+9dP4O06fSfCFjY3Wrf2w8CFRe+UY/NXJ24BZuAMAHJyBmvCNCstnhPT7XTYvJ8Yf8ACTtPaKBtuUtWly8mPveQUzk/dP1oS/ecv9bpfqJv3Ob+tm/0Pb/+FceCP+hN8P8A/grg/wDiaP8AhXHgj/oTfD//AIK4P/ia8W8fajaP4qvtR08XMV5pnieyhlvLrmaIFcMsTAAx2/Tgkhi2eO/cT2UWl/GO3v0j0zW21S5Jj81duoaaRHsLxt1e34II4ALd80o6pPv/AJJ/qOWl/L/Nr9Dsf+FceCP+hN8P/wDgrg/+JrnvEWlfD3wzrGjWF98P9Mk/tm6FpBcQ6VamNJD0D5ww4ychT0rjPh1aaxqOr3V5ea9Z2vifT7y7F7p7WLfbLkMGEaySGXmEZUphNq4GDWPYLbPofw+uhaz3Gvw+IBJrxjgeW5WQF9xnCgtkZGN3O3pxTiruPy/Fim3FSt0v+B7Z/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNY/xfjv5PB9obLzDax6navqKx55tQ/wC8yB1Xpu7YznivK/GFzZyeC/ifb6a9mfDUEtj/AGWsJUwJMwRnEOPlGcg4X1J7mpvo32/4H+f4FqN2l3/r+vI9s/4Vx4I/6E3w/wD+CuD/AOJrlPElp4D8N+I9M0WT4YWt/c6ruFm9ppdhskZRllzI6kEDnkAc8E1i/Dy+02L433tnpF3bfZ7nw3aStHBKGEsoC/McH5m2kc9cGrXxY1TS4/if4Et7rxFFo0lvLdSzXCzwq9srRYVj5oZQGIIBZcHnHNU1Zpd/+Cv0Ig+ZPyX6XLunSfCu9stamvPBelaVNoPOo2l9o1uJYARlThAwYEdNpOa1NO8N+B728itbr4cWGnTThmhF1o9qVkRQMtuj3KOo+ViG/wBng1xnhOTTrq88e209hceIvDt40Kya6kbSTaiXwjICgw+zJx5SjG3pk1f8LNN4R8ZW+naN4vHiHwpHDM97HeyrLJomxSQWl/gB+7tbBHPHBIF0v2/TX/gDfW3f/hjpNR0P4ZaV4o0rQLzwpoCX+rCQ2yf2VBg7Bk5O3jPb1ra/4Vx4I/6E3w//AOCuD/4mvKPijeXmt+F4/HOiPobW2k6gl5YakuqnznVPl8ny/KAyTk7PMzk9M8V7H4V8T6b4v8OWusaPcxzwToCwRsmN8AlGHZhnoaErxv1X9IHo15lP/hXHgj/oTfD/AP4K4P8A4mj/AIVx4I/6E3w//wCCuD/4mukopAed+PvAPg+z+G3iW6s/CehwXEOk3UkUsWmwq8bCFiGUhcggjIIroP8AhXHgj/oTfD//AIK4P/iaPiP/AMks8V/9gW8/9EPXSUAcxL8O/BMcLungnQZWVSRGml2+5j6DKgZPuQK5HwzJ8MfE+s6lo0PgHTrDWNOyZNPvtItUkkAOCyFSysM8Z3Y/DmvU5JEijaSVlREBZmY4CgdSTXk2v+Gbbx3oNt4q+H2q2p8SaLczG0vLWZXWXEjEwOQcYIPGf73oaWz12/LzH08/60Om0Twb4M1jT/tUvw60vTDvZBDeaZab+DjP7suMZz3zxWj/AMK48Ef9Cb4f/wDBXB/8TXnHjiZ7rwp8OfEetWcdlPBrdtNeyyLtFkrklwzH7q7sA5PUDNcfez6K3w5+LsTPahBrXmW8RwpBLDYyr1GSDg9+ab0T8r/hy/5/gEVe3nb8b/5fie7/APCuPBH/AEJvh/8A8FcH/wATXPaxpfw60Txdonh678B6U1xrRkFtPHpNqYlKDLBs4YcY6KeteZX48K3fj6+je+tTYN4MS5liW7AiublV+VpQDiRwpDDdk9D2FS6XcRalpvwh1HVZVudPs7e7GoXMx3RQIFCfvWPCjOF+bjsarl9639faX6Ep3Xyb/BP9T2n/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia8X1H+27L4d3MlgXh8Kt4sLR+ZE0sCaZnqUUgm33c4BAK+xq947sdP0T4Y6P8Aatf07UoZPEkFxp9xawCCG2iZgzJDl3xGozyGwBx2pJXt6pffb/P8GN6fj+F/8vxPWv8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrW0zStP0uCf+yYEhjupWuX8skh3YDLfjgdPrXg+mS3Wnnw2m5E8av4reHUiT/pMlqWkJD/xGLYAVz8vAI6URV5KPp+iD7Ll/Wzf6HeRWXw5ufF0ugWPw+sbyS2mFvdXkGiW7QW0hQuFkONw4H3tpXJAznithvCHw6TXI9HPhTw6b+SBrkQjTICRGrKpY/LwMsAPXn0rlPhIfDx+JXxA/sj+zfO+3p5P2YR7vK2jdt2/w7+uOM+9PvNN0xP2nRc6lp9ufM0ASWskluGL3CzcshI5dV7jkD2pR15b9Vf8L/1/TF/N5O342O1Pw58EAH/ijPD59v7Lg/8Aia5/wdpfw68a2F7daf4D0q1+w3kllNHd6TahhImN2Nm4Ec9c15t4Y1G1k+JvgjVdJ+0W0GoXWpW9xLd4+1XG3O1biQABzkfKpyVAHJqva2LJ4X1m3sYTD4vl8WyXGjjbtufKaZA0qZ58oqH3MPlIHNXGN2r9f80vydwl7t12/wAn+qPUNH0v4daz4v1rw5D4D0uG90byzO02k2wjcSDKlCuSePUCtu98C/D/AE6xmvL7wp4ct7aBDJLLJpsAVFAySTtry+41C8/4WJ8XIvDlyG1k6Xb/AGVIHBlZkiw+wdSQTjjoSKrR6JFqPwW8RahYapp+qRXOjIJNLsNOZPs91H8zSSZkc+fydxIUnAPas2/c5vJP8/8AIuy5+Xz/AMv8z1mz8B+A76xgu7fwdoBiuI1lTOlQA7WGR/D71P8A8K48Ef8AQm+H/wDwVwf/ABNeaa9o+jL4F8OavpMWg3FnZ6eC2jX0Cra3xkC7jEwGFuCVIVgCSSR612vxRjivvgfrzXNpsH9ltKsEygmJgu4df4lOOfUVVS0VJroRTvLlv1Nb/hXHgj/oTfD/AP4K4P8A4mj/AIVx4I/6E3w//wCCuD/4mvLvDwVfF3hT/hBdn2r/AIRx/wC2xD13eSvkefn+Pf8Ad3c46cVX+Hdml34budV17XdPW4gsLuDX9LlsSlxIxyd927SncRt+VigGCQKJrlv5X/Btfp+KCL5redvxs/1/A9Z/4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJrkvgPp2l3Hwv8PatEsc2oW9tNatOr5ZFMu4xkDjspwen4nPqNOUeV2FGXNG5wmp+E/Dmg+LfB91oegaXptw+rSxtLZ2UcLspsLslSVAOMgHHsK7uub8Uf8jF4M/7DUn/AKb7yukqSgrm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xoA6Siuc8eeJZPCvhG41C2jWS7eSO2tUboZZHCKT7AnJ9hXDfFSG60K08HN/bOuu82sQ2t9JZ3lyj3MTBmkHlwEZJxwFXI6Chav52/r70H+Vz1yivHPDt/4gk8Q+M7LwrqN+1rFp4fS7LXppGukuSvDqk581Yiem/gmrvgHxhYahr9ro91ca5oniBNz3uka1PJJ9qOwgvEzkjaG5ATaMAnbwDTSv939fkJu39en+f5noR02+k8QNd3OpCXT1VGgsfs4BikAYFvMBywIb7pHBAINaleZfFLxVq/hbVNC1uymK6Hp2opDq6KT86yrjJ7YUEH/AHmX0re8da/L4W0u18T287SWUM8MV5BnKSQSOF3j0ZSwbI6gYPbAtUrd7f1943o/lc6+igHIBHQ0UgCiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/iP/wAks8V/9gW8/wDRD10lc38R/wDklniv/sC3n/oh66SgAooooAKKK5G61m41X4mJ4atZ5Le206yW/vWjOGmZ2KxxZ6hflZjjrwOmcnWwdLnXUVw3hXx/qfiaTUFXw9HAul6tLp1663+8IqLkyrmNd3OBt4POcnpUGjfFSLVU0S9l0z7NpWv3Ulpp1ybndIZFLgeZHtAQNsOCGbryBTs3+H47feEvdvc9Aoryw/GS6j0M6hP4ciVo/EX9gzRLqJO1uB5qnyhuGc8ED61Z174sXmi614qsF8OxXCeG7WK7km/tAp50b4PA8o4YA9OQcdRS/r8E/wAmh2f9etvzPSqK4bUPG8erahY+H9FsZLq41PSv7SnY3jWptrZsAEOgLeYSeACvT7wrjfAvxM/sD4R+G5tevftup6tdXMEM2q35jQbJHy0s77tqgADoTyABTs1e/wDWrX6CWquv60v+R7XRXn8XxUtNVsNBTQLJb3Udemmggt2uvLjTyc+a7SqrHaMcEKc5HSqvwZvb66tvFcGoXl7ciz8QXFvAt5dvcNDGoXCB3JJA+tNRbv8A11S/UOl/66/5HpVFeZaz8XLrR4vGZk8PwyP4VktwwGoEC5SbowPlfKQCOOe/PGTfl+Ieqv42Tw3p3h23uJ5tHXVYJpNSMalSQCjDyiVOcgEbs8cDJxP9fhf8h2f9fJfqjvqKwfCHi2z8YeEbbX7OOSCKZW3xSfeiZCVZT64IPPeud0X4qQ6quiXk2mfZdJ1+6ktNPuftO6QyKXA8yPaAgbYcEM3XkCnZ3sLZXZ6BRXFeH/HOqa/q2r2EHh6NX0jVRY3Lrf5HlkZ81cxjJAx8n6+ul4r8Wf8ACO3Gk6faWYvtU1i5NvaW7zeUnC7md32sVUD0UnkcUuiff9Q6tdv0/wCGOjorxnw141n8J2fje61htQv1stdSztLS4vnnKFwoVFkkJIXJzn07Z4rptV+JN/pll4hi/wCEfiuNY0CFLq5so78+XJbsCfMjkMeSQAcqUHPc8El1a/8AWyf6jtd2/rex3V5FNPYzxWlx9mneNljn2B/LYjhtp4ODzg1BpNjPY2IW+uVu7yTDXFwsXliV9oGQmTtGAOMmuGh+KV1c65aWEGjWjxX2jHU7W6/tF9krBFYwgeTnI3Dn0IOM/LSav8TtV0fxReaFN4btZLm00M6w7pqZ2YXho8mHPUMAcc8cDJw2nHf+rXv+T/qwl7239Xt/mv6uej0Vj+HtfXxL4PsddsINgvrVZ44ZXxtJH3SwB78Zx+Fee+F/inqx8AL4i8Q6dbSPqGqmysI7a6bLyNKyBGDIAiqAPmBYnk4B4os1Jx6/8GwLWPMtv+Bc9aornfDfiwa3q2raNe2qWeraO8a3UMU3nRkSLuRkcqpII9VBBB+tc5qfxM1XTNY8TaZJ4age60W1S8toxqTbr+FmxuUCE7SPTnnjp81J6b+o7M9ForyHx/4w1bVvgzqOtaan9mx/2da3kF7YanKJUlkdcx/KicBTyd3OR8tbem/EyO0m1LTdcsZIZNI0SLVWnSfzTPEUycjA2vntlgfWh6XT6f8AB/yFuk11/wCB/mj0OiuG0rx9/bN1p+m6pp39nNr2mvfac8N4ZC0YVSVYhVMcgDZ+UsOPvVxXgH4m/wBg/CbQJdfvvt2p6pe3MEM+q35jjAR2JaWdwxVQMDoTyABTs1e/9a2Baq6/rS/5Ht1FYnhPxRaeMPDMOsaaBskZ4yu8MA6MVIDDqMjgjqMGuF0740T3MOnXF/4cS2trvXm0OR47/wA1o5R0dV8tdyk9clSPQ0JNy5ev9L9RX0v/AF3/AEPVaK8y1n4uXWjxeMzJ4fhkfwrJbhgNQIFyk3RgfK+UgEcc9+eMnTvfiDqEHi6y0K00CKdr/SG1KCd7/YAVHMbDyyQP9oZ69PRdL/1tf8irO9v66L9Ud1RXl+gfGZtbk8Myy+Gp7Kw8QTvaw3El0rMsyg5wgX5o8jG4lTnPy1g+FvHep+F9P8aanqaXWr6VpniOS3ke4v3eW1gLKoEauG3AEj5dy8HjNOzvb+t0v1Furr+t/wDI9uorzjX/AIz6JoXiK601jbNFYCA3jzXghlPm42iGIqTMVBDNyuAe54rRHjrU7jxprnhvT/D8dzcaZbw3MLi/2i4SQ98x4RgM8ZOfUdaLNg9DtqK5HRddntfiDqXhG9lecR2ceoWUshy/lMxRo2P8W1hweuG56ZPXUulw62CiiigDm/iP/wAks8V/9gW8/wDRD10lc38R/wDklniv/sC3n/oh66SgAoornvF3ixfDEWnRRWn23UNUvFs7K2Mnlq8jZOWfB2qACSQCfagDoaK8k8IeIdU0nXviI93DquqDTbq38jTY7qS8aMtHlli3Enbk54A47cYrVsvihqGo2/ie3sfD0F1q/h1Y5JLWDUi0Vwjru+SUxA7gAflKDkYzR0v5X/L/ADBa/fY9Gorl/Cvi268VWGkaha2FoLG/sjczyx3rO1u+cCPaYxu5yCcrgq3HTMOqa3Pf/Eez8J2c0lvHFYtqV9JGcM679kcQPVQTkkjnC4702mpcv9ab/kJNNX/r+tTrqK8lsvinqunxeNNY8Q6fbNpuiaibKKO1umMm8FFVApQAhi2S5YY6beM10N18QLu2j1+wuNMtoNc0nTf7SSAXZkhmiIbBD7A2RtwRt6kYJ61L0jzeV/wv+RVnzcvnb8bfmdzRXnPh3xv4hPw70HU9R0eG7vdUVSs0d04t41Kb/MnfyiYQTkYCuAcDd6cx4o8f3HijwV4N8Q6PJfaPJceJIbO4hgu2AYbmDoSuA6kqMZH4Cr5Xzcvml97sJax5vL9G/wBD22isPxh4ptfB3hqfV7yKScIyRxQRnDSyOwVVGemSevauE0bV9ZtfjXrkWpJe7E8PpetpUF/Jdxeb5mD5IfaASABgKvOeOcmVq/v/AAVxPRfd+Lser0V51pfxQuNT1290OXQ1tdRTSTqdvGbxvu5x5c2Yg0MgOMja2PU9+LsPE99qVh8KtSsb/WLdNQ1GeG4iudTeYzoGbiVgFEnI4yvA4p2d18vxbX6A3ZX9fwVz3miuB0b4ga1q11rumv4ds7XWNIu4bf7E+qMfOWTpKHEHC7eRwc4OduK3/GPiuDwhoK389u11NNPHa21sjhTNNIcKu49B3JwcAHg9KXRPv+v/AA4+tjfrE8ZeH5vFXg7UtCt71LFr+EwNO8Bl2KfvYXcuTjOOePfpXnen+Kb3w18Q/HN54ge8Fnp2lQXr2C38l1FG5yW8nfjAJ4+6v0ArpIviU0DvDrGjNBcvpDaxaQ2lx9oM8KgEpyq4kGemCPRjSaTjr/W/+TGrqVl/W3+aOn8NaXdaJ4asNLvruK8ls4Vg8+KAwh1UYX5SzYOAM88n06VqV563xWgs/Aw8Tapb6eLa4nigsmsdT8+KV37PI0aeVt53ZBwAevSqt38RBqPgvUvFGizRGfw5OVvbe1uhc21ygCs4WQABgVOVfAII54yDcruTb+f9fNExSSSXyPTKKitLmO8s4bqA5imjWRD6gjI/nUtJqzswTTV0c34o/wCRi8Gf9hqT/wBN95XSVzfij/kYvBn/AGGpP/TfeV0lIYVzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY0AL488NSeK/CVxp9tIsV2kkdzau33RLG4dc+xIwfY1k+JPDWr+OU0C+t7+LQ30q7S9Nreac07+egI2lhKgKcnp16hq6LxXrv8AwjHhHVNb+zfavsFs8/keZs8zaM43YOPrg0y28S2cNvYR+ILzTNM1K9iMkdn9uDFh1OwsEZ8DqdoxQtPvv8/6X4A/zv8Ad/T/ABOct/hpPN4m1HxJrXiCWbWry0FlFPYWwto7WIMG+RGZyWyM5Yke1adx4RvdR16x1PV9Ttrl9KLvp2yxMbI7IU3St5h8wc52qIxn8MakXivw7Otm0OvaXIt85S0KXkZ+0MDghOfmIPYZqg3ibUX1zWdLtdJt5JdPtkuIZWvSI5NxI2SERkxthSQAHyCDxnFDdl6f8OFr/wBfIwtW+FNrr/hfULTW00G71293BtbOiASKD3x5u7cBwCHAGBxgYNa78Ea1deCdN8C6nqP9rwLNA1xqQtDbhLWJgwQ5dt8hKBeMcHJHHzdn4R1//hKfCOm659m+y/boFm8jzN/l57bsDP5Ctiq1g7en4C0av/WoAYAA6CiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Ef/klniv/ALAt5/6Ieukrm/iP/wAks8V/9gW8/wDRD10lABRRRQAVyVzo1xpfxLXxLawyXFtqFktheJGMtCyuWjlx1K/MynHTg9M462ijrcOljkPA3gm68Itrv23VYdSXWL+S/YJZmDy3f7y8yNkcDHTHPXPGXYfClbCbQrZNWV9G0HUJL6ysza/vAzbiFaXfghWckYQHGAfWvQ6Kd3p5W/Db7get79f1PK9S+DNzdW95aWPiRLa1m14a7Ekun+YyS90ZhKu5c9MBSPU1Z134UahrOseK71fEVtAviSyjs3jOmsxgVMAEHzhk4B7Dkj0wfS6KXS39bJfkkO7vf+t7/mcLafDmew1TRtVs9ZSPULHShpN1J9kyl1AMEEJv+RwRkHLD1BrNtPg3Hpfh7Q7PSfEFzHqGg3r3dleXNukirv8A9ZG0a7co3P8AFkE9e1emUU+Z3v8A1vf8yUrK39bW/I5TXfBs+s6poWspqcdvrWiyO0dx9mLQyLIu2RDHvBwR0+fIPc0/wb4KTwfNrMkep3N8dWvnvpVmRFWN2PO3aM9MDknoMAc11FFF2h7/ANf13PNfE/wjl1668VNZ6+LG38TR24uY3svNaN4cYKtvUbSByuM57jpXOztJa/tB2OlW2v2FtqcXhVbMTyQhkebzM7fK8wHJX5gu/PTqOvtlFJaen/Aa/Uq+j/rqn+hheEPClp4P8J22hWkj3EUIYvLKBuld2LMxA6ZJPHauZsPhSthNoVsmrK+jaDqEl9ZWZtf3gZtxCtLvwQrOSMIDjAPrXodFO7vcndWZyfg7wbeeF9a8Q313q0N+utXn2zy0szCYW6Yz5jbhjA6Dp71Y8WeET4iu9H1GzvRYano1ybi1neHzUORtdHTcpKkejA8Cukrk9L8cRXNxr82sJY6RpWj3xsfttxfgeY4CnLBkVUB3gD5iSaS6JdP0sv8AIO77/rf/AIJkv8JLS4s/EMN7rN5O+uXqX7Hy41W3mRtysgAzxgAgnkD3zWrovgmSz8Qa5rWt6hFqN5rNvDbSCG1MEccaIVICl3PJJPJrXPivw6FuGOvaXttolmnP2yPEUbfdduflU5GCeDmp7jXtItNITVbrVbGDTnAZbyS5RYWB6EOTtOe3NHS3y/T/AIAbu/8AXf8A4JyenfCuw07S/ClpHeyu/hu4aZJ2X5pwysCh54HK+vCAVF4g+G17rXjfUvEEOuW9sL3Rn0gW72DSeWjZJfd5q5OT6AY4966UeLdGu9DvNT0TUbPV47UYIsrpJQZP4UypIBJIH41l+O/HsHgzQbm7iWwvtRtYRcSaZJqAhmMWcFlG1icEjsB157USf83n+Ks/wHG9/d/qzv8AmaXgzw7L4U8GadoM96t8bGLyRcJB5W9QTj5dzYOPf8q5my+E0Nr4I/4RuXVnlit9R/tDT5/s4V7dxIZF3fMd/JIONuQcYB5rrZPE+kWVjY3GsalZaa18iNEl1dJGXZgDtXcRuPPapJPEmhxawmky6zp6alINyWTXSCZhjOQmdx4GenSqlfmbe/8ATJjblstv6X6mT4X8HyaH4g13XNQv477UNaeFpWhtjCkaxx7QqqXc9cnr39qmvvBtnfePbHxRLIRNaWMtmYdvEodgQSc9vm4x/FntVW58cxjxFoFrpcdhqela1NJbpqFrf7zHIiO7DYqFWHyYzvzk9OK6yk76N/1pb8h7XX9f1oefXvwrWT4TXXgfT9W+zQ3ErH7VJbeYUTzd4QLvHQBVzntnFNtfhdM3ie+1PWdYt722v9FXR7i0isWiygUDeHMrYJOTjHcDtk+h0Uu/n/lb8g/r8b/mkcFpXw2ubDV9JvbnWorr+w9Ml07Tl+xFCgYAB5D5h3sFUA4Cg+1ZGk/Bm40jw1otlB4jT+09Bv5Lywvxp+FAkOXjkjMh3A88hlPT059Uop3d7/1vf8w6W/ra35ENulwlqq3MySz4+aRY9q59lySB7Ek+9eVR/BXUY9KsrP8A4Si1P2XXzrgcaU3zSHnZjz+Fzn36enPrdFCdpcy3/wCDf80HS39bW/U818T/AAjm1658VGz18WMHiaO3FzG9l5rRvDjBVt6/KQOVxn/a7Vcm+HuryeK9M12PxDZpJYaQ2miE6YxVyy8yf64EfNg7eeBjPOa76il0t/W1vyY7v+vl/kjyrS/g7qOmWHhKzHia2li8MXkl1HnS2Bn3tkqT53HVuR6jjjm9L8I0ktdX046yx0nXdRbUNSt2tv3rsXDBI5AwCL8oByrE84IzXo9FO7vf+un+SFtt/W/+bOQtvA0ulePL7xFoOqLaRapFHHqFnLa+aHMY2o8bbxsYDjkMD6U7S/Bt7p/xL1fxVLq8U8OpW8dv9iFmVaIR/dPmeYc98/LzntiutopdvIDkdF0Oa7+IWpeLryF7cSWcenWUUow5iVi7SMP4dzEYB5wuT1wOuooo6WDrcKKKKAOb+I//ACSzxX/2Bbz/ANEPXSVzfxH/AOSWeK/+wLef+iHrpKACuc8YeEh4oj0yaC8NjqGk3i3tncGLzFVwCCrpldykEggEH3ro6KPMDzq/+FE13beKzD4ovbW78TGNp5IoUCRFMD5VGGwQNpG/oecnmp9M8MWXw71rxB4s1XWk+w6hDbJOjWmxYDGvlggqT8pz0xx3Nd9RQm1t6Acx4E8MWXhjRbmLTQ6wXl5NdRq7ZCI7kqqjsuDkAevrmodT0Sew+I9n4stIXuIpLFtOvooxl1XeHjkA/iwcggc4bPautop31T7f5W/IN0/P/O/5nn8nwotLmy8V6fealJJp/iK7+2+WsIWS2m4O4PkhgCoIG0d85qzb/DyWbVta1LXtWS8utW0pdLLWtp5AhiAbJAZ3ySWz+FdvRU20t8vwt+Wg7u9/n+N/zPP4vhpex6H4U01vEZaPw7Osm0WeI7pVGEDJv4ZeDuyRnJx0xkH4LXcXhDTNBtPE0appusnVop5tO3ljuJVGAlUcEnJGM+gr1eiqu73+f5f5IXS39df82YPjLwpB4z8LTaPeXD27OySx3EQ5ikRgysAevI6enesOT4c3dz4g1DXrnxNcx6pfaSdMd7O3WKNBjh1UlmBDHcPn698cV3VFTb+vlb8g/r9fzPNNH+Etzouq22pW3iGN7mDQTox8ywyrc7hLgSA5zyRk59RVTTPg5qOmaZ4Rso/E9u6eGLyS6iY6Wcz72ztb99xjLcj1Hpz6tRV8zvf+t2/zbE0mrP8ArS35HGaPp+h6/wCP5PGOjztM0do1hKy5VGkWRgcqcHeoDDnswxWn408Jw+MdBWwkuWtJ4LiO6tblU3+TNGcq23jI7EZGQeoroKKnol2/zv8AmPq33/yt+Rwknwxi1DWNc1HXdXnu313T1sLu3ghSKEKFADKDuYEHJGWPXnOKk0n4f3ll4jtdYvtcW5msNKOl2flWXl+Wu7PmNl2DPgAdAOpxzgdvRQtNv63/AM2D1/r0/wAkedan8I7XVbLVfMvorO+vryG9hnsLTyo7eaInY/lFmDMdx3HI3e1aXi3SNZ1rwY/hmaZby81VRb3F7BbmCGCLI3vgs3O3IC7iST2GcdnRR0t0DrfqRWltHZ2cNrAMRQxrGg9ABgfyqWiim3d3YkklZHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJSGFc3ff8lT0L/sC6l/6Psa6SuN8RxarN8SdAXQ7yzs7j+ydRLSXlo1whXzrLICrJGQc45yeh45yACT4rf8AJJPE/wD2DZv/AEGuZ8b28s/iv4byx6VfXsNncma4mt7GSdIFMYUFmVSB82Pyz2rpNW8OeK9c0i60vVNb8Pz2d3EYpov7DuF3qeCMreAj8DT9O0Lxjpenw2Vp4i0UwwrtTz9Iupnx7u96WP4k01o7+af3A9Vb1/Gx4jPoN2PCmuTW3hfWV1O78Yrdo66NcCRrUPvVvuZ2j5uPU+pr3uy8LaToo1C/0yO7SW9WSWUTXs8ilm5YiORyqk4HQA8YqP7D43/6GHw//wCCGf8A+TKr3+ieMtSsZbO58R6KIpl2uYdHuoXx7Ol6GH4EVMvg5V/WiX6D+3zP+tW/1IvhL/ySPw1/14pXY1x2keG/FWhaPbaXpWt+H4LO1jEcMX9iXDbVHbLXpJ/E1d+w+N/+hh8P/wDghn/+TKub5pNomKskjpKK5v7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kypGdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAHxH/wCSWeK/+wLef+iHrpK878fWfjFfht4la813Q5bcaTdGWOLRZkdl8lshWN0wUkdCQceh6V0H2Hxv/wBDD4f/APBDP/8AJlAHSUVzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQB0lFc39h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlAHSUVzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQB0lFc39h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlAHSUVzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQB0leNX8U1z8OfinbWtpcXlxcatdQxQW0DTO7tFEBhVBPU9e3WvQfsPjf/oYfD/8A4IZ//kysrTPBviXR9Sv77Ttc0WKbUZfOuQdKu3jdz1YRtfFVJwOVA6Cla979U1+Kf6Dva3k7/g/8zzyDS1fxv4bvLzwzqjW2n+EfIDtotwRDdBSQuPL+/jdj3IxyRWfYzf8ACI/Cb4f6l4jF1pl1omoTk2upWlxHExPmYEhWNmThhtYI3JxjqR7R9h8b/wDQw+H/APwQz/8AyZWVrPhTxtq8ltPH4x0vTru1LeTc2mhPuXcAGG2S5ZDkDHKnHbFW5PW3e/4t/qSorRPorfhb9DB+GA0zUvDNja6FqyaxaPqk+oXskMUiRW7bt6wgOAVw7IRkDcFY4rE8ReHtafSfiXo8ui3uoajrV2lzp80duWjmi+RUHmH5FKYPykg9wDXeaR4W8Y6QLh18UaNd3V06vc3VxoUvmTMFCgkLdKo4A4UAe1aX2Hxv/wBDD4f/APBDP/8AJlTKz27W/L/JFRbWvnf8/wDNnl/jjT9b1K01CytPCmowXEvhNI5LlI2la4kDDFv8pMYK/M3GXPQHsd3VdA1VNA8B+JdCtWi1zS1trS4huEaJnhlVY3SQHn5WIbBHGDXZ/YfG/wD0MPh//wAEM/8A8mVmt4X8av4g/tR/F+mMPKVBZNo0xt1ZScSBfteQ/wAxGc4PGRwMVfW/nf8AFv8AG9iOVW+VvwS/S5B4rtks/Gfw+giHypqFwM+p+yyZJ9yea72uGvPBniTUNfsdavNc0WS90/P2YnS7sRxkgqW8oX2wthiMlc4+grV+w+N/+hh8P/8Aghn/APkylfQrr8jpKK5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkykB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQB0lFc39h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZQAfEf8A5JZ4r/7At5/6Ieukrzvx9Z+MV+G3iVrzXdDltxpN0ZY4tFmR2XyWyFY3TBSR0JBx6HpXQfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXLzQ+MraMPceJ/DkSFgoaTQ5lBJOAObzqTxUn2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlAHSUVy6Q+MZZpIo/E/hx5IiBIi6HMShIyMj7ZxxzUn2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlAHSUVzf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUAHij/kYvBn/Yak/wDTfeV0lcJqdt4jh8W+D21zVdLvLf8AtaULHZ6ZJbuG+wXeCWaeQEYzxgdRzxg93QAVzd9/yVPQv+wLqX/o+xrpK43xHrelaD8SdAutc1Oz023fSdRjWW8uFhRmM1kQoLEDOATj2NAEnxJu7iDw7Z2ttJJCuo6paWU8kZIZYpJQHwR0yMrn/aqr4dhg0H4mar4e0e3jtdJ/sy3vUtYUCxwSmSRG2qPu7goJHcgnqTUus+L/AIea9pMun6h4v0FoZCpymrQqyMpDKyndwQQCD6iqOn6/4F06C+dPiNps2pXyhZdVl1OzNxhQQgAAEYC5OBsxySQSTTi7L+u23yeoPVf13vf5rQt/EDw3oNxo95fXmiafqGrXmyztJr21Sdo5JCI0C7gcKC27A9zTPE3g2eXTtKi0+z0rVNM0a3KLomo2+Y7ghQqsHyQrAAgZRh8x6cETXPjHwHeXWnz3PjjRZGsHMiA6rbgO5QruYA9QGOMYGT9Kr6l4q8G6lfCYfE2ytIDH5ctpbavaLHKOeSSC6nnqjKanpZf1/Wo763f9f1odJ4e1HTLnwhYajp0Men6a9osscRVYlgj25xgcKAPw4qbSPEOi6+kraFq9hqawkCQ2VykwQnpnaTjpWPbePvANnaxW1r4t8OxQQoEjjTU4AFUDAA+apf8AhY/gj/ocvD//AINIP/iqqTTbZK2OC1RvtfhPxp4vuFxrekahcLp9ww+e1SAqEjQ9lfBLAfe3nOeK7nxzm7+G+ob9Q/st5rdf3xDHDEjCYXk7j8mBz83Fc9eX3w2vdTuLl/HWlJbXkyXF5p6avbfZ7qVNu13By38K5CsAdoyDVzV/EXw/16wv7HV/Hmk3FneFCsP9q2yfZimCDGy4YHcA2WLcjjA4pfYS9P0v9/8Aw5X27+b/AOB9xz0Nrp8GneL7O1Y+CT/ZUSPYJFsWBvnzcqI/lbcSFyhLHbzhuBseAbexsfFlza22ljw5OumxeZpMcXlpO247rkbfkbsuc7/7wHFQG5+G93Z30Ou+P9O1qS+thayXF5rFqsixA7gq+VsVcNzkDJOMk4FXNG17wHpV/wDb7r4i6dq96sH2eO4v9WtN0UWQSiiMIOSASSCxwMniqT1u/wCt/wCvy6Eu9rf10/y/z6noNFc3/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVSM6Siub/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqAOkorm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqgDpKK5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKoA6Siub/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqAOkorm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqgA+I//JLPFf8A2Bbz/wBEPXSV534+8feD7z4beJbWz8WaHPcTaTdRxRRalCzyMYWAVQGySScACug/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6SmyIJI2RtwDAg7WKn8CORXO/8LH8Ef8AQ5eH/wDwaQf/ABVRzfEPwVLBJGnjfQoWZSBJHqduWQ+o3EjI9wR7UAc3pUljovxUvoLbw9daA8mmytAipH5OqFHBaVvLY/OMrgthiHOfSsvSMWXhbwV4shGdb1nUIBf3H/LS6WfduRz1KoDlV/h2DGK6PTfEvgazvUvb/wCImmavexxtFFcXup2YaNGILKqxBFGdoycZ461T0+++G2nahBOnjrS5ra0meeysJdXtjBaSPncyYw38TYDMwGTgCnHS1+lvzba+f9aCeqduv+Vvw/rU7XVvENloskaXkOpSGQEqbPS7m6Ax6mKNgv0OKNJ8Q2etSSJZw6lGYwC32zTLm1Bz6GWNQ30Gaz/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqQzmvHkenaX4o0XUJtAu4c6hAZ/EduI2aLL4WEnd5mxmIUjG0BuMnpN430j7Hq03inXdL0nxFo9rFGptLq0BmsIwcvLGWLK5yckbVJCgA8cvm8ReCL2+aXVPiTp9/aecsyafNqdksMbK25cbFV2AIBwzMOBnNFx4h8D3moTS33xKsbmylcOdMk1a0FuCMEcgCQjI+6XKnJyKcdLet/wAgerZ36kFQV6EcUtc3/wALH8D/APQ5eH//AAaQf/FUf8LH8Ef9Dl4f/wDBpB/8VSA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAD4j/APJLPFf/AGBbz/0Q9dJXnfj7x94PvPht4ltbPxZoc9xNpN1HFFFqULPIxhYBVAbJJJwAK6D/AIWP4I/6HLw//wCDSD/4qgDpKK5v/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgDpKK5v/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgDpKK5v/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgDcv7aK7sZYbmFriJl+aFWx5mOdvUAg9ME4PQ8Vw3w0ltIda8S6db6Pc+HpYriKX+x5ERYoI2TCvH5bMnzlWJ2nGR+J09R8eeDr2xeC2+IOj6dI2MXFtqVozpz2Em9eenKmq+leLPAWlyTTt460a9vbgKJ7y51W28yQKMKMIVUAZPCqBkk45oWjYPYmhf8Atj4sXsF2qvBodjBJbRtziaYvukx6hUCg9tzetY19Hp2j/FzRcaBd6V9oeWL+2IhGV1KVoyRFKwYuQAGILjOVGMDkyXfi/wAIWnjBNf0vxb4emNzAtnfw/wBrQKzIrExyKS+MqWbIPUN1yADLbeIvBC38V3qnxJ07V3t5DLbLeanZKsDEFcqIlTJwSMtuIzxTXRhLW/8AXT/P/M5u6k8zwRrvjiRP+KgtNYlW2uCP3kUcVyIlgUnojKuCo4JYnrzXdePfEmqeGdDs73SLS0uHmv7e2lF1IyhFlkCZAUHJyw7jHXnocCW9+G02qS3LeOtK+yT3S3k2mjV7b7NJcKQRKR9/OVU4DBSRkjNT+Ldc8BeL9Ngsrn4iabYRw3EdyDZaraBmdGDJnzA3AYA8Y6c8ULaK9P0v+oPVt+v62+4g1bxr4o0xfFsf/EneXw5Cl7v+zS4uIXRmEe3zPlb5SN+SOnyel3W/GurRXUqaTFY26WejLq8v29Wb7Sp3ZiRlZdhG3lyGxuHy1hXsfgC/m1+S4+KkBOv26W14BqmngBF4AX93x8pZe/DHvgjndb8QfD9/Etraa343MkNjaww6feJHY6gsrAklyfIkWFhlRnbHnbkk44XS39bP/gev3j0/r1X/AATudQ1e5Nh4S8X/AGOKxvL67t7a5hhlMgkt7j5VRmZEJKlkbleCCBwTn0KvLIPF3h7Wp9HGv+MdBW20qb7Vuk1W1El1KAwi3KjbV2hgWxgFxwABz1//AAsfwR/0OXh//wAGkH/xVU7a27v7tP1uQr6X7L79f+AdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVSUdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSVwmp+LPDmveLfB9roev6XqVwmrSyNFZ3sczqosLsFiFJOMkDPuK7ugArm77/kqehf8AYF1L/wBH2NdJXN33/JU9C/7Aupf+j7GgDQ8Ra9b+HNGe/uUeU+YkMMMeN00rsERBnjliBnt1qtoXiGfUNSvNJ1eyjsNVs445pIYbgzxtG+drq5RCeVYEbRgjuME1PiBpV3qegWsunwvcT6dqNtfiBD80qxSBmUe+3OB3IFUNKZrnxnq/jGS0v4NOXTYbOBJbKZZ5dju7sICvmfxAAbcnnAxjLja2v9aafe9Ae2n9a6/hqT6543u9P17UNO0vSIr3+yrJb69ee98giNt2BEuxt7YRupQdBnniW48Y3NxqCWPhzSVv7pbGO/uI7m5+zeVFJnYo+RsyHaflOBxywrnPGMVzqHiK/XULLV0iewjGi3Wm2MkwaQ5MiTAKRgts+SYBMDPXOJ9XsdQNzY3tlDq0PjGXTI4bkafGEspPaWWSNowquWPyHzMdByKWtv68/wDgX7A9/wCvL/g2/wCAdvoGtW3iLQbPVrEOsF1GHVZFwyHoVI7EEEH6VoVieGPD7eGfBtlottcCSa1g2G4kQsHkOSzlcjILEnGR9ataRBrUKS/27f2F6xI8s2Vi9sFHfIaWTP6VUrczsJXsrlC58US23j2y8NvpUwjvLaWeO/aVNjeXt3KFBLZ+YcnHtmty5leG1llhge4kRCywxlQ0hA4UFiACenJAriteuynxe8NsLHUpIYLW6iluIdOnkhjaUx7AZFQqM7Tk5wMc4rrjqcAe8Xy7rNmoaX/RJcNld37s7f3hx2Tdzx14qfsp+v5ldTI8L+KJ/E3hQ6vHpUltP580H2J5lZg0crR8t0HK5OM47Z7yaBr1/qOp6jpmr6WljeWHlszW9ybiCRXBI2uUQ7hjlSoxkdQa574c6gth4FvW1Cw1a2MOoXcrxSaXcrKyS3DuhRNm58qwPyg474qbwNojab4i1e80qTVl0G9jikjh1VpjJ9py3mOBP+8A27B82Mke1VpzMl7ad/1O5oooqRhRRRQAUUUUAFFFFABRRRQAUUUUAc38R/8Aklniv/sC3n/oh66Sub+I/wDySzxX/wBgW8/9EPXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2RikbMqM5AJCrjLewzxTqZNKsEEkzhysaliI0LsQPRVBJPsBmgDB03xDqUvih9F1jR47R2tjdQT210bhGQMFw+UXY/PT5gcHDHFMsvFVxrWsy2/h7TVu7C0uDBd6jPceVGGHDrEArGRlPB+6ueN3BrC0XSPP8AH0uueHJdat7C8tJU1FNUW5jV5ty+UUjuMONuX+6AoBwPSub8PeFntYvDFhZ6Jdad4l0e9A1DUhaOsc1uCxkP2jAWVZM5CAkgtyBg0462v/Wv5JfhqJ7Nr+tPzv8A5HstFZeraTe6lJG1n4g1LSQgIZLOO2YSe582Fz+WKNJ0m902SRrzxBqWrBwAq3kdsoj9x5USH880hmZ4r8bW/hjUNIsRaSXlxqV7DbFUbasCyPt8xzg456D+Ig+hIS98WXD+LZPD3h+30u9vLaFJrpLvUzbtGGzgKqxSFjgZOcAZXnmuS8a+F/Fm6xmtNQsb4zeILW4Jj0aVpYlEnys7CfBjRcA4VeOcgkmt3xcsXiW0l0SHTr5tctnRrS+OnSxxW8oIPnJOw2YGclQ5YjIwacdUr9/wsvyv/XQlvp2/VncfWikUEKATk45NLSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/iP8A8ks8V/8AYFvP/RD10lc38R/+SWeK/wDsC3n/AKIeukoAKKKKACiiigAooooAQkKpLEAAZJPaua8K+NLfxZqut2tnaSRQ6XNHEk8h/wCPgOm4Oq44XHQ85BBrR8SaXe6xoz2WnXsFm8jL5jXFs06SJn5kKq6HB6HDDjNcl4E0nxFYfEDxdPrMlsbWaW32vDpslus5EKgNGWlYBVAKkfNz3HSiOrd/62B7HUX2tzf8JJbaHpccUlyYvtN3JKTtt4d2BwOSzHIUcDhiemDS1Lxtb2PjzSPDEVpJcTagZBLcBsJb7Yy4U8fMxA+7xgEE9RmrZxS2fxc1rzSsZ1PSrdrORhncYWkDrjvjzEOP9qubvfC/i2x8a+D2/tCwvo4bu5lnu4dGmXaWhO55T9oYZboD8oBxwQNtOO6/rv8AkEuv9dLnSz+PvKuLq6TTg+hWd6LC41H7R86y7ghKxbTmNWYKWLAgg4UgZrqrq9tbGES3tzDbRswQPNIEBYnAGT3J4Aryy40TUR4V1jwKlheNc3+qySxXnkOYDbSziVpDKBsDKCw2E7iQMDBrY+L9lFd+FtNiOk3Gpyxarayotvp8l00aJKpkbCK20bAw7ZzjnOKFtHzt+Nvy/rYHu/n+F7fedW3izw6tuZ21/SxCJ/sxkN5Ht83/AJ55z97/AGetWb/WtL0uW3j1PUrOzkun2QJcTrGZW/uqCRuPsK8k8Qq9zefEv7LoerN/aGlQw2bLo1x+/kEbIwQ+XzyU/AZ6AkLrlxO98FtdNurj+0/DcVldJeabeP8AZgWcbgkUEjBs7so4TdhcN1wul/62f+X4jtr/AF5f5/gem3mty6X4jtLPUUiFlqT+TZ3CEgrMFLeW4P8AeCsVI9MEdCdqvNLrT7FPCngfQfDxWTbqNtIhjt/IIWAl5pGjwChypDAgHc+Dya9Lqmkr+rX5f18iU27en+YUUUVIwooooAKKKKAOb8Uf8jF4M/7DUn/pvvK6Sub8Uf8AIxeDP+w1J/6b7yukoAK43xHFqs3xJ0BdDvLOzuP7J1EtJeWjXCFfOssgKskZBzjnJ6HjnI7Kubvv+Sp6F/2BdS/9H2NAB9h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZW7e2kV/Yz2lx5nlTIUfypWjbBGDhlIZT7gg1yvwoQR/DTTUBZgrzgF2LMcTv1J5J96BXLv2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJlZXj2ziPirwVfbphMusLDgTOEKmGVjlM7ScqOSM+9ZXxc8Vacvh/WfD/APwkFnplymnSTTK92kU8pKExxRqTk7iOSO3A5bIlu0b/ANdy1G8lHv8A5tfodV9h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlTeEdTsLnwHpV7bXtvNapYx7545VaNdqANlgcDBBB9MGrukeIdF19JW0LV7DU1hIEhsrlJghPTO0nHStJR5ZOPYzjLmipdzM+w+N/8AoYfD/wD4IZ//AJMo+w+N/wDoYfD/AP4IZ/8A5MrK1azih+Nnhy7RpvMuNOvFkVpnZPk8rbhCdqn5jyAM9812N/bRXdjLDcwtcRMvzQq2PMxzt6gEHpgnB6Hip+zf+ty7amH9h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlcJprWQ8PePdKiiuvBMiIH+xuiiOyjaMqskflMVO8q2QhHPA55Oz4Bt7Gx8WXNrbaWPDk66bF5mkxxeWk7bjuuRt+Ruy5zv/vAcU0rv+u1yXov68v8zovsPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SikM5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAPO/H1n4xX4beJWvNd0OW3Gk3Rlji0WZHZfJbIVjdMFJHQkHHoeldB9h8b/APQw+H//AAQz/wDyZR8R/wDklniv/sC3n/oh66SgDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6Squpaja6RpdzqOozLDa2sbSyyMeFUDJNGwbmL9h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlcDoXijS7742w6hJ4j0+8ku9DlVLe3vo5UgbzUKwptOC+1Sx7k57AYNA1Wa6udE8WeMtGhv4NdvVXT7prnzP7MLlvIVYCm1cjGZAxbceRgCqSvbz/zat87Cel/L/K5332Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmVoat4hstFkjS8h1KQyAlTZ6Xc3QGPUxRsF+hxRpPiGz1qSRLOHUozGAW+2aZc2oOfQyxqG+gzU7jM/7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kysDxXpH9m+In8T6/peleIdMEkESpPaD7Rpibsb4yxZX+dgxwEOPXAFHjfSPserTeKdd0vSfEWj2sUam0urQGawjBy8sZYsrnJyRtUkKADxyLW39f1+XmHc3/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5Mro1IKgr0I4paAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDzvx9Z+MV+G3iVrzXdDltxpN0ZY4tFmR2XyWyFY3TBSR0JBx6HpXQfYfG/wD0MPh//wAEM/8A8mUfEf8A5JZ4r/7At5/6IeukoA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkytfWbS7v9Fu7TTrwWN1PE0cVyYvM8okY3bcjOPqK5XwLZ2eh6rqGgnw/pel6lbQQyyXWmQBEvom3BXPG4MGV8qxbHXJzQtWD2uS6npHiedIJNU8Q+GgIJleGR9EnQpJnA2t9sBBOce+cd6vfYfG//Qw+H/8AwQz/APyZVSF/7Y+LF7BdqrwaFYwSW0bc4mmL7pMeoVAoPbc3rWW+kf2B46g1PxDpelawdU1Ax2+rLaBbqwYriKP5i2UwpXcpXk528k010Xf+vxB9fL/hzf8AsPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyvP7qTzPBGu+OJE/wCKgtNYlW2uCP3kUcVyIlgUnojKuCo4JYnrzXdePfEmqeGdDs73SLS0uHmv7e2lF1IyhFlkCZAUHJyw7jHXnoRLRedvxt/mD0b8r/huTfYfG/8A0MPh/wD8EM//AMmVg3fgnxxLrkmqWHjyz0yWcILmK20NnjnC8DKy3D7eOMptPNQat418UaYvi2P/AIk7y+HIUvd/2aXFxC6Mwj2+Z8rfKRvyR0+T0u63411aK6lTSYrG3Sz0ZdXl+3qzfaVO7MSMrLsI28uQ2Nw+Wlolf+tr/ox2e39dP8195Jpnh3xDY3k5sNf8OG7VVjmY6NPJIo+9gk3pIzncfUknknNan2Hxv/0MPh//AMEM/wD8mVg6hq9ybDwl4v8AscVjeX13b21zDDKZBJb3HyqjMyISVLI3K8EEDgnPoVU01v0dv6+8lNPbtf8Ar7jm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TK6SipGc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZXSUUAc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZXSUUAcJqdt4jh8W+D21zVdLvLf+1pQsdnpklu4b7Bd4JZp5ARjPGB1HPGD3dc34o/5GLwZ/wBhqT/033ldJQAVxviPW9K0H4k6Bda5qdnptu+k6jGst5cLCjMZrIhQWIGcAnHsa7Kubvv+Sp6F/wBgXUv/AEfY0AQ3XxB8F3FpLDF460S1eRCqzxanbF4yf4huJXI9wR7VieHta8D+GvDMmi2PxNspIyXMNzPqdi0sBYknbhQp5JPzK3X04rvr2eW2sZpre1ku5Y0LJbxMqtKQOFBYhQT7kCszwj4hPinwva6wbNrI3BcG3dw7JtdlwSOM/L2/XrR3Dscl4h1jwP4iuNLml+J1lZPpcwnh+y6nY/PKFK723o2ThmGBgc9Olaus+MfAOuaDfaTeeNdDWC9t3t5Hj1W3DhWUqSCWIzz6VoeKPEOp+HraS+g0VL3T7cA3D/a9kxBIH7qMIQ556FkJPTNM1TxRdx67Jo+gaXHqN5bWqXd0s119nEcbFgoX5G3OdrYBCjjlhSdmrPYabTuun9fmQWHjvwJp+nW1lD4z0Fo7aJYkL6rASQoAGfm68VY/4WP4I/6HLw//AODSD/4qtTQNatvEWg2erWIdYLqMOqyLhkPQqR2IIIP0rQqpXu7kxsloedajrXgbUfF9h4hPxMsbeawRo4raHU7LySrY3g7lLHdtGfmyMcYq/deNPCdwt2Ifidp1qbgoY2h1GxJtsdQm9Wzu7793tita58US23j2y8NvpUwjvLaWeO/aVNjeXt3KFBLZ+YcnHtmtjUNQtdK024v9QmWC1tozLLK54RQMk0to+RWtzgpdU+Gt5pOoWWreNtH1JtSiWK7urjV7dZZAo+XBQqq4PI2gDJJ6mpNG17wHpV/9vuviLp2r3qwfZ47i/wBWtN0UWQSiiMIOSASSCxwMniuh0jXtW1e1e+TQGtrGSLfaefdBbibJ4LRbcRqRzkuW9VzxTtA16/1HU9R0zV9LSxvLDy2Zre5NxBIrgkbXKIdwxypUYyOoNPVMnRoh/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukopDOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA878fePvB958NvEtrZ+LNDnuJtJuo4ootShZ5GMLAKoDZJJOABXQf8LH8Ef8AQ5eH/wDwaQf/ABVHxH/5JZ4r/wCwLef+iHrpKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKRmVFLOQqqMkk8AUAcO/ib4eyeLY/ELeNdF+1x2TWQj/tW38sozhycZznKjvjHasywuvhtp13AYvH2mvYWtwbm00uTV7U29tKcncuMPwWJCsxUZ4AwMdL4W8VXXitmvbC20x9ELusV1DqRlmbaxALRCLaucZx5hIGOM8U+y8VXGtazLb+HtNW7sLS4MF3qM9x5UYYcOsQCsZGU8H7q543cGmr6L+t/wDNg+t/6/pB/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVdJRSA8/fxD4HuNQkmv8A4k2F7aNMJk0+bVrTyI2BBGNoDkAjO1mI9qLjxD4HvNQmlvviVY3NlK4c6ZJq1oLcEYI5AEhGR90uVOTkVuX/AIqnbXptE8N6auqahbIr3RluPIt7YN90PJtY7iMkKqscDnGRUV54tuX8WSeHtAt9LvL22hSa7S71M27R7s4CqsTljgZOQoGV9aF0t/X9dwfW5L/wsfwP/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0n1ooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvx94+8H3nw28S2tn4s0Oe4m0m6jiii1KFnkYwsAqgNkkk4AFdB/wsfwR/0OXh/wD8GkH/AMVR8R/+SWeK/wDsC3n/AKIeukoA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5DUvHXgvULCS2h+IGkWDtjbcWuq23mJg543ll/MGodK8XeA9MaWZ/Hej3t5OFE13darbGSQL90YUqqgZPCqBkk4yTXW6hqFrpWm3F/qEywWttGZZZXPCKBkmsvw/rWpa4PtcujHT9Mlj320lxcf6RJk8FoQuEBHIy+7nBUULyBnLXfi/whaeME1/TPFvh6Y3MC2d/D/a8CsyKxKSKS+MqWYEcZDdcgAy2XiHwPBeR3GofEmw1YwSGS2jvdWtNtuxBGR5YUtgEgF9xHY1019rc3/CSW2h6XHFJcmL7TdySk7beHdgcDksxyFHA4Ynpg1YvFVxquuT2HhvTVvoLK4EF9fT3Hkwxt/EkeFYyOoxkYC5ONwOaa6W/rX/ADB+f9f0vwOalvfhtNqkty3jrSvsk90t5Npo1e2+zSXCkESkffzlVOAwUkZIzU/i3XPAXi/TYLK5+Imm2EcNxHcg2Wq2gZnRgyZ8wNwGAPGOnPFaU/j7yri6uk04PoVneiwuNR+0fOsu4ISsW05jVmCliwIIOFIGa6q6vbWxhEt7cw20bMEDzSBAWJwBk9yeAKS2Vv62t+gPd/1/XmeWXsfgC/m1+S4+KkBOv26W14BqmngBF4AX93x8pZe/DHvgjndb8QfD9/Etraa343MkNjaww6feJHY6gsrAklyfIkWFhlRnbHnbkk449lbxZ4dW3M7a/pYhE/2YyG8j2+b/AM885+9/s9as3+taXpctvHqepWdnJdPsgS4nWMyt/dUEjcfYUdv6/rcP6/r7jzmDxd4e1qfRxr/jHQVttKm+1bpNVtRJdSgMItyo21doYFsYBccAAc9f/wALH8Ef9Dl4f/8ABpB/8VVq81uXS/EdpZ6ikQstSfybO4QkFZgpby3B/vBWKkemCOhO1T6B1Ob/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SikBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHCan4s8Oa94t8H2uh6/pepXCatLI0VnexzOqiwuwWIUk4yQM+4ru65vxR/yMXgz/sNSf+m+8rpKACubvv8Akqehf9gXUv8A0fY10lcb4ji1Wb4k6Auh3lnZ3H9k6iWkvLRrhCvnWWQFWSMg5xzk9DxzkAHW3dwlpZy3EqyskSF2EUTSOQB2RQWY+wBJri/hpe/YvhtGb6x1O1ks3nM0M+nTpLgys42xlNz5DD7oPp14rV+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKAMT4g2tr4mszp9iPEEWtwR+dp0trDdwwpNgFGd8CE4OM7zkcgYPFJ4l0+4TWobvRRrH/CUPYpbySWcWy0nXJx50skbRgKxZsKfMAJwK3PsPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5Mo0tb+v67h/X9foWfDHh9vDPg2y0W2uBJNawbDcSIWDyHJZyuRkFiTjI+tWtIg1qFJf7dv7C9YkeWbKxe2CjvkNLJn9KzPsPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5Mpt3bYkrKxla9dlPi94bYWOpSQwWt1FLcQ6dPJDG0pj2AyKhUZ2nJzgY5xVj4hWc3iXwfqmk6ZbT3FxbyQSS27wvEtyiyLI0aOwCvuVSOCQCcHFXfsPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKXReX+dyr63Oc0GCz0/xZqOv6NpWo6VoMmnqt3bLpc8Tz3RfO9YAm8sFyC4XnI5ODi94G0RtN8RaveaVJqy6DexxSRw6q0xk+05bzHAn/eAbdg+bGSPatX7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TKd7f1/XyJt/X9fidJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUhnSUVzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJlAHSUVzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJlAHSUVzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJlAHSUVzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJlAHSUVzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJlAB8R/wDklniv/sC3n/oh66SvO/H1n4xX4beJWvNd0OW3Gk3Rlji0WZHZfJbIVjdMFJHQkHHoeldB9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lMnl8i3klKO4jUttjXczYHQDufaue+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKAM20todd8ZW2v6HY3mnAWk0N9PdWUlo1xux5aFJFVmKnLbsYHIB5Nch4e8LPaxeGLCz0S607xLo96BqGpC0dY5rcFjIftGAsqyZyEBJBbkDBr0H7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkymnZq39df1B6prv/AMMaGraTe6lJG1n4g1LSQgIZLOO2YSe582Fz+WKNJ0m902SRrzxBqWrBwAq3kdsoj9x5USH881n/AGHxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUtgPPta8KsR4nsJdEupfEV/qL3mi6vDau4j3BdjeeBiHZt2kMwyFGN2QK6zxYkXiSxk0OHTr9tctWRrW/bT5Ejt5Rt/fpOVCYGckBskZGD0rV+w+N/8AoYfD/wD4IZ//AJMo+w+N/wDoYfD/AP4IZ/8A5MprRJdv02/IHq2/X8dzo1BCgE5OOTS1zf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUgOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAOkorm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKAD4j/8ks8V/wDYFvP/AEQ9dJXnfj6z8Yr8NvErXmu6HLbjSboyxxaLMjsvktkKxumCkjoSDj0PSug+w+N/+hh8P/8Aghn/APkygDpKK5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TKAOkorm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MoA6Siub+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkygCL4kaNd694FvLLT4PtMvmQytbBtv2hElV3jz0yyqRzxzWV4R0yAeO7zV/DumXWkaNPYqlzbz2T2gnut+d4icKdwXIL4w2RycVtfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZTWn9eVv68weqt/Xcp2Mb2Xxf1g3ACrqel2zWrn+LyWkEij6eYh/4FXEaZ4UltrXSNMt9GubTxXp2rebNq62jiOW388vI5uMbWV0J/d7idx5Xgmu11PSPE86QSap4h8NAQTK8Mj6JOhSTOBtb7YCCc498471e+w+N/+hh8P/8Aghn/APkyhOzT7f53/wCHB6prv/lY4q40TUR4V1jwKlheNc3+qySxXnkOYDbSziVpDKBsDKCw2E7iQMDBrY+L9lFd+FtNiOk3Gpyxarayotvp8l00aJKpkbCK20bAw7ZzjnOK3fsPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MoTtbyt+Fv8AIHq353/E878Qq9zefEv7LoerN/aGlQw2bLo1x+/kEbIwQ+XzyU/AZ6AkLrlxO98FtdNurj+0/DcVldJeabeP9mBZxuCRQSMGzuyjhN2Fw3XHof2Hxv8A9DD4f/8ABDP/APJlYN34J8cS65Jqlh48s9MlnCC5ittDZ45wvAystw+3jjKbTzS3Vv62a/Ud7a/10/yK11p9inhTwPoPh4rJt1G2kQx2/kELAS80jR4BQ5UhgQDufB5Nel1w+meHfENjeTmw1/w4btVWOZjo08kij72CTekjOdx9SSeSc1qfYfG//Qw+H/8AwQz/APyZVOV7+bv+X+RCVrelv6+86Siub+w+N/8AoYfD/wD4IZ//AJMo+w+N/wDoYfD/AP4IZ/8A5MqSjpKK5v7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kygDpKK5v7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kygA8Uf8jF4M/7DUn/pvvK6SuE1O28Rw+LfB7a5qul3lv8A2tKFjs9Mkt3DfYLvBLNPICMZ4wOo54we7oAK5u+/5KnoX/YF1L/0fY10lcb4j1vStB+JOgXWuanZ6bbvpOoxrLeXCwozGayIUFiBnAJx7GgDq720iv7Ge0uPM8qZCj+VK0bYIwcMpDKfcEGuV+FCCP4aaagLMFecAuxZjid+pPJPvU918QfBdxaSwxeOtEtXkQqs8Wp2xeMn+IbiVyPcEe1Ynh7WvA/hrwzJotj8TbKSMlzDcz6nYtLAWJJ24UKeST8yt19OKF1E1qip4qutV1/xfq1nFpseqaL4fto2udNkvDbi8lkUsd2EbzAqYwjYUknJ4FZvjbxx4e1H4aTabousWOh28uifaktjPHbzFGiJigjjz3xg7ewwPvZG3qWqfD/UNSe/h+Iun6fc3EC215JaavaL9sjXOA+4HB5b5k2sMnBFX73xL8ObzwnP4dXxfoNtp81m1mFg1WAGOMptwuWIBA6ZBqWrwcf66/8AAt92xpFpTUv66f8AB/Pc2vCOp2Fz4D0q9tr23mtUsY988cqtGu1AGywOBggg+mDV3SPEOi6+kraFq9hqawkCQ2VykwQnpnaTjpWJYeO/Amn6dbWUPjPQWjtoliQvqsBJCgAZ+brxVj/hY/gj/ocvD/8A4NIP/iq1m05NmME4wSMrVrOKH42eHLtGm8y4068WRWmdk+TytuEJ2qfmPIAz3zWr8QoxN4B1WM6j/ZpeIBbjDHncMJheTuPy4HPzcVz2o614G1HxfYeIT8TLG3msEaOK2h1Oy8kq2N4O5Sx3bRn5sjHGKsav4i+H+vWF/Y6v480m4tLwoVh/tW2T7MVwQ0bLhgdwDZYtyOMDis94pf1ua3XNc56G10+DTvF9nasfBJ/sqJHsEi2LA3z5uVEfytuJC5Qljt5w3A2PANvY2Piy5tbbSx4cnXTYvM0mOLy0nbcd1yNvyN2XOd/94DioDc/De7s76HXfH+na1JfWwtZLi81i1WRYgdwVfK2KuG5yBknGScCrmja94D0q/wDt918RdO1e9WD7PHcX+rWm6KLIJRRGEHJAJJBY4GTxVp63f9b/ANfl0Id7W/rp/l/n1PQaK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqkZ0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAB8R/+SWeK/wDsC3n/AKIeukrzvx94+8H3nw28S2tn4s0Oe4m0m6jiii1KFnkYwsAqgNkkk4AFdB/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lU9Y1FNI0O+1KRS6WdvJOyjqQqlsfpWP/AMLH8Ef9Dl4f/wDBpB/8VTJfiF4EnheKbxf4eeORSro2pwEMDwQfmqZXadhxsmrnGeGbuaw1bQdU8caRDealrqPLZ6t9p842zmIyeSkRQCFdgIBRjux83JqvoGqzXVzonizxlo0N/Brt6q6fdNc+Z/Zhct5CrAU2rkYzIGLbjyMAVsaRffDnSLm0ceP9NvLfTwy6faXWr2rR2QIKnZjDH5TtBdmIHAxTbC6+G2nXcBi8faa9ha3BubTS5NXtTb20pydy4w/BYkKzFRngDAxrdc2m36X/AD8/+CTrytPf9f8ALy/4B3GreIbLRZI0vIdSkMgJU2el3N0Bj1MUbBfocUaT4hs9akkSzh1KMxgFvtmmXNqDn0MsahvoM1n/APCx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVUDMTxr4N8N30tpbyaFp1xqms36I95PapJMEX95Id5G4YjQqOeMqBUfjbRxY6rL4o1zS9J8Q6NaxRobS6tAZrCIHLyxFiyucnJG1ThQAeOdJ/GfgGXW4dUk8a6G00EDwxodVg2KGILNjdncdoGc9BVC48Q+B7zUJpb74lWNzZSuHOmSataC3BGCOQBIRkfdLlTk5FOOlv6/rQHrc79SCoK9COKWub/AOFj+B/+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqQHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAHxH/5JZ4r/AOwLef8Aoh66SvO/H3j7wfefDbxLa2fizQ57ibSbqOKKLUoWeRjCwCqA2SSTgAV0H/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQBtalplpq9i9lqUK3FrJjzIXGVkAOdrDuPUdD3rlPB3h/RrLxZr2paHpFjptvGU06MWdskKuUG6RvlAz8z7ef+edaB+I3ggj/kcvD4/7ikH/AMVVPSfGfgHR9MisrfxrocioWZpJdVty8jMSzMxDAZJJJ4HWhaO4PVWFif8Atn4r3tvdhWg0Oxgktozziacvukx6hUCg9tzetUNS8GeGh4z0G1sdB05LxZn1K5vBaIZ2WLoWlxuLNI6HJPO01Fd+L/CFn4wj1/TPFvh2Y3MC2d/AdWgUsisSkikvjKlmBHGQ3XIAOnD4z8Aw6zdan/wmuhvPcRxxHfqsG1ETJAX5uMliT1prSz7f1/wfwB63Xf8Ar/P8zjLqTzPBGu+OJE/4qC01iVba4I/eRRxXIiWBSeiMq4KjglievNd1498Sap4Z0OzvdItLS4ea/t7aUXUjKEWWQJkBQcnLDuMdeehwJb34bTapLct460r7JPdLeTaaNXtvs0lwpBEpH385VTgMFJGSM1P4t1zwF4v02CyufiJpthHDcR3INlqtoGZ0YMmfMDcBgDxjpzxQtor0/S/6g9W36/rb7iDVvGvijTF8Wx/8Sd5fDkKXu/7NLi4hdGYR7fM+VvlI35I6fJ6Xdb8a6tFdSppMVjbpZ6Mury/b1ZvtKndmJGVl2EbeXIbG4fLWFex+AL+bX5Lj4qQE6/bpbXgGqaeAEXgBf3fHyll78Me+COd1vxB8P38S2tprfjcyQ2NrDDp94kdjqCysCSXJ8iRYWGVGdseduSTjhdLf1s/+B6/ePT+vVf8ABO51DV7k2HhLxf8AY4rG8vru3trmGGUyCS3uPlVGZkQkqWRuV4IIHBOfQq8sg8XeHtan0ca/4x0FbbSpvtW6TVbUSXUoDCLcqNtXaGBbGAXHAAHPX/8ACx/BH/Q5eH//AAaQf/FVTtrbu/u0/W5Cvpfsvv1/4B0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFVJR0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQAeKP+Ri8Gf9hqT/033ldJXCan4s8Oa94t8H2uh6/pepXCatLI0VnexzOqiwuwWIUk4yQM+4ru6ACubvv+Sp6F/wBgXUv/AEfY10lc3ff8lT0L/sC6l/6PsaAN29nltrGaa3tZLuWNCyW8TKrSkDhQWIUE+5ArM8I+IT4p8L2usGzayNwXBt3cOybXZcEjjPy9v161q3dwlpZy3EqyskSF2EUTSOQB2RQWY+wBJri/hpe/YvhtGb6x1O1ks3nM0M+nTpLgys42xlNz5DD7oPp14oXUTvdFnXPG93p+vahp2l6RFe/2VZLfXrz3vkERtuwIl2NvbCN1KDoM88S3HjG5uNQSx8OaSt/dLYx39xHc3P2byopM7FHyNmQ7T8pwOOWFc54xiudQ8RX66hZaukT2EY0W602xkmDSHJkSYBSMFtnyTAJgZ65xPq9jqBubG9sodWh8Yy6ZHDcjT4wllJ7SyyRtGFVyx+Q+ZjoORRrb+vP/AIF+w3v/AF5f8G3/AADt9A1q28RaDZ6tYh1guow6rIuGQ9CpHYggg/StCsTwx4fbwz4NstFtrgSTWsGw3EiFg8hyWcrkZBYk4yPrVrSINahSX+3b+wvWJHlmysXtgo75DSyZ/SqlbmdhK9lcxde8X6joDpeXGhb9F+0payXK3JFwrPIIw4g2YKbiOd+7Bztrp7mV4bWWWGB7iRELLDGVDSEDhQWIAJ6ckCuN1jxBY3uuC01HTdbkttOnWSOKLRLuRbqdeVbeItmxTgglsFhk4ABPVDU4N14pjugbNQ0v+iS/Nld3yHbiQ47Ju5468VP2SvtGT4X8UT+JvCh1ePSpLafz5oPsTzKzBo5Wj5boOVycZx2z3k0DXr/UdT1HTNX0tLG8sPLZmt7k3EEiuCRtcoh3DHKlRjI6g1z3w51BbDwLetqFhq1sYdQu5Xik0u5WVkluHdCibNz5VgflBx3xU3gbRG03xFq95pUmrLoN7HFJHDqrTGT7TlvMcCf94Bt2D5sZI9qrTmZL207/AKnc0UUVIwooooAKKKKACiiigAooooAKKKKAOb+I/wDySzxX/wBgW8/9EPXSVzfxH/5JZ4r/AOwLef8Aoh66SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACo55Ght5JEiaVkUssa9XOOg+tSUUActbeIfESeJdO0rV9D0yBb1JZC9rq0k7xIgGWKNboCNzKv3urVLZeKrjWtZlt/D2mrd2FpcGC71Ge48qMMOHWIBWMjKeD91c8buDT7GzuL3xRrGpzpJCqRrYWfmIV+UDc8gz2ZmAz38sV534e8LPaxeGLCz0S607xLo96BqGpC0dY5rcFjIftGAsqyZyEBJBbkDBpxs2r/1d/otweibX9af56L/AIJ7LRWXq2k3upSRtZ+INS0kICGSzjtmEnufNhc/lijSdJvdNkka88QalqwcAKt5HbKI/ceVEh/PNIDnbz4gXMGpar9m0ZJ9N0e7js7yY3m243uFwY4dhDL868l1J5wDjm9e+Lbh/Fsnh7w/b6Xe3ltCk10l3qZt2jDZ2hUWKQscDJzgDK881x+vQavc69q7iw1KLX0vo20h4LNpLK5gUKUEz7TFwd5Jch1P3O2eh8YCDxNbz6LbaZfjWreRWs71rCRI7aQEETJcFQmBnkBskAjB6U46qP8AXRf1+APdo7f60UighQCcnHJpaQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38R/8Aklniv/sC3n/oh66Sub+I/wDySzxX/wBgW8/9EPXSUAFFFFABRRRQAUUUUAZPijX4fC/hm81m5ieaO1QMY0IBYkhRyeAMkZPYc1U0HxFfahrF1pOsaZFY3tvbxXObW6NzC8chYLhyiHdlGyNvpgmneNzqn/CG6gNCtftd2yBfJ2qzNGWAk2huC2zdgHgnFYnga3kg8Qai2lRammgy28RT+1raSKZJwSCimUCVkC4+9lR0U44BHd/1/X9IHor/ANdP6/E6C+1ub/hJLbQ9LjikuTF9pu5JSdtvBuwOByWY5CjgcMT0wcPTfiBc6hdW8w0ZV0i61KTTIbhbvdcCVGZcvDswq5RuQ5IGCR6TWEb2Xxg1g3AAXU9MtntWP8fktIJFH08xD/wKuW0yDWJdfsrg2GpW3iJNVdtQjezb7A9uWKmRZCvlhvK24ZD5hPDZGcOOrX9df69Nwlonb+tL/n/kdTP4+8q4urpNOD6FZ3osLjUftHzrLuCErFtOY1ZgpYsCCDhSBmuqur21sYRLe3MNtGzBA80gQFicAZPcngCvLLjRNRHhXWPAqWF41zf6rJLFeeQ5gNtLOJWkMoGwMoLDYTuJAwMGtj4v2UV34W02I6TcanLFqtrKi2+nyXTRokqmRsIrbRsDDtnOOc4oW0fO342/L+tge7+f4Xt951beLPDq25nbX9LEIn+zGQ3ke3zf+eec/e/2etWb/WtL0uW3j1PUrOzkun2QJcTrGZW/uqCRuPsK8k8Qq9zefEv7LoerN/aGlQw2bLo1x+/kEbIwQ+XzyU/AZ6AkLrlxO98FtdNurj+0/DcVldJeabeP9mBZxuCRQSMGzuyjhN2Fw3XC6X/rZ/5fiO2v9eX+f4Hpt5rcul+I7Sz1FIhZak/k2dwhIKzBS3luD/eCsVI9MEdCdqvNLrT7FPCngfQfDxWTbqNtIhjt/IIWAl5pGjwChypDAgHc+Dya9Lqmkr+rX5f18iU27en+YUUUVIwooooAKKKKAOb8Uf8AIxeDP+w1J/6b7yukrm/FH/IxeDP+w1J/6b7yukoAK43xHFqs3xJ0BdDvLOzuP7J1EtJeWjXCFfOssgKskZBzjnJ6HjnI7Kubvv8Akqehf9gXUv8A0fY0AH2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mVtajZPqFr9nW5ltkdh5rQMUdl7qrAgrn+8OR2weRzfgq3vbbVtfgW+u7zRYblI7BryZp5FYL++AlclnUOcDcTghhnihagy19h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZVDxrJfWvifwjPaapeW8E+qi2ntI2URTKYpGy3G4kFRxnHtTfiVq+pW/hLWLfw9cG2vLfT5bma7XrbIqkgD/AG2IwPQZPYApu0eYpRbko9/87Gj9h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/Jlafh2WSfwvpUsztJJJZws7ucliUBJJ7mtGrkuVtGcZc0VLuc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlZXi/S9Qt5bK90fV9QGuT6hEkEa3L/AGdofMBkVoN3llVi3Etjdkdegrsb+IT2MqPLPEpXLNbkiTA5IGATkjjjn0wanpcrrYw/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyuQ0XVpr7w341tvDOu3lvNZ5FnFrbTCew/d53O043hWIYru3Yx+A1PAV0k2vXUNhqGoG1isYTcWOq3ck08dwxOXHmkuE2gDI+RjyvQ00rsHov6/rqbf2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJldJRSA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkyukooA878fWfjFfht4la813Q5bcaTdGWOLRZkdl8lshWN0wUkdCQceh6V0H2Hxv/ANDD4f8A/BDP/wDJlHxH/wCSWeK/+wLef+iHrpKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKiuhKbOYW7rHMY28t26K2OCfbNJuyuNaswPsPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyuP8DX0w1rS4ptavXvvsU0usR3l7JNFdsCAslurnGzO5t0QCgYB5wKTQfFkut6tpus+JhrVnYardbNFFvKIrMDLeWJdjh3dwM/Ovl8gDnObtrb+t7fj0J6N/wBf13Ox+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkytDVvE+gaBJHHrut6bpjygtGt5dxwlwOpAYjNGk+J9B1+SSPQtb07U3iAaRbO7jmKA9CQpOKncZn/AGHxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV59r3iqSzh8T395rlzYeJtJvmNhphu2WOW2DKIwLfIWVZM4L4JBbhhgCul8VPeWut/2t4jgvx4cjjiRJNK1ae3a1Yn55Z44ym5clRkM+AM45NNK6T7/1/XmD0bXb+v68jc+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6QY2jHI7UUgOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTK6SigDm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukooA878fWfjFfht4la813Q5bcaTdGWOLRZkdl8lshWN0wUkdCQceh6V0H2Hxv/wBDD4f/APBDP/8AJlHxH/5JZ4r/AOwLef8Aoh66SgDm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TK6SigDm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TK6SigDm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TK6SigDm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKZ8Q9Sv9J8F3F3pZlR1lhWeWFdzwwGRRLIoweVQsenHXtWP4Q1m1bx1d6R4f1qTWdFbTI71JJLxrvyJDIykCZmZiGAztJOCpxjpQtf68rg9Ff8Arexo3mgeLdQ8k3et+HpGt5RLC39hTho3HcEXmRwSPcEg8GrX2Hxv/wBDD4f/APBDP/8AJlVZpm134jXGlzbjY6JaQ3RhD4We4lZthYdwgjyAeMtnqBXD6f4rkS30fUTrl0fFM2sx2WqaNLdMwVZJWUx/ZydsYVPmV1UEhcktk00rtLv+rsD0Tfb/ACv/AF5noX2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mVxdxrmoSeFdZ8dLqF2s9hqkkUFos7/Z/s0U4iaMxA7WZgGO8gsCRggDFdr4y8Vv4T0i0vo9Km1EXF5DalYpUj8vzHChiWPqQMAHnrgcgtovP9bf5g92v603E+w+N/8AoYfD/wD4IZ//AJMrBu/BPjiXXJNUsPHlnpks4QXMVtobPHOF4GVluH28cZTaeak1D4ianpyeIhN4ehM3h9FuLpRqPyvbspYMh8vJfCn5CAMj7/Sr2reOpbW6kh0jSft/2XTk1S78y48lkgbdgRjawd/kb5SVHH3qXmPXb+v61RHYeFfE+mTNNaa14fEzoEaV9EuHcjOcZa8PUkk+pJJ5NaH2Hxv/ANDD4f8A/BDP/wDJlY1zroj/AOEd8Xafb3Fnb61dQ2t3bTuhMkcoKxSEIzKGB2HIOdpIPYDvabTW/p/X3k3XT1/r7jm/sPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukopDOb+w+N/8AoYfD/wD4IZ//AJMo+w+N/wDoYfD/AP4IZ/8A5MrpKKAOb+w+N/8AoYfD/wD4IZ//AJMo+w+N/wDoYfD/AP4IZ/8A5MrpKKAOE1O28Rw+LfB7a5qul3lv/a0oWOz0yS3cN9gu8Es08gIxnjA6jnjB7uub8Uf8jF4M/wCw1J/6b7yukoAK43xHrelaD8SdAutc1Oz023fSdRjWW8uFhRmM1kQoLEDOATj2NdlXN33/ACVPQv8AsC6l/wCj7GgDO1zx34Zv9Jkt9G+IPhnT7lyB5815FMAueRtWZDkjjIbiqWmeNNJsrGaG4+JHgtmWER2a2wSKKEju6m5Zn7cBl7/h3Go36ada+a0Mtw7MEiggALyseirkgfiSAOpIFZ3h/wAUWuv3F9aC1u9Pv9PdVurK8VRJFuGVbKMyspAyCrEULrYGcb4p8Q+H9fu9EnsfiV4TsjpVyLsiWSObzZArL2uF2rh245PTn1d4sn+FHi3Tr9L7XPBp1G7tmgTUZZrWWWElSFYEtu+XORyPrXW+IfFcXhtGnvNL1GaxhAa5vYI0MdsvqwZwzDnkorY74o1bxZb6Zf8A2G2sL7VLpYBczRWKoTDCSQHbe6jkg4VcscHANJ2asxptO66f1+Zi6L4n+HOieGrbRLbxR4XFrDAInjjvbdI5OPmJQNj5jkn1yetP0jxN8LtASVdC1vwhpizEGQWV3awhyOmdpGetdVpep2etaVbalpkyz2l1GJIpF/iU/wAvpVurlfmbe5KSsktjzKfxXYtrVze23xS8FRpL8kQljSSSCL+6rfawuc85KcnGQQABr3Pj/Q2juxZfEPwhEzFPsrTTRyeUB97eBcLvz2xsx71o6p44s9Huk+26fqC6c062zaqsaG3SUtsCn5/MxuwN2zbk9a37y7gsLGe8u5BFBBG0kjt0VQMk1P2fIr7XmeaXl54D1fTNYj1rx/4fkv8AWLeOC4u7S+ghVFjyUCIZG4DEn5mbOcZxxVnRvEPha210azr/AMRfDGoX8dp9jia1uIbZBGWDEspmcsxKjnIA7AZOeptfFSnSbvVNY0jUNEsbaHzzPftBh0xnIEcjsCB2YA8jvUmi+J4NYvZLKSyvNNvEiWdba9VFeSFiQJF2swxkYwSGHcDNPW5Olv68v+AVv+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SikM5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvx94+8H3nw28S2tn4s0Oe4m0m6jiii1KFnkYwsAqgNkkk4AFdB/wsfwR/0OXh/wD8GkH/AMVR8R/+SWeK/wDsC3n/AKIeukoA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqgvfHngO/0+4s5/GWgiK4iaJ9uqwg4YYODu4PNdXWJrHiaLSr+Owt9PvtUvniM5trFULJEDguxd1XGeAM7jzgHBpOzVmNXWqOE0W98JWU2kDWPiT4a1G20ONotPSOeCGQKUMf71/NYOdhx8qoM8kHjDNPn8GWa6fp0/wAR/DtzoOlXQurGyN1AJY2Ukory+aQyITwAingZJxz3beNNDXw3a64LsvaXhCWypGzSzSHI8tYwNxfII24yMHPStLS76XUbBbifTrrTmYn9xd+X5gHYnYzAZ9M59QKtt3u9/wCvxJsrW/r/AIYx/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukqnq+qQ6LpNxqF1HcSxW67nS2gaaQj2RQSf6dahtJXZSTbsjhbvxD4R1jVY5tf8AiH4curC2nE9tp8F5DFHuByjSkysZGUjIxtXODtyBS6j4o8OaxPdWmpfEjwtJolwRus45oVmK8ZRpTMQVODnCA4PUV06eMNMbwbZ+JWE6Wl7FFJbxFAZZDLjYgUE5YlgMZ/Go08baaul393qEVzp8unOsdzZXCqZkd8eWoCMysW3ALtJBJx1BqrOLt2/r/L8BXv8AMYPiN4HAwPGPh/H/AGFIP/iqX/hY/gj/AKHLw/8A+DSD/wCKq7oniKHWZbm2a0udPvrXaZ7K82ebGrZKt8jMpBwcEMehBwQRWvSA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKrpKKAOb/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiq6SigDzvx94+8H3nw28S2tn4s0Oe4m0m6jiii1KFnkYwsAqgNkkk4AFdB/wsfwR/wBDl4f/APBpB/8AFUfEf/klniv/ALAt5/6IeukoA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukqO5nW1tZZ5FkdYkLlYoy7EAZwFUEk+wGTQByupfELwvLYSJpPjzwva3RxsmubyKdF55yglQnj/AGh+PSqOheJvAWiyXdzJ460S+1C+cPdXk+qW+6THCqAGwqKOAo9zySSdzSvGuk6r4Qm8Sgz2enQmbzGu4vLdBE7KxK9Ryp4PPsDxUui+J4NYvZLKSyvNNvEiWdba9VFeSFiQJF2swxkYwSGHcDNOzTsDOPuPGvg/SfHja7beK9DuLbU7aOzvFi1OFmhdGYxybd2SuHZWxyPlOMZIltvEPhCfWoNV8SfEPw7qVxZljZww3kMFvbkgguEMrkvtONxY4GcAZNdlqetrY6hZ6dbQG6v7zc0cIYKFjXG+Rj2UZA6EkkACobfxVY3PjG48NJDeLe29t9paSS3ZImTIHys2N/LdVyODzmhdLeYPq35f5HBz3Hgiae6tP+FieHhoF3fC/n077ZDvMu8OVEvm4EZdQxXYTkn5gDirvjjxB4V8V6PbWNh8RfDGneTdw3TPLcxT7jE4dQAJkx8yjPXj0610s3jjTYNUltmgu2tYLlbOfUgq/Z4rhiAIiS24nLKMhSoJwSDxRqfjjTtL1G4t5Le7mgsdv9oXsKoYbHcMr5hLBuhBO0NgEE4HNC2Vvl8rf8D8Ae7uefak+g6lP4qkk+KfhFB4js47RwBH+4VAVBH+lfMdrN6c4PQYOff6l4c1zXFtJ/iD4YX+zNNitJJpjIkN2DksF8q7jDqQFDIzSDI6DnPuoIIBByD0Iopf1/X3hf8Ar7v8keRr448L+I/7BsbvxJ4fs7TSrhLu5db2KGOUx58lI0ZyVB+VyDnbgLknOO4/4WP4I/6HLw//AODSD/4qukrLudbWx1620+9gaKK8+S1utwKSSgEmMjqrYBI7HB5zxTvfQVktTP8A+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukopDOb/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KrpKKAOb/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KrpKKAOE1PxZ4c17xb4PtdD1/S9SuE1aWRorO9jmdVFhdgsQpJxkgZ9xXd1zfij/kYvBn/Yak/9N95XSUAFc3ff8lT0L/sC6l/6Psa6Sub17RNcvPFWl6roN/p9l9ksrq2lN7avcbvNe3YbUWSP/nicktxwMHOQAamua7p3hzSZNR1m7htLaMhd80ioCxOAuWIGSfWue8L634bb+2NWj8Q6XeXMxW51Ge3u0khtUC7UQuDtUKo6kjJ3HjoLv2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUIDA+JF9bapprWWh+LorbWrdBc2+kQPBMb1xho1eIqXZSQOmBg5OccR+I5W0fxOur6XqsK+JLvTo4LjQ0tvtUl0ATsZVDqY8MzDzGygHXpXR/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZR0sBJ4O0S78NeBNP0uZo7i+t4CZCWKo0rEswzg4XcSM4PHar+kT61Mkv9u6fYWTAjyxZXz3IYd8loo8frWZ9h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlNu7bElZWMfxF4r8Japqw0bU/EelQQafcpLdQSXkYlmmRgyRKmdxwwUnA5ICjPOOi1jV/DT6bqEGuXmnSWduES/humRkiD4KiVT90Hg/MKq/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUulh9bnDazo73nhbxLb+DZZLzw75FrcWkMLGaNpI5N8sduckFCipwvy7iQO4rotPvbbxR8UrPWNBuUutO0/SZYJ7iFtyebLIhEWR/EojJI6jIzjNa/2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJlNOzv/W1vyE9V/XkdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUhnSUVzf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlAHSUVzf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQAfEf/klniv/ALAt5/6IeukrifEfh3xvrfhXVdK/4SDw+326ymtsf2NPHnehX7/2ptvXrtbHXB6VpfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJXA+MGg0jxhBrel6zFDrj2X2ZtKFr9qlvod+V2xq6spDEjzM7Rk7uBW19h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlLqM87Xw2vhy68Kf8J3fPaWMdpeyT3kV21vFb308gcgyqQU+VnVWyOmM88914BfWJvBcovLt5pBc3Cafd3imRpLcORC7jKlvlweoJGDnJzVr7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMqr3Vv63v/AMD0J/r+vz9Q+w+N+/iHw/8A+CGf/wCTK0vEF7bab4avrrUrqG2gjt23zTOEQEjA5J4ySB+NZv2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mVMlzRcSouzTOD06aG9+DngHVLK4S6tNFuLGW/EBEnlqibH3Y6bCwY+gU1F4ggfX9e1TxXo7fbdFtrvSj5tv+8S5W3lZ5XQjhgokHIzypHavQfsPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrRzbm5ed/np/kRbSz7W+Wv+ZmeHZ4te+Jmq+IdIuI7rSP7Mt7KO6hcPFPKJJHbaw4baGAJHc47Gu3rm/sPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKnpYrd3f9dDpKK5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMpAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAdJRXN/YfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAHxH/wCSWeK/+wLef+iHrpK4nxH4d8b634V1XSv+Eg8Pt9usprbH9jTx53oV+/8Aam29eu1sdcHpWl9h8b/9DD4f/wDBDP8A/JlAHSUVzf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQB0lMnnitbeSe5lSGGJS8kkjBVRQMkkngADvXPfYfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmUAed6W8XiX4Fa3b6BcxX88Gp3Nw8Nq4ldkF60u3AP8aDj1yK63T7228UfFKz1jQblLrTtP0mWCe4hbcnmyyIRFkfxKIySOoyM4zWv9h8b/wDQw+H/APwQz/8AyZR9h8b/APQw+H//AAQz/wDyZVX1v/W1hPVP+utynAGj+NV4bgcT6HF9lJ77Jn80D/vuPP1FUX1zSR8e47E6nZ/a/wCxGh8jz13+YZVfZtzndt+bHXHPSrmo+G/F+pPbyy+ItDiuLV98FxDoUyvGehAP2vkEcEHINXvsPjf/AKGHw/8A+CGf/wCTKlaNPtf8b/5jl71/O34W/wAjz65Ux+CNd8EeYD4ivNYlMNt0kkjluRItwB1KKjZLdAVIzmrGqSLpWl/EDw7dsG1fXLiV9MtzgPfCW3RF8sfxbSCGx93GTgV3P2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUdLPtb8v8h3alzLvf56/5nM/FuO3034G3Vtql75MsVvDEj/aDEZZRgY4I3ZAY7eQfTiuavZfBc/jjxBZi60ibTZvDUd3JG1wjxSTguRKwJw0mwodxy2NpzXpf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUSvK/nf8Vb/gij7qSXS35p/pb5nlL+IdIuPDPga88Q3FprdpJobxyWlzfQRgXIEY87dO6IXUhlPzb1ySB1ropLOWL4SeF7UaqNY1KbVbFlu4r57sSyidWcrIzNkBFfOOMA8CulHhzxqPEDasfFejl2txbi3OgyGJQGLbh/pW4E5GecHaOOKrWngzxXa6sdRfxJotzcbneMzaFLtiZ/vMqi7ABIwueuBjPJzfN73N53/G9ibaW8rfhY7yiub+w+N/+hh8P/8Aghn/APkyj7D43/6GHw//AOCGf/5MqCjpKK5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkygDpKK5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkygA8Uf8AIxeDP+w1J/6b7yukrkpNB8VXfiDQrvVdX0e6tNNvXuZIrbTZbaQ5tpohhmnkB5lHGBxznjB62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z" alt="" width="750" height="249" vspace="0" hspace="0" border="0" style="width:750px;height:249px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The duration of treatment depends on the success of treatment and the tolerability of the drug. Fludara oral should be administered until best response is achieved (complete or partial remission, usually 6 cycles) and then the drug should be discontinued.<br />Dose adjustments for the first treatment cycle (start of therapy with Fludara) are not recommended (except in patients with impairment of renal function, see &lsquo;Patients with renal impairment&rsquo;).<br />Patients undergoing treatment with Fludara should be closely monitored for response and toxicity.<br />Individual dosing should be carefully adjusted according to the observed haematological toxicity.<br />If at the start of a subsequent cycle cell numbers are too low to administer the recommended dosage and there is evidence of treatment associated myelosuppression, the planned treatment cycle should be postponed until granulocyte count is above 1.0 x 109/L and platelet count is above 100 x 109/L. Treatment should only be postponed up to a maximum of two weeks. If granulocyte and platelet counts have not recovered after two weeks of postponement, the dose should be reduced according to the suggested dose adjustments in the table below.</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM1NAAAkpIAAgAAAAM1NAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMjoyNjoxOAAyMDIxOjA2OjI3IDEyOjI2OjE4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTI6MjY6MTguNTQwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAKUC3gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAorktN8cXur6Vaalp/gnxBNaXkKTwSebYLvR1DKcG5BGQRwRmrP/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXJXXji9srmygufBPiBJb6YwW6+bYHe4jeQji54+SNzk4HGOpFWf+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkoqjomqwa9oGn6vZpIlvqFrHdRLKAHVXUMAwBIzg84Jq9QAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQldJQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFABRRUN4sz2M62pCzmNhGT2bHH60m7K41q7GPdeNNDtdUk04XM91dQsFmjsbKa68g8cSGJGEfX+LFamnapY6vafatLu4ruDcU82Fwy7hwRkdweD6HIryr4IXE+l/C/UbMW8L+JLG9uH1C0u5jC7Sls7pGCsRlcYbac4rF8QeOb/AMTfA1vFWm20nhh5NWi8g2OpyF5CZQkhfaqDB5+XkHrwau2tvT8bEt2Tfr+Fz3mivOvGYj0e40mxHiHVVk1rU8/Y/tLg3H7sAosysrQRqQHO0nkkAHOK86l8T67e/s32eqtruoLqEGsrbpeQ3jpKY/O2YZlI3/Kf4s54PWktXb0/Gy/Ub0jf+ur/AEPoqoby6isbKa7uSwhgjaSQpGzsFAycKoJJ9gCa8Tu9V1WKf4u6VHq+p+TpVpFdWLfbpfNt5DCXOx924LuAO0HHbGDijRtb1Cfxz4bt5dXvZ4brwT9puoJLx3R5dn+sZC2N3vjJpSuo3Xa/4N/oUlrr/WqX6nsOgeINM8UaHb6xoVz9qsLnJim8tk3YJU8MARyD1FaNfPngO+v1+HPww0uG5uLbS9TvbqG+ktpmhZsGRkTzFIZckHoQeKuf8JtrI02306/vruPSf+Ewl0eXUhMyy/ZF+6pmHzA5O3fndx1zzVyj77iu9vxS/VGafucz/rf/ACZ7vUVzdQWcQkupViQusYZjjLMwVR9SSB+NeX/EHSL3wt4bsNf0jXtcvYtAvVlvbeTU5T59qXBZH2sN5QEEFskgYYtWZ8StLieHwdcPdaoqar4ogkeOTULgGNHBIVQX/d4AB+XG05xipirteqX32/z/AAKen3N/df8Ar5ntFFeLXmo+LdY+Jmv6NoF9DbDRIbR9Oa91WeFPKIDPIyKji53cqWc/LwRzzW/JLqel/FKK41mS9vdN1C8ENhc2OpSCK1k8rH2ee23BGBIZg+0nOM44wJXt5/1/X3bg9L+X9f1/kelUUVynxL1hND8CXl6+rTaUQ8arPBD5sjEuB5ajcvLfdzuGM5yMUho6uivC7HW9W/4Rf4q2DapfKuirvsT/AGjLLNanyi+BOT5hwy9z6jpTvB2v61beMPDMP9p398uo+DhezwXV08oluByGAYnDHGMjGe+TzR0v5J/em/0EtVfzt+KX6nrWr+KtI0LVNO0/VbiSC41SUQ2n+jSskkn93eqlVPsSK1Zpo7eCSaZgkcal3Y9FAGSa+eH1QXnh/wCGXiHW9ZmmvtQ8QCa8NzdHy42BdSFRjiMLwuFAHPOTXuPiX/SLO30teupTrA4/6ZDLSfmisPqRVcrS872/L/MlSvLytf8AP/I1oZUngjmiJKSKGUlSDgjI4PIp9cX8W9W1XQvhfqt/oEjw3cKx4ljGWiQyKHYfRSee1cdrmqX+nXnjbQ7HU9QOnWnhpdSguGv5Wltrg7z8sxbeA2AcbscYAwcVLejfr+Cv+RaTbSfX/NL9T2WiuO+GtvPceC9D1q91O/vLq80m3EwuLlpIy23O/aejnOC3U4Ga7GqlHlk49iU7q4UUUVIwooooAKwfEXjXQ/ClxaQa5NdQveuI7fyrCecSueiAxow3HsvU+lb1eX/GsTM3glbSWKG4Pia28qSaMuithsEqGUkZ7Aj6ihayS7tL72HRvyf4HTv8SfCkWj3+py6k8cGmsq3qPZzLNbFjgb4SnmKD6lcd66S1uYryzhurZ98M8ayRtgjcpGQcHnoa8e+Ifgk6H8P/AB34k1TU/wC0NY1azSOZ44PIhREYBVSPcxHGOSzE4rM8a+Ip7XQPI0zX72K70/wvDfJbW0z2yWrjaFlMiMPNLZx5bKy8ZyO6urPyt+Tb/L+tws7pLrf9F+v9PQ90muoLeWCOeVUe4fy4lJ5dtpbA/BSfwqUnAJrxTWca38QfhXc6pd3QN5ps887w3kkALC3VtwKMu3knOMZHByOKl8L6p4y8S+N9Xu4ry2t10nX2tZ4bnUpYwtmOBGLUIULNncJS24njpWji07ev4O39eRKknHm8l+Kb/rzPT/DninR/FlnPdaDdNcxW9w1tMXgkiKSLjcpV1ByMjtWlc3UFnEJLqVYkLrGGY4yzMFUfUkgfjXzhpviHVNC8EaqNIkEKX/jya0u5/PaDZCxGR5qgmLJAG8AkA8c1v+NdK1qHTvCNl4pvQ7N4shiiFlqk8jR2zAsqPKQjM69nI3Ywc5JpJX5bdbfjy/5/11p6X+f4X/y/rp7rRXmN61/ovxFtbq+nv9Q0K4uLe1sp7LVZT9ikKhRFPBu2yq5O7zDubnnsa9OpdLh1sFFFFIAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgCtqN/Bpeny3t2JjDCNz+RA8z49kQFj+ANcvZfFXwnqOnpf2NzqM9i7bRdpo14Yc5xzJ5W0c8cniurvTiwuM/8APJv5V47+z5aaxN8OdJeS7s5dEL3SvaC2Il3Fzgs5ch168BR1HWnHVu/SwS0imj1HRPFOj+IrrUbbSLppptMn+z3aPBJEYpPT51GenUZFa9fOurXV1Z6B8YLzTL26s7u11iGSKazuHidTkA8oQcYJ46V0MniPWNP+I/iw6ZfXd59l8KJew2b3LyxrcbR8wjJIBOBwAM596lP3U/K//kvMOzv82v8AyZL9T1G88V6Pp/iex8P3lzJFqWoKzWsRtpdkoUEtiQLsyAORuyOPUVsV4DbXMCeMPhDqN7rM11cajBcXFxLeXbSZlkhUfKGJ2AsdoVcLkYAzUtj4svZPiN4Xn03xHfahaalq97aTyyzMkVzGgBCrblmRQhIUOApbGSO50cbNR66r7nYTtbmXa/5v9P63PeaK8t8ARXOr+J/GEF1rmqyQaV4gBtU+3yNsULkxncTmMkkbOn9OYsfFl7J8RvC8+m+I77ULTUtXvbSeWWZkiuY0AIVbcsyKEJChwFLYyR3MR95pd7fjb/MHpfyv+F/8j2LQPFOkeJxenRbppzYXLWtyHgkiMcq9VIdQePbirEWt6fNr1xosVxu1C3gS4lh2N8sbEhTuxg5KngHNeAQXV3pXhf4i6zo9/d22q2XitjaJBMwWV2kRdjRg4kDAkYYH2xXTX2pamvj74g2bapqMccPhpbuOBb6ULbzbMloxu+Q5A+7ik3aKl5X/APJeYtx95xXe3/k1j2iivCPBWva1D4j+HwfV9Qvf7Y0C4lu47q6eVZpEBZW2scBu2RyR1JrU+E2peL/ErWHiK+vrb7NPNcw6nDLqUruzhj5aJbGPZCUx/C2WU5OTV8utvX8G1+hkpXV/T8Vc9jrJ8R+KNI8J6fHfa/cva20kywLIsEkoDt0B2KcZ6ZOBXDfEGa4T4ueBbNNW1Cys9S+1w3cNvfSQpMFjyoIVgM5Y/MMNyMHIGOC8V6nqF/8ACPxDZXt5NeW2m+LEsrG7mcySPEsq4BdslypJG45PHNKKu15//JJfqXNcqv5fo3+h9GdaK8L1HxR4j0ef4r2mk6jdzf2TFaz2ImlMzW3mJmVlLZwAMtjoMcAVrLfazH4s1DwzoOtzxW954YS/jvL66ef7NdM+0OHclgGB6A4GMgCi35X/AAb/AEC3f+tl+qPXqq6nqVto+l3Oo6g7Ja2sZlmdI2kKqBknaoJOB6CvD/FWrajYfCvVEE2u6Drel6rapcltamuAu8oN0czOS0bKc7W6E8itjVr68svE3jbQra/ur7R28LPft9puWn+zzsHGFZiSoZedo4GOAKmWkW15/grhCzkk/L8XY9W0jV7LXtHtdU0mbz7K7jEkMuxl3qehwwBH4irleC/DzU77Sta+G9jDqNyLLUvD8zXNvJMWiJQFlYIflUj1ABI65o8P+K765+JPhBrDxDfalYa1LqEVzNNM6JdrHnYy25Zli2kYBXaWwSQM1o4+/wAq8/wbX6ERlePM+lvxVz3WG6guJZ44JVke3cRyqpzsbaGwffDA/jUtfOun6lfeFvhp8RNc0K5uv7Uh1+5t0aS6llEcXmRqZNjMV3AH75UnpkkV6x8P7XXbaO8OrXdrNp1wsU2nxx6pNfyRqV+YtLKiswYjI64yQOAKlK6v5L8Vcp6O3m/wdjode17T/DWjTarrMskNlbjMsscEk2wepCKTj1OMCrVleQajYQXtm/mW9xGssT4I3KwyDg8jg968U8a6jc6xa/FNdX1C5gXRrRLextFuGjiEbxZ3MmdshcnALAkdsGjTtYu9QP2c6vd2+m6f4Mgv7BrO7aJTMowzkoRv2lQCrZXsRzU3XK2/J/Kzf5IWvMkvT53S/U9yorxm/wBX8Q3/AIR8OeKtTe7udPXSEn1S00zUXs7mFjg/alVGUSDAPyNx6CkTWPF/iT4k+IbfSL23tTo1zam3W71GW3RLYgM5NusbLLvGRucjbkYxV8r5uX1/B2/ry89Bc3u839f1/W2p7PRRRUlHN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJXSUAFFFFAHN/Dj/klnhT/ALAtn/6ISukrm/hx/wAks8Kf9gWz/wDRCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAZeqeF9A1u4jn1nQ9N1CaLiOS7tI5WT6FgSOlSal4f0bWLKOz1fSbG/tYm3RwXVskqIcYyFYEA4J/OtCijyApXGjaZdpapdadaTrZsGtlkgVhAQMApkfKQOOKqT+EPDVzZGzufD2lS2pmNwYJLKNkMp6vtK43HJ5681sUUAZln4Z0HT7u4urDRNOtbi5UpPNBaRo8qnqGIGWHsarJ4I8KR+X5fhjRl8pHjj26fENiNnco+XgHccjvk+tblFAGXD4X0C30h9Kg0PTYtOkbe9mlpGIWb1KAbSeB27VJ/wAI/ow0l9K/six/s6QkvZ/Zk8liTkkpjByeelaFFAGFfaTdkWulaXbabBoDQvDdQ7SjovG0RKo2bSNwIOMZBHTB07/TLDVbX7Nqdlb3sG4N5VxEsi7gcg4YEZBq1RQBRudD0m91C3v7zS7K4vLXi3uZbdGkh/3WIyv4U86VpzakmomwtTexqUS5MK+Yqk5IDYyAT1FW6KACq9/p1lqtm9pqlnb3ttJjfDcRLIjYORlWBB5qxRQBlyeGNAmW7WXQ9NkF6qrdBrSM+eF+6H4+YDAxnOMVHa+EPDdhe295Y+HtKtrm1XZBPDZRo8S88KwXKjk8D1Nc7430uw1jx14Ns9Wsba+tWluy0F1CsqEiHIJVgRwan103tp8T/CvkapdpZXS3MUunqyrAdkRIbAGSee5I4GAKaE2dJBoWkWtxJcWulWUM0svnSSR26Kzyf3yQMlvfrUE+u6NH4ih02aQHUMbYz9ncqhYZ2GXbtVmAztLAkDoa43Ubu/1y/wDGV3Bqd3ZN4cHk6fHBOyRiVYBKzyICBJksF2tkADgAnNSWGlXfinVdK12EXljp94tpqd4jyRGGeVYwUEajMgYHYGLFVwowCTkJa27afc9vwQ5aX76/ev8Ahz0N0WSNkkUOjDDKwyCPQ1kx+EvDcNjcWcPh/S47W6VVngWyjCShfuhlxhgO2elcD42hkuPCsevQX2o2c99rdsiPZX81vut3mSEA+WwBDINwznG84xmvSH0ixm0f+yru3F7ZeWI2ivWNx5ij++ZCxf6sSaLe7f5fgn+obO39b/8AAJNP06y0mxjstLs7eytYs+XBbRLGiZOThVAA5JNWa4n4SwxW3gQwW8aRQxanfpHHGoVUUXUgAAHQAdq7anLcXkFFFFIYUUUUAFZWreF/D+vzRy67oWm6nJGu1HvLOOZkHXALA4FatFAFK90bS9S0wabqOm2l3YgKBazwK8WF+78hGOMDHHFVx4V8PBVUaDpgVbc2qj7HHgQnrF0+5/s9K1aKA2KB0LSGhs4m0qyMdgwa0Q26YtiBgGMY+Qj2xSnQ9JOrnVjpdkdRKeWbw26edt/u78bse2avUUAZFt4R8N2djdWVp4f0qC1vMfaYIrKNY5/99QMN+NTv4f0aTSY9LfSbFtPiKmO0NshiQg5GExgYPTitCigCo+k6dJqEN/Jp9q95ACIrloVMkYPUK2MjOO1W6KKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7yukoAr3+n2eqWMlnqdpBeWsoxJBcRCRHGc8qQQeRVXSPDmieHxKNB0fT9ME2PN+xWqQ78ZxnaBnGT19a0qKAMq38LeH7RrxrXQtNha/BF2Y7ONftIJJIkwPnzk9c9aWy8L6Bpl2l1p2h6baXEcXkpNBaRo6x/3AwGQvt0rUooAoWWhaRpzbtP0qytG3s+YLdEO5vvHgdTjk96iXwxoCMjJoemqY5zcoRaRjbKesg44Y5+91rUooAz9O8P6No9xcXGkaRY2E10czyWtskTTHJOWKgFuSevrUa+GNARkZND01THOblCLSMbZT1kHHDHP3utalFAGe2gaO+oQXz6TYteW5Yw3BtkMkRY5ba2MjJJJx1qvN4R8N3F7c3lx4f0qW5u1KXE72UbPMp6h2K5YHA4PpWxRQBi2vg3wxY3Vtc2XhzSbee0GLeWKxiRoRknCELleWJ49T61ctdE0qy1G41Cy0yzt726/19zFbokk3+8wGW/Gr1FFwOC8a+DtY8QePvDGr2dvpdxp2kCcXMF7O6tMJV2MAoiYEAc8nnpx1rp7jwr4eu9Kg0y60HTJ9Pt23Q2klnG0UR55VCMA8noO9a1FHSw223czLLw3oem3k93p2i6faXNwu2aeC1RHlHozAZI+tOsPDuiaU0raZo9hZtMAJDb2qR7wCSAcAZ5JP1JrRooEcF8RPAlxrvgQ6B4Os9KsDJex3MgkJt4xtcOTiONssSB2HUnPaulsfDulppE1tc6Fpdv9vG+/toIVeGaQj5txKL5n1ZQT6VsUUdLf1/WgdbmLbeDfDFldW1zZ+HNIt57UYt5YrGJWhGScKQuV5Ynj1PrU0XhjQYGgaDRNNja2laaApaRgxSN951wOGPcjk1qUUAU49H0yGW7kh060jkvjm6dYFBuOMfOcfNxxzml0zSdN0WzFpo2n2un2wJYQ2sKxICep2qAKt0UAUbjRNKu74Xt3plnPdrGYhcS26tIEPVdxGce1N1HQNH1eKKLVtJsb6OEERpc2ySBMjBwGBxxx9K0KKAKVxoulXkcCXemWc6WzK0Cy26sIiv3SoI+UjtjpST6JpVzqsOp3OmWc1/bjEN3Jbo0sY9FcjI/A1eooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKAOb+HH/JLPCn/YFs//AEQldJXnfgHwD4PvPht4aurzwnoc9xNpNrJLLLpsLPIxhUlmJXJJJySa6D/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAM/xlK9j4y8Kak9pfT2lrLdee9nZS3Jj3Q7VysSsQCeM4q7rfhzVdW8W6LrNlq9pa2+ll2FtLp7SPL5i7Xy/mrj5eny8Hk56U/wD4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaFoKxW1jwTNf3+qPYar9istbjWPVLf7PvaQBdm6N9w8tinykkPwBgAjNdDPp/wDxI307T5BZj7OYIXVd3lDbtBAzzisf/hXHgj/oTfD/AP4K4P8A4mufs/APg9viTrNq3hPQzbx6TYSJEdNh2KzTXgZgNuASEUE99o9BR0sVfW5seMPB974h0Ow0rSNTtdLtrOeGb97YtcFjCytGBiVMDK89cjpin/Ytcs7+PV/E2tW97Z2EbslnpWjTKzSMNu8gSyu5ClgFUfxZ7VL/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE0XYtCn8L4LiDwWftVrcWrS6hezLHcwPC+x7mRlJRwGGVIPI712Fc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE027sDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQAeKP+Ri8Gf8AYak/9N95XSV534j8A+D4Ne8JxweE9DjS41aSOZU02ECRfsN021gF5G5VOD3UHtXQf8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AHw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUAFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZmn+IdM1TULixsp3a5tgGdHgePcpJAZCygOuQRuXIzxmgDTooooAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooA5v4cf8ks8Kf8AYFs//RCV0led+AfH3g+z+G3hq1vPFmhwXEOk2scsUupQq8bCFQVYFsggjBBroP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkrhL5rrxN481nSf7RvLG20WxgkhFncPCWnl3ne+0jeFCLhDlTk5B4xr/8ACx/BH/Q5eH//AAaQf/FVzOsa74Sutbm1TRPiP4d02e8tltL3fdwzCSNSxUp+9XbIN7AMdw55U0nfoNf1951XgjXLjxH4C0nV7lV+1XVqryADapfoT7AkVheFzc2HipbTxZHqEWu3aSzxTJqs89hcKG+ZY4yVRCqleDGDjkE8mlsvFvg3R9Ns9L0Px14YtdOtLQ26RvexSSBgAEYP5oGBzkFTn1FRad4r8L/2hb6h4i+IfhfULu1R0tza3MNvGm7G5tpmcliBjO7GM4Aq21zton7Nj0GoL23e6sZ4Irma0eRCqzwbd8ZI+8u4EZHuDXHat4h+FWvyRPrur+DtTeEERNeXNrMUB643E46DpV65+Ifg42Ukdh428NQT7CInlv4XRGxwSokUkewI+oqHsV1E+GV1d3nw90+bUbua9uS0yvcTtud8TOASfoPpWTfTXniTxP4pt49TvLGPw/BEloLWdox57xGQyOFIEgGVAVsrweOaq+FPEXh7wx4QbRz8SfCd3cRtI1tc+ZGipuYt86faCXwzHoy8YHvUeq6t4TvNRvLvTviV4dsDqlsltqSi6hfzQoIDxfvR5b4YjJ3jGOOM053bdv6YoWS1O38I6y/iLwZpGsTII5L6zindR0DMoJx7ZrYrk9P8cfD/AEvTbawsfF3h6K2tYlhiQapD8qqMAfe9BVj/AIWP4I/6HLw//wCDSD/4qqm05NrYmN1FJnSUVzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FVJR0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lc3Y/8lT13/sC6b/6PvqP+Fj+CP+hy8P8A/g0g/wDiq5+z8feD1+JOs3TeLNDFvJpNhGkp1KHYzLNeFlB3YJAdSR23D1FAHolFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAF7xPDq9x4bu4PDhhXUJE2RtNO0IUE/MQ4ViGxnBx1xXCXOvDTPDM2n6R/aum6tNq9rplyupX8t5JbmVlHmRvI7jBQkqRxnqMgit/VviB4auLMLovxA8L2NyHB8y5uobhCvdSglQ8+oYVjXepeA9R0m8iv/H2gvqN5PFcvfRahAnlyxEGMom84VSo4JJOTknOaFo9fL81+lwZteH55dJ8fal4XW5urqyTT4b+3a7neeSMs7o6mRyWYEqCMnjJxxgDsa890LxL4O0/UrzV9W8feG7/VrxEhknhvYYI1jTO1EQyuQMsxJLHJP0AtP4g+FMmtjWZNX8HNqgIIvmubUzggYB8zO7px16U+wdXb+v6ZY+KrXsPwz1q70zVLzTLi0tnnWW0ZVZtqn5SSCQD6rg8cEVH4jvri717wx4bjup7aHVFmnu5beVo5WjijB2K6kMuWdckEHAODzVHxp4n8J+KfCV7oll8QfDOn/bozDLPLdxT4QjB2qJUwfckj2qG/8Q+Fb6z0ic/EXwxFreksWhvEuYvJclSjK0XnZKkHpvzkA5o0t8wfT5lE+I9SN1/wiAvrkE+Izpf27zD5/wBm8j7Rjf137fk3/exznPNdT4TvJ7fxN4h8OS3E9zBpjQS2slxI0sixypnYzsSz4ZW5JJwea5k3XgT+xwkfxB0BdXGof2p/aJvoCDc9MmPzPubfk27s7eN2ea1fD/ifwTo8l/eXnjvw7ealqUqy3dwl/DGrFVCqqJ5jFVAHALE8k55prb+tdF+t/wCmJ76f1q/0t/SO+orm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqpGdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSV534j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSVieLFtF0KWfUZNW+zQjc8WkmYTOe2PI/ecH0IHrxVb/hY/gj/ocvD/AP4NIP8A4qs/VfiBoEwi/sT4g+EbMhj5v2ueO43j0XbcR7T7nNJq6GtDn7LxHdah4J8JWNrrc9y+uai1pNfAslxFEokdoyxAIkCoIy2Ac5I5wa6fwneT2/ibxD4cluJ7mDTGgltZLiRpZFjlTOxnYlnwytySTg81z0178P8A+w4LSx8e6Db31tftqUN62oW7YuWZmZigcZVtzAqCPlOMjrWh4f8AE/gnR5L+8vPHfh281LUpVlu7hL+GNWKqFVUTzGKqAOAWJ5JzzV3Wv9dv+D/TJtsv63f6W/pDdS+Jd5ZN4nePw25g8NSJ9rea9RDJEy7i8YUNk7cMFJGQeSDxV2T4g/2fqWp2+taZ9mis9J/teKSCfzmlgBIIZdo2vkdAWHvXFakNA1FfF8f/AAtXwlHH4nCq4xGTbqqhAAftPzHYOuBzzjHFR65reiWNxdeIP+FkeGLqRdD/ALK+yWsSO756OB57/wAZyRtb5cjnrUdP67P9bFaX/ruv0ud7pfji6n1+LSNY0NrOaayOoJPb3aTQpb9MuW2MGzgFVVgMjnHNULXxTfaZrGlaTDoclzeeIo7jUFuJbhIo0IGQjfeb5VMak7fTGeQOP0i88L6RIlk3jvwndQ6jb/Zp50nkEsECjOwSTXcu1T90RjbgtuA+Uiug1nXfDWo+N9H1+x+JHhS1i0uGWJLWSWKUyeYAGJcTrjhVwNvHPXPFu1/68/8AgfcSr21/rb/gmhY/Eq4urbR7u40JYLTUNSbSpmF6HeG5DMvyrsw8e5CNxKn/AGav/wBpXkOq6prGpeHb6z+y2rxW800tuySKGyFURyM5Z2wfmAAwB168BFBocOiafYL8WPCBax1p9YWUpH87s7PsI+1dNzt36Y9MnvdS8beCNSjto5PG/h9Y4rhJpF/tKE+ZsO4D7/HzBT36Y70tP67WX/BH18v8m/8AgFa8vri00+Twnplh/aV7Dp32jUpPtjWuxZN2SrqpYyMwcgDaOOWHFc74a8aXvhj4P6BcRaSt5DDo/wBsubm7u/s8YCn7iuUYPKeSFOM+taGqa14Sm8UvruifEjw7p891arZ3sct1BOk0aklSv71Sjjc2DyOeVNc1Z6T4RstLtrAfFjQLqKLSZNMJu5LZzGrZ+eHEiiM84Od5IAGeM0m3Z23/AP2v+ANJXV9v+Gv+p6Fb+NL6XxfpumS6RDDp2qWDXtrfvenc21VJjMfl4DDdn7+MAn2rb8OaleaxoNvf6hZRWUlwN6xRXBmGw/dbcUQ8jBxjjNeaeJtX8I3vg7QdLXx5oT6jp9xbxx3ttewptUDZK2N7bQYi45PUjviu5j+IfgWKJY4/GHh5UQBVUapBwB/wKqdtbd/6/O3yIV7K/b+v8zpqK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqko6Siub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqAOkorm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qgDpKK5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKoAPhx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iErpKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5ux/5Knrv/YF03/0ffV0lc3Y/wDJU9d/7Aum/wDo++oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAoqK5leC1llihe4eNCyxRkBpCB90ZIGT05IFc5p2pN4lneC41L7BJGMy6XAGiuFGSMuzgPg44KKvThmFG4HUUV43dP5ngfXfG8iH+37PWJVtrg/6yKOK5ESwKT0RlXBXoSxPXmvUtfsL3VvDl3Y6berp9zcxGNbh4jJ5eevyhlOcZHUY60fZuP7VjSorjfAkFlpV7qmiJ4e0vRdQsxE07aZCqRXcbBvLk4AOflcFWyQQeTnNdlTasSgooopDCiiigAooooAKKKKACiiigArm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76gDpKKKKACiiigAooooAKKKKACiiigAooooAKKxfEGtz6QbcR2p8mbPmXrozxW2MY3KgLc577V4OWHGat1pd1rfhq6OmeI/MuL+3McV8q+ZAit1KRoyg8ZwxYsM9e1LpdB1szpKK8j1C7Xwr4L8TaZpehafoGsWoto5bjR4QiTRTP5aTggAggb+GyVI6nrXQadZW3hf4pWejaFbpa2F/pEs9xBEML5sUiBZSP7zCRgW6tgZziqSu7f1tf8hX0v8A1vY7yiiikMKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8rpKACiiigAooooAKKKKACiisrXtJ0jU7Mt4ihiurCBGaS3uVDwnodzIRgkY4z0z60mBq0V5P/AGde6b4d8MeHb4zpYazrsoktpHJMVniWWO2J6gYVAV9Mr0rpfB23TvGHijQLFFi0yxe2ltoUACW5kjy0aAfdXKhsdtxqrf193+Yn/X3tfodnRXmerePfE9mPGc0VppMUPhd43Ct5srXMRTzCM5XYxUjnDAHIwetXp/HGr6XrGq22oWltexwaEdZto7ON0cAEgxMWY7zwPmAX/dpdL/1tf8irO9v63t+bR31MjmilaRYpEcxtscKwOxsA4PocEHHuK4XSfGurr4hj07WF0m5tpNK/td720eSLyIemzYd4c5/i3oCMkDjFQprXiHS/EOgaFa22nxnXbe6vZ7m5Z3eGUfOV2DaCF3qB83IBHy4BLs/6+f8Akybp/wBf13R6HWRp/iKK+1ufS5LG9sp44/OjNyihbiPO0umGJAB4IYKeRxzXFaf8QNflsdCv7yHTfIu9ZfRrqGKKQMZA7p5qMXwoymdhDHB+9W9LNr2nXGq6tqmn6an7kxWb299JK7ndiKPY0SBcs3J3NkkdgMLz/rb/AIK/4cfl1/4Nv0f/AAx1SXEEsJmjmjeJSwLqwKgqSDz7EEH6UltdQXtslxZzx3EEgyksThlYeoI4NcPfT3kjXHgvR00+RNP0pJb99SgaZbgSblEYUMvLbGJY5AyPlbPHKaH4s1fw18IfDraYdNijh0Nrv/S42ne4ZP8Alkkcbq68cmTDKvGRQ7JNv+t/8v60Czdkv62/z/rU9oorhV8Wa1D4s0RdQk0230HWbBp4W8h/OSZYw5iMhk2ngswO3kKRjvXS+GrjU7zw9a3WuNbtdzr5pFtA0SqrcqCrOxzjGeetOzW/9f1YSaaujVooopDCiiigAooooAKKKKAOb+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiErpKACiiigDzvwD4+8H2fw28NWt54s0OC4h0m1jlil1KFXjYQqCrAtkEEYINdB/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVVLUfGHw41aNE1HxR4bn8s7o3Opwh4jjG5GD5U+4INdjRQB5rJe/DaXVJbhvHWl/ZJrlbybTf7XtjbyXCkESkH585VTgMFJGSM1pX3i/wjeJcrH8T7G0850aI2+p2QNtt6hNynIbvv3e2K7iijpYOtzi9K8X+AtLWVv8AhOdGu7qcgz3VzqtuZJSBgZ2kKB7KABk8cmtD/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqufs/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RXolFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FVjXfiH4ey+fJpnjjRtGurhg0l1p2qWqM5BHLK25GPAGWUnHFd7RQBwI134cS6RfWGo+M9F1EajH5d5Pc6tB5k427edpULx0ChQDkgDNJoviDwDpF7Ley+P9L1K9kiWAXN7q1qXSJTkRrs2gDJznGT3JwK7+igOljm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvxH4+8Hz694Tkg8WaHIlvq0kkzJqUJEa/YbpdzENwNzKMnuwHeug/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qsfX/FPgzXFthH8S9O0z7PJ5g+x6lZMJG7bhKrg46jjrz1ArvKKAPOptZ8CXujmy1P4k2N9OtwtzDfS6taLNBIuNrIECoMY6bMHJznJq7onin4f6HFceV430W6ubqXzrq7uNVtzLO+Au5tpCjAAAAAAA6V3FFAHkl9b/AA+v/wDhIhN8U4QniPAvUXVbDAAG0BP3eQNo29zj35qvr1/4Ps47rXNP+I8d/qSaT/ZqW8erWC+ZH68Kp3Anfww5GBxxXsdFHS39dvyHfW/9d/0PDvCuv/DwL9l0TxzbJptyf+JjDe29jpwbABAGIImdicAn5ht3cg4NdVq2r+BNW8Wadr//AAsqxtLjTo3jght9UsvKw/38h1YkkAd+MDGOc+j0U27knj8dj8PYtKtLBPitGI7PUm1SJ/7V0/d55Ytk/u8EbmY4x/Ee2AOyvPHHgO++zifxpoW2CZZgo1WDDsvTd83QHB4xyBXXUUf1/X3D/r+vvPOtV1b4e6nrq6xD8QdO029MH2ad7LWLYC5hyTscNuHBJwwwwycEViWWlfC7TrJLSx+IsEUH9ntpsynXreTz4SScEvkrgsSNm0dsEcV7BRS6W/r+tWO7vf8Ar+tDyDxB4j+HuqaNpfg9fGVjcyWMttIL2S9jQJEhwxMy7YyxQMhVTn5uRjNd0PiN4HUADxj4fAHQf2pB/wDFV0tFO7e/qTb8Dm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SikM5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v4cf8AJLPCn/YFs/8A0QldJRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==" alt="" width="734" height="165" vspace="0" hspace="0" border="0" style="width:734px;height:165px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Dose should not be reduced if thrombocytopenia is disease related.<br />If a patient does not respond to treatment after two cycles and shows no or little haematological toxicity a careful dose adjustment towards higher fludarabine phosphate doses in subsequent treatment cycles could be considered.<br />Patients with renal impairment<br />Doses should be adjusted for patients with reduced kidney function. If creatinine clearance is between 30 and 70 ml/min, the dose should be reduced by up to 50% and close haematological monitoring should be used to assess toxicity (see section 4.4).<br />Fludara oral treatment is contraindicated if creatinine clearance is &lt; 30 ml/min (see section 4.3).<br />Patients with hepatic impairment<br />No data are available concerning the use of Fludara in patients with hepatic impairment. In this group of patients, Fludara should be used with caution.</p><p>Paediatric population<br />The safety and efficacy of Fludara oral in children below the age of 18 years have not been established. Therefore, Fludara is not recommended for use in children.<br />Older people<br />Since there are limited data for the use of Fludara in older people (&gt; 75 years), caution should be exercised with the administration of Fludara in these patients.<br />In patients over the age of 65 years, creatinine clearance should be measured (see &ldquo;Patients with renal impairment&rdquo; and section 4.4).<br />Method of administration<br />Fludara oral should be prescribed by a qualified physician experienced in the use of antineoplastic therapy.<br />Fludara oral can be taken either on an empty stomach or together with food. The tablets have to be swallowed whole with water, they should not be chewed or broken.<br />Precautions to be taken before handling the medicinal product<br />For instructions on handling of the medicinal product, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Renal impairment with creatinine clearance <30 ml/min.
- Decompensated haemolytic anaemia.
- Lactation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Myelosuppression</u></em><br />Severe bone marrow suppression, notably anaemia, thrombocytopenia and neutropenia, has been reported in patients treated with Fludara. In a Phase I intravenous study in adult solid tumour patients, the median time to nadir counts was 13 days (range 3 &ndash; 25 days) for granulocytes and 16 days (range 2 - 32 days) for platelets. Most patients had haematologic impairment at baseline either as a result of disease or as a result of prior myelosuppressive therapy.<br />Cumulative myelosuppression may be seen. While chemotherapy-induced myelosuppression is often reversible, administration of fludarabine phosphate requires careful haematologic monitoring.<br />Fludarabine phosphate is a potent antineoplastic agent with potentially significant toxic side effects. Patients undergoing therapy should be closely observed for signs of haematologic and non-haematologic toxicity. Periodic assessment of peripheral blood counts is recommended to detect the development of anaemia, neutropenia and thrombocytopenia.<br />Several instances of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported in adult patients. The duration of clinically significant cytopenia in the reported cases has ranged from approximately 2 months to approximately 1 year. These episodes have occurred both in previously treated or untreated patients.<br />As with other cytotoxics, caution should be exercised with fludarabine phosphate, when further haematopoietic stem cell sampling is considered.</p><p><em><u>Autoimmune disorders</u></em><br />Irrespective of any previous history of autoimmune processes or Coombs test status, life-threatening and sometimes fatal autoimmune phenomena (see section 4.8) have been reported to occur during or after treatment with Fludara. The majority of patients experiencing haemolytic anaemia developed a recurrence in the haemolytic process after rechallenge with Fludara.<br />Patients treated with Fludara oral should be closely monitored for signs of haemolysis.<br />Discontinuation of therapy with Fludara is recommended in case of haemolysis. Blood transfusion (irradiated, see below) and adrenocorticoid preparations are the most common treatment measures for autoimmune haemolytic anaemia.<br />&nbsp;</p><p>The effect of chronic administration of Fludara on the central nervous system is unknown. However, patients tolerated the recommended intravenous dose, in some studies for relatively long treatment times (for up to 26 courses of therapy).<br />Patients should be closely observed for signs of neurologic effects.<br />When used at high doses in dose-ranging studies in patients with acute leukaemia, intravenous Fludara was associated with severe neurological effects, including blindness, coma and death. Symptoms appeared from 21 to 60 days from last dose. This severe central nervous system toxicity occurred in 36 % of patients treated intravenously with doses approximately four times greater (96 mg/m&sup2;/day for 5 - 7 days) than the recommended dose. In patients treated at doses in the range of the dose recommended for CLL, severe central nervous system toxicity occurred rarely (coma, seizures and agitation) or uncommonly (confusion) (see section 4.8).<br />In post-marketing experience neurotoxicity has been reported to occur earlier or later than in clinical trials.<br />Administration of Fludara can be associated with leukoencephalopathy (LE), acute toxic leukoencephalopathy (ATL) or reversible posterior leukoencephalopathy syndrome (RPLS). These may occur:<br />&bull; at the recommended dose<br />o when Fludara is given following, or in combination with, medications known to be associated with LE, ATL or RPLS,<br />o or when Fludara is given in patients with other risk factors such as cranial or total body irradiation, Hematopoietic Cell Transplantation, Graft versus Host Disease, renal impairment, or hepatic encephalopathy.<br />&bull; at doses higher than the recommended dose<br />LE, ATL or RPLS symptoms may include headache, nausea and vomiting, seizures, visual disturbances such as vision loss, altered sensorium, and focal neurological deficits. Additional effects may include optic neuritis, and papillitis, confusion, somnolence, agitation, paraparesis/ quadriparesis, muscle spasticity and incontinence.<br />LE/ ATL/ RPLS may be irreversible, life-threatening, or fatal.<br />Whenever LE, ATL or RPLS is suspected, fludarabine treatment should be stopped. Patients should be monitored and should undergo brain imaging, preferably utilizing MRI. If the diagnosis is confirmed, fludarabine therapy should be permanently discontinued.<br />Tumour lysis syndrome<br />Tumour lysis syndrome has been reported in CLL patients with large tumour burdens. Since Fludara can induce a response as early as the first week of treatment, precautions should be taken in those patients at risk of developing this complication, and hospitalisation may be recommended for these patients during the first course of treatment.</p><p><em><u>Transfusion-associated graft-versus-host disease</u></em><br />Transfusion-associated graft-versus-host disease (reaction by the transfused immunocompetent lymphocytes to the host) has been observed after transfusion of non-irradiated blood in Fludara-treated patients. Fatal outcome as a consequence of this disease has been reported with a high frequency. Therefore, to minimise the risk of transfusion-associated graft-versus-host disease, patients who require blood transfusion and who are undergoing, or who have received treatment with Fludara should receive irradiated blood only.<br /><em><u>Skin cancer</u></em><br />The worsening or flare up of pre-existing skin cancer lesions as well as new onset of skin cancer has been reported in some patients during or after Fludara therapy.<br />Impaired state of health<br />In patients with impaired state of health, Fludara should be given with caution and after careful risk/benefit consideration. This applies especially for patients with severe impairment of bone marrow function (thrombocytopenia, anaemia and/or granulocytopenia), immunodeficiency or with a history of opportunistic infection.<br /><em><u>Renal impairment</u></em><br />The total body clearance of the principle plasma metabolite 2-F-ara-A shows a correlation with creatinine clearance, indicating the importance of the renal excretion pathway for the elimination of the compound. Patients with reduced renal function demonstrated an increased total body exposure (AUC of 2F-ara-A). There are limited clinical data available in patients with impairment of renal function (creatinine clearance &lt; 70 ml/min).<br />Fludara must be administered cautiously in patients with renal insufficiency. In patients with moderate impairment of renal function (creatinine clearance between 30 and 70 ml/min), the dose should be reduced by up to 50% and the patient should be monitored closely (see section 4.2). Fludara treatment is contraindicated if creatinine clearance is &lt; 30ml/min (see section 4.3).<br /><em><u>Older people</u></em><br />Since there are limited data for the use of Fludara in older people (&gt; 75 years), caution should be exercised with the administration of Fludara in these patients.<br />In patients aged 65 years or older, creatinine clearance should be measured before start of treatment, see &ldquo;Renal impairment&rdquo; and section 4.2.<br /><em><u>Pregnancy</u></em><br />Fludara should not be used during pregnancy unless clearly necessary (e.g. life-threatening situation, no alternative safer treatment available without compromising the therapeutic benefit, treatment cannot be avoided). It has the potential to cause foetal harm (see sections 4.6 and 5.3). Prescribers may only consider the use of Fludara, if the potential benefits justify the potential risks to the foetus.<br />Women should avoid becoming pregnant while on Fludara therapy.<br />Women of childbearing potential must be apprised of the potential hazard to the foetus.<br /><em><u>Contraception</u></em><br />Women of child-bearing potential or fertile males must take effective contraceptive measures during and at least for 6 months after cessation of therapy (see section 4.6).</p><p><em><u>Vaccination</u></em><br />During and after treatment with Fludara vaccination with live vaccines should be avoided.<br /><em><u>Retreatment options after initial Fludara treatment</u></em><br />A crossover from initial treatment with Fludara to chlorambucil for non-responders to Fludara should be avoided because most patients who have been resistant to Fludara have shown resistance to chlorambucil.<br /><em><u>Change to Fludara IV</u></em><br />The reported incidence of nausea/vomiting was higher with the oral than the i.v. formulation. If this presents a persistent clinical problem it is recommended to switch to the i.v. formulation.<br /><em><u>Excipients</u></em><br />Each Fludara 10 mg film-coated tablet contains 74.75 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a clinical investigation using intravenous Fludara in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukaemia (CLL), there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of Fludara in combination with pentostatin is not recommended.<br />Dipyridamole and other inhibitors of adenosine uptake may reduce the therapeutic efficacy of Fludara.<br />Clinical studies and in vitro experiments showed that during use of Fludara in combination with cytarabine the intracellular peak concentration and intracellular exposure of Ara-CTP (active metabolite of cytarabine) increased in leukaemic cells. Plasma concentrations of Ara-C and the elimination rate of Ara-CTP were not affected.<br />In a clinical investigation, pharmacokinetic parameters after peroral administration were not significantly affected by concomitant food intake (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Fertility</u></em><br />Women of childbearing potential must be apprised of the potential hazard to the foetus.<br />Both sexually active men and women of childbearing potential must take effective contraceptive measures during and at least for 6 months after cessation of therapy (see section 4.4).<br /><em><u>Pregnancy</u></em><br />Preclinical data in rats demonstrated a transfer of Fludara and/or metabolites through the placenta. The results from intravenous embryotoxicity studies in rats and rabbits indicated an embryolethal and teratogenic potential at the therapeutic doses (see section 5.3).<br />There are very limited data of Fludara use in pregnant women in the first trimester.</p><p>Fludara should not be used during pregnancy unless clearly necessary (e.g. life-threatening situation, no alternative safer treatment available without compromising the therapeutic benefit, treatment cannot be avoided). Fludara has the potential to cause foetal harm. Prescribers may only consider the use of Fludara, if the potential benefits justify the potential risks to the foetus.<br /><em><u>Lactation</u></em><br />It is not known whether this drug or its metabolites are excreted in human milk.<br />However, there is evidence from preclinical data that fludarabine phosphate and/or metabolites transfer from maternal blood to milk.<br />Because of the potential for serious adverse reactions to Fludara in breast-fed infants, Fludara is contraindicated in nursing mothers (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fludara may reduce the ability to drive and use machines, since e.g. fatigue, weakness, visual disturbances, confusion, agitation and seizures have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of safety profile</u></em><br />Based on the experience with the use of Fludara, the most common adverse events include myelosuppression (neutropenia, thrombocytopenia and anaemia), infection including pneumonia, cough, fever, fatigue, weakness, nausea, vomiting and diarrhoea. Other commonly reported events include chills, oedema, malaise, peripheral neuropathy, visual disturbance, anorexia, mucositis, stomatitis and skin rash. Serious opportunistic infections have occurred in patients treated with Fludara. Fatalities as a consequence of serious adverse events have been reported.<br /><em><u>Tabulated list of adverse reactions</u></em><br />The table below reports adverse events by MedDRA system organ classes (MedDRA SOCs). The frequencies are based on clinical trial data regardless of the causal relationship with Fludara. The rare adverse reactions were mainly identified from the post-marketing experience.</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM1NAAAkpIAAgAAAAM1NAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMjoyNjoxOAAyMDIxOjA2OjI3IDEyOjI2OjE4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTI6MjY6MTguNTQwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAKUC3gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAorktN8cXur6Vaalp/gnxBNaXkKTwSebYLvR1DKcG5BGQRwRmrP/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXJXXji9srmygufBPiBJb6YwW6+bYHe4jeQji54+SNzk4HGOpFWf+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkoqjomqwa9oGn6vZpIlvqFrHdRLKAHVXUMAwBIzg84Jq9QAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQldJQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFABRRUN4sz2M62pCzmNhGT2bHH60m7K41q7GPdeNNDtdUk04XM91dQsFmjsbKa68g8cSGJGEfX+LFamnapY6vafatLu4ruDcU82Fwy7hwRkdweD6HIryr4IXE+l/C/UbMW8L+JLG9uH1C0u5jC7Sls7pGCsRlcYbac4rF8QeOb/AMTfA1vFWm20nhh5NWi8g2OpyF5CZQkhfaqDB5+XkHrwau2tvT8bEt2Tfr+Fz3mivOvGYj0e40mxHiHVVk1rU8/Y/tLg3H7sAosysrQRqQHO0nkkAHOK86l8T67e/s32eqtruoLqEGsrbpeQ3jpKY/O2YZlI3/Kf4s54PWktXb0/Gy/Ub0jf+ur/AEPoqoby6isbKa7uSwhgjaSQpGzsFAycKoJJ9gCa8Tu9V1WKf4u6VHq+p+TpVpFdWLfbpfNt5DCXOx924LuAO0HHbGDijRtb1Cfxz4bt5dXvZ4brwT9puoJLx3R5dn+sZC2N3vjJpSuo3Xa/4N/oUlrr/WqX6nsOgeINM8UaHb6xoVz9qsLnJim8tk3YJU8MARyD1FaNfPngO+v1+HPww0uG5uLbS9TvbqG+ktpmhZsGRkTzFIZckHoQeKuf8JtrI02306/vruPSf+Ewl0eXUhMyy/ZF+6pmHzA5O3fndx1zzVyj77iu9vxS/VGafucz/rf/ACZ7vUVzdQWcQkupViQusYZjjLMwVR9SSB+NeX/EHSL3wt4bsNf0jXtcvYtAvVlvbeTU5T59qXBZH2sN5QEEFskgYYtWZ8StLieHwdcPdaoqar4ogkeOTULgGNHBIVQX/d4AB+XG05xipirteqX32/z/AAKen3N/df8Ar5ntFFeLXmo+LdY+Jmv6NoF9DbDRIbR9Oa91WeFPKIDPIyKji53cqWc/LwRzzW/JLqel/FKK41mS9vdN1C8ENhc2OpSCK1k8rH2ee23BGBIZg+0nOM44wJXt5/1/X3bg9L+X9f1/kelUUVynxL1hND8CXl6+rTaUQ8arPBD5sjEuB5ajcvLfdzuGM5yMUho6uivC7HW9W/4Rf4q2DapfKuirvsT/AGjLLNanyi+BOT5hwy9z6jpTvB2v61beMPDMP9p398uo+DhezwXV08oluByGAYnDHGMjGe+TzR0v5J/em/0EtVfzt+KX6nrWr+KtI0LVNO0/VbiSC41SUQ2n+jSskkn93eqlVPsSK1Zpo7eCSaZgkcal3Y9FAGSa+eH1QXnh/wCGXiHW9ZmmvtQ8QCa8NzdHy42BdSFRjiMLwuFAHPOTXuPiX/SLO30teupTrA4/6ZDLSfmisPqRVcrS872/L/MlSvLytf8AP/I1oZUngjmiJKSKGUlSDgjI4PIp9cX8W9W1XQvhfqt/oEjw3cKx4ljGWiQyKHYfRSee1cdrmqX+nXnjbQ7HU9QOnWnhpdSguGv5Wltrg7z8sxbeA2AcbscYAwcVLejfr+Cv+RaTbSfX/NL9T2WiuO+GtvPceC9D1q91O/vLq80m3EwuLlpIy23O/aejnOC3U4Ga7GqlHlk49iU7q4UUUVIwooooAKwfEXjXQ/ClxaQa5NdQveuI7fyrCecSueiAxow3HsvU+lb1eX/GsTM3glbSWKG4Pia28qSaMuithsEqGUkZ7Aj6ihayS7tL72HRvyf4HTv8SfCkWj3+py6k8cGmsq3qPZzLNbFjgb4SnmKD6lcd66S1uYryzhurZ98M8ayRtgjcpGQcHnoa8e+Ifgk6H8P/AB34k1TU/wC0NY1azSOZ44PIhREYBVSPcxHGOSzE4rM8a+Ip7XQPI0zX72K70/wvDfJbW0z2yWrjaFlMiMPNLZx5bKy8ZyO6urPyt+Tb/L+tws7pLrf9F+v9PQ90muoLeWCOeVUe4fy4lJ5dtpbA/BSfwqUnAJrxTWca38QfhXc6pd3QN5ps887w3kkALC3VtwKMu3knOMZHByOKl8L6p4y8S+N9Xu4ry2t10nX2tZ4bnUpYwtmOBGLUIULNncJS24njpWji07ev4O39eRKknHm8l+Kb/rzPT/DninR/FlnPdaDdNcxW9w1tMXgkiKSLjcpV1ByMjtWlc3UFnEJLqVYkLrGGY4yzMFUfUkgfjXzhpviHVNC8EaqNIkEKX/jya0u5/PaDZCxGR5qgmLJAG8AkA8c1v+NdK1qHTvCNl4pvQ7N4shiiFlqk8jR2zAsqPKQjM69nI3Ywc5JpJX5bdbfjy/5/11p6X+f4X/y/rp7rRXmN61/ovxFtbq+nv9Q0K4uLe1sp7LVZT9ikKhRFPBu2yq5O7zDubnnsa9OpdLh1sFFFFIAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgCtqN/Bpeny3t2JjDCNz+RA8z49kQFj+ANcvZfFXwnqOnpf2NzqM9i7bRdpo14Yc5xzJ5W0c8cniurvTiwuM/8APJv5V47+z5aaxN8OdJeS7s5dEL3SvaC2Il3Fzgs5ch168BR1HWnHVu/SwS0imj1HRPFOj+IrrUbbSLppptMn+z3aPBJEYpPT51GenUZFa9fOurXV1Z6B8YLzTL26s7u11iGSKazuHidTkA8oQcYJ46V0MniPWNP+I/iw6ZfXd59l8KJew2b3LyxrcbR8wjJIBOBwAM596lP3U/K//kvMOzv82v8AyZL9T1G88V6Pp/iex8P3lzJFqWoKzWsRtpdkoUEtiQLsyAORuyOPUVsV4DbXMCeMPhDqN7rM11cajBcXFxLeXbSZlkhUfKGJ2AsdoVcLkYAzUtj4svZPiN4Xn03xHfahaalq97aTyyzMkVzGgBCrblmRQhIUOApbGSO50cbNR66r7nYTtbmXa/5v9P63PeaK8t8ARXOr+J/GEF1rmqyQaV4gBtU+3yNsULkxncTmMkkbOn9OYsfFl7J8RvC8+m+I77ULTUtXvbSeWWZkiuY0AIVbcsyKEJChwFLYyR3MR95pd7fjb/MHpfyv+F/8j2LQPFOkeJxenRbppzYXLWtyHgkiMcq9VIdQePbirEWt6fNr1xosVxu1C3gS4lh2N8sbEhTuxg5KngHNeAQXV3pXhf4i6zo9/d22q2XitjaJBMwWV2kRdjRg4kDAkYYH2xXTX2pamvj74g2bapqMccPhpbuOBb6ULbzbMloxu+Q5A+7ik3aKl5X/APJeYtx95xXe3/k1j2iivCPBWva1D4j+HwfV9Qvf7Y0C4lu47q6eVZpEBZW2scBu2RyR1JrU+E2peL/ErWHiK+vrb7NPNcw6nDLqUruzhj5aJbGPZCUx/C2WU5OTV8utvX8G1+hkpXV/T8Vc9jrJ8R+KNI8J6fHfa/cva20kywLIsEkoDt0B2KcZ6ZOBXDfEGa4T4ueBbNNW1Cys9S+1w3cNvfSQpMFjyoIVgM5Y/MMNyMHIGOC8V6nqF/8ACPxDZXt5NeW2m+LEsrG7mcySPEsq4BdslypJG45PHNKKu15//JJfqXNcqv5fo3+h9GdaK8L1HxR4j0ef4r2mk6jdzf2TFaz2ImlMzW3mJmVlLZwAMtjoMcAVrLfazH4s1DwzoOtzxW954YS/jvL66ef7NdM+0OHclgGB6A4GMgCi35X/AAb/AEC3f+tl+qPXqq6nqVto+l3Oo6g7Ja2sZlmdI2kKqBknaoJOB6CvD/FWrajYfCvVEE2u6Drel6rapcltamuAu8oN0czOS0bKc7W6E8itjVr68svE3jbQra/ur7R28LPft9puWn+zzsHGFZiSoZedo4GOAKmWkW15/grhCzkk/L8XY9W0jV7LXtHtdU0mbz7K7jEkMuxl3qehwwBH4irleC/DzU77Sta+G9jDqNyLLUvD8zXNvJMWiJQFlYIflUj1ABI65o8P+K765+JPhBrDxDfalYa1LqEVzNNM6JdrHnYy25Zli2kYBXaWwSQM1o4+/wAq8/wbX6ERlePM+lvxVz3WG6guJZ44JVke3cRyqpzsbaGwffDA/jUtfOun6lfeFvhp8RNc0K5uv7Uh1+5t0aS6llEcXmRqZNjMV3AH75UnpkkV6x8P7XXbaO8OrXdrNp1wsU2nxx6pNfyRqV+YtLKiswYjI64yQOAKlK6v5L8Vcp6O3m/wdjode17T/DWjTarrMskNlbjMsscEk2wepCKTj1OMCrVleQajYQXtm/mW9xGssT4I3KwyDg8jg968U8a6jc6xa/FNdX1C5gXRrRLextFuGjiEbxZ3MmdshcnALAkdsGjTtYu9QP2c6vd2+m6f4Mgv7BrO7aJTMowzkoRv2lQCrZXsRzU3XK2/J/Kzf5IWvMkvT53S/U9yorxm/wBX8Q3/AIR8OeKtTe7udPXSEn1S00zUXs7mFjg/alVGUSDAPyNx6CkTWPF/iT4k+IbfSL23tTo1zam3W71GW3RLYgM5NusbLLvGRucjbkYxV8r5uX1/B2/ry89Bc3u839f1/W2p7PRRRUlHN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJXSUAFFFFAHN/Dj/klnhT/ALAtn/6ISukrm/hx/wAks8Kf9gWz/wDRCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAZeqeF9A1u4jn1nQ9N1CaLiOS7tI5WT6FgSOlSal4f0bWLKOz1fSbG/tYm3RwXVskqIcYyFYEA4J/OtCijyApXGjaZdpapdadaTrZsGtlkgVhAQMApkfKQOOKqT+EPDVzZGzufD2lS2pmNwYJLKNkMp6vtK43HJ5681sUUAZln4Z0HT7u4urDRNOtbi5UpPNBaRo8qnqGIGWHsarJ4I8KR+X5fhjRl8pHjj26fENiNnco+XgHccjvk+tblFAGXD4X0C30h9Kg0PTYtOkbe9mlpGIWb1KAbSeB27VJ/wAI/ow0l9K/six/s6QkvZ/Zk8liTkkpjByeelaFFAGFfaTdkWulaXbabBoDQvDdQ7SjovG0RKo2bSNwIOMZBHTB07/TLDVbX7Nqdlb3sG4N5VxEsi7gcg4YEZBq1RQBRudD0m91C3v7zS7K4vLXi3uZbdGkh/3WIyv4U86VpzakmomwtTexqUS5MK+Yqk5IDYyAT1FW6KACq9/p1lqtm9pqlnb3ttJjfDcRLIjYORlWBB5qxRQBlyeGNAmW7WXQ9NkF6qrdBrSM+eF+6H4+YDAxnOMVHa+EPDdhe295Y+HtKtrm1XZBPDZRo8S88KwXKjk8D1Nc7430uw1jx14Ns9Wsba+tWluy0F1CsqEiHIJVgRwan103tp8T/CvkapdpZXS3MUunqyrAdkRIbAGSee5I4GAKaE2dJBoWkWtxJcWulWUM0svnSSR26Kzyf3yQMlvfrUE+u6NH4ih02aQHUMbYz9ncqhYZ2GXbtVmAztLAkDoa43Ubu/1y/wDGV3Bqd3ZN4cHk6fHBOyRiVYBKzyICBJksF2tkADgAnNSWGlXfinVdK12EXljp94tpqd4jyRGGeVYwUEajMgYHYGLFVwowCTkJa27afc9vwQ5aX76/ev8Ahz0N0WSNkkUOjDDKwyCPQ1kx+EvDcNjcWcPh/S47W6VVngWyjCShfuhlxhgO2elcD42hkuPCsevQX2o2c99rdsiPZX81vut3mSEA+WwBDINwznG84xmvSH0ixm0f+yru3F7ZeWI2ivWNx5ij++ZCxf6sSaLe7f5fgn+obO39b/8AAJNP06y0mxjstLs7eytYs+XBbRLGiZOThVAA5JNWa4n4SwxW3gQwW8aRQxanfpHHGoVUUXUgAAHQAdq7anLcXkFFFFIYUUUUAFZWreF/D+vzRy67oWm6nJGu1HvLOOZkHXALA4FatFAFK90bS9S0wabqOm2l3YgKBazwK8WF+78hGOMDHHFVx4V8PBVUaDpgVbc2qj7HHgQnrF0+5/s9K1aKA2KB0LSGhs4m0qyMdgwa0Q26YtiBgGMY+Qj2xSnQ9JOrnVjpdkdRKeWbw26edt/u78bse2avUUAZFt4R8N2djdWVp4f0qC1vMfaYIrKNY5/99QMN+NTv4f0aTSY9LfSbFtPiKmO0NshiQg5GExgYPTitCigCo+k6dJqEN/Jp9q95ACIrloVMkYPUK2MjOO1W6KKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7yukoAr3+n2eqWMlnqdpBeWsoxJBcRCRHGc8qQQeRVXSPDmieHxKNB0fT9ME2PN+xWqQ78ZxnaBnGT19a0qKAMq38LeH7RrxrXQtNha/BF2Y7ONftIJJIkwPnzk9c9aWy8L6Bpl2l1p2h6baXEcXkpNBaRo6x/3AwGQvt0rUooAoWWhaRpzbtP0qytG3s+YLdEO5vvHgdTjk96iXwxoCMjJoemqY5zcoRaRjbKesg44Y5+91rUooAz9O8P6No9xcXGkaRY2E10czyWtskTTHJOWKgFuSevrUa+GNARkZND01THOblCLSMbZT1kHHDHP3utalFAGe2gaO+oQXz6TYteW5Yw3BtkMkRY5ba2MjJJJx1qvN4R8N3F7c3lx4f0qW5u1KXE72UbPMp6h2K5YHA4PpWxRQBi2vg3wxY3Vtc2XhzSbee0GLeWKxiRoRknCELleWJ49T61ctdE0qy1G41Cy0yzt726/19zFbokk3+8wGW/Gr1FFwOC8a+DtY8QePvDGr2dvpdxp2kCcXMF7O6tMJV2MAoiYEAc8nnpx1rp7jwr4eu9Kg0y60HTJ9Pt23Q2klnG0UR55VCMA8noO9a1FHSw223czLLw3oem3k93p2i6faXNwu2aeC1RHlHozAZI+tOsPDuiaU0raZo9hZtMAJDb2qR7wCSAcAZ5JP1JrRooEcF8RPAlxrvgQ6B4Os9KsDJex3MgkJt4xtcOTiONssSB2HUnPaulsfDulppE1tc6Fpdv9vG+/toIVeGaQj5txKL5n1ZQT6VsUUdLf1/WgdbmLbeDfDFldW1zZ+HNIt57UYt5YrGJWhGScKQuV5Ynj1PrU0XhjQYGgaDRNNja2laaApaRgxSN951wOGPcjk1qUUAU49H0yGW7kh060jkvjm6dYFBuOMfOcfNxxzml0zSdN0WzFpo2n2un2wJYQ2sKxICep2qAKt0UAUbjRNKu74Xt3plnPdrGYhcS26tIEPVdxGce1N1HQNH1eKKLVtJsb6OEERpc2ySBMjBwGBxxx9K0KKAKVxoulXkcCXemWc6WzK0Cy26sIiv3SoI+UjtjpST6JpVzqsOp3OmWc1/bjEN3Jbo0sY9FcjI/A1eooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKAOb+HH/JLPCn/YFs//AEQldJXnfgHwD4PvPht4aurzwnoc9xNpNrJLLLpsLPIxhUlmJXJJJySa6D/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAM/xlK9j4y8Kak9pfT2lrLdee9nZS3Jj3Q7VysSsQCeM4q7rfhzVdW8W6LrNlq9pa2+ll2FtLp7SPL5i7Xy/mrj5eny8Hk56U/wD4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaFoKxW1jwTNf3+qPYar9istbjWPVLf7PvaQBdm6N9w8tinykkPwBgAjNdDPp/wDxI307T5BZj7OYIXVd3lDbtBAzzisf/hXHgj/oTfD/AP4K4P8A4mufs/APg9viTrNq3hPQzbx6TYSJEdNh2KzTXgZgNuASEUE99o9BR0sVfW5seMPB974h0Ow0rSNTtdLtrOeGb97YtcFjCytGBiVMDK89cjpin/Ytcs7+PV/E2tW97Z2EbslnpWjTKzSMNu8gSyu5ClgFUfxZ7VL/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE0XYtCn8L4LiDwWftVrcWrS6hezLHcwPC+x7mRlJRwGGVIPI712Fc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE027sDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQAeKP+Ri8Gf8AYak/9N95XSV534j8A+D4Ne8JxweE9DjS41aSOZU02ECRfsN021gF5G5VOD3UHtXQf8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AHw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUAFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZmn+IdM1TULixsp3a5tgGdHgePcpJAZCygOuQRuXIzxmgDTooooAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooA5v4cf8ks8Kf8AYFs//RCV0led+AfH3g+z+G3hq1vPFmhwXEOk2scsUupQq8bCFQVYFsggjBBroP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkrhL5rrxN481nSf7RvLG20WxgkhFncPCWnl3ne+0jeFCLhDlTk5B4xr/8ACx/BH/Q5eH//AAaQf/FVzOsa74Sutbm1TRPiP4d02e8tltL3fdwzCSNSxUp+9XbIN7AMdw55U0nfoNf1951XgjXLjxH4C0nV7lV+1XVqryADapfoT7AkVheFzc2HipbTxZHqEWu3aSzxTJqs89hcKG+ZY4yVRCqleDGDjkE8mlsvFvg3R9Ns9L0Px14YtdOtLQ26RvexSSBgAEYP5oGBzkFTn1FRad4r8L/2hb6h4i+IfhfULu1R0tza3MNvGm7G5tpmcliBjO7GM4Aq21zton7Nj0GoL23e6sZ4Irma0eRCqzwbd8ZI+8u4EZHuDXHat4h+FWvyRPrur+DtTeEERNeXNrMUB643E46DpV65+Ifg42Ukdh428NQT7CInlv4XRGxwSokUkewI+oqHsV1E+GV1d3nw90+bUbua9uS0yvcTtud8TOASfoPpWTfTXniTxP4pt49TvLGPw/BEloLWdox57xGQyOFIEgGVAVsrweOaq+FPEXh7wx4QbRz8SfCd3cRtI1tc+ZGipuYt86faCXwzHoy8YHvUeq6t4TvNRvLvTviV4dsDqlsltqSi6hfzQoIDxfvR5b4YjJ3jGOOM053bdv6YoWS1O38I6y/iLwZpGsTII5L6zindR0DMoJx7ZrYrk9P8cfD/AEvTbawsfF3h6K2tYlhiQapD8qqMAfe9BVj/AIWP4I/6HLw//wCDSD/4qqm05NrYmN1FJnSUVzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FVJR0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lc3Y/8lT13/sC6b/6PvqP+Fj+CP+hy8P8A/g0g/wDiq5+z8feD1+JOs3TeLNDFvJpNhGkp1KHYzLNeFlB3YJAdSR23D1FAHolFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAF7xPDq9x4bu4PDhhXUJE2RtNO0IUE/MQ4ViGxnBx1xXCXOvDTPDM2n6R/aum6tNq9rplyupX8t5JbmVlHmRvI7jBQkqRxnqMgit/VviB4auLMLovxA8L2NyHB8y5uobhCvdSglQ8+oYVjXepeA9R0m8iv/H2gvqN5PFcvfRahAnlyxEGMom84VSo4JJOTknOaFo9fL81+lwZteH55dJ8fal4XW5urqyTT4b+3a7neeSMs7o6mRyWYEqCMnjJxxgDsa890LxL4O0/UrzV9W8feG7/VrxEhknhvYYI1jTO1EQyuQMsxJLHJP0AtP4g+FMmtjWZNX8HNqgIIvmubUzggYB8zO7px16U+wdXb+v6ZY+KrXsPwz1q70zVLzTLi0tnnWW0ZVZtqn5SSCQD6rg8cEVH4jvri717wx4bjup7aHVFmnu5beVo5WjijB2K6kMuWdckEHAODzVHxp4n8J+KfCV7oll8QfDOn/bozDLPLdxT4QjB2qJUwfckj2qG/8Q+Fb6z0ic/EXwxFreksWhvEuYvJclSjK0XnZKkHpvzkA5o0t8wfT5lE+I9SN1/wiAvrkE+Izpf27zD5/wBm8j7Rjf137fk3/exznPNdT4TvJ7fxN4h8OS3E9zBpjQS2slxI0sixypnYzsSz4ZW5JJwea5k3XgT+xwkfxB0BdXGof2p/aJvoCDc9MmPzPubfk27s7eN2ea1fD/ifwTo8l/eXnjvw7ealqUqy3dwl/DGrFVCqqJ5jFVAHALE8k55prb+tdF+t/wCmJ76f1q/0t/SO+orm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqpGdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSV534j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSVieLFtF0KWfUZNW+zQjc8WkmYTOe2PI/ecH0IHrxVb/hY/gj/ocvD/AP4NIP8A4qs/VfiBoEwi/sT4g+EbMhj5v2ueO43j0XbcR7T7nNJq6GtDn7LxHdah4J8JWNrrc9y+uai1pNfAslxFEokdoyxAIkCoIy2Ac5I5wa6fwneT2/ibxD4cluJ7mDTGgltZLiRpZFjlTOxnYlnwytySTg81z0178P8A+w4LSx8e6Db31tftqUN62oW7YuWZmZigcZVtzAqCPlOMjrWh4f8AE/gnR5L+8vPHfh281LUpVlu7hL+GNWKqFVUTzGKqAOAWJ5JzzV3Wv9dv+D/TJtsv63f6W/pDdS+Jd5ZN4nePw25g8NSJ9rea9RDJEy7i8YUNk7cMFJGQeSDxV2T4g/2fqWp2+taZ9mis9J/teKSCfzmlgBIIZdo2vkdAWHvXFakNA1FfF8f/AAtXwlHH4nCq4xGTbqqhAAftPzHYOuBzzjHFR65reiWNxdeIP+FkeGLqRdD/ALK+yWsSO756OB57/wAZyRtb5cjnrUdP67P9bFaX/ruv0ud7pfji6n1+LSNY0NrOaayOoJPb3aTQpb9MuW2MGzgFVVgMjnHNULXxTfaZrGlaTDoclzeeIo7jUFuJbhIo0IGQjfeb5VMak7fTGeQOP0i88L6RIlk3jvwndQ6jb/Zp50nkEsECjOwSTXcu1T90RjbgtuA+Uiug1nXfDWo+N9H1+x+JHhS1i0uGWJLWSWKUyeYAGJcTrjhVwNvHPXPFu1/68/8AgfcSr21/rb/gmhY/Eq4urbR7u40JYLTUNSbSpmF6HeG5DMvyrsw8e5CNxKn/AGav/wBpXkOq6prGpeHb6z+y2rxW800tuySKGyFURyM5Z2wfmAAwB168BFBocOiafYL8WPCBax1p9YWUpH87s7PsI+1dNzt36Y9MnvdS8beCNSjto5PG/h9Y4rhJpF/tKE+ZsO4D7/HzBT36Y70tP67WX/BH18v8m/8AgFa8vri00+Twnplh/aV7Dp32jUpPtjWuxZN2SrqpYyMwcgDaOOWHFc74a8aXvhj4P6BcRaSt5DDo/wBsubm7u/s8YCn7iuUYPKeSFOM+taGqa14Sm8UvruifEjw7p891arZ3sct1BOk0aklSv71Sjjc2DyOeVNc1Z6T4RstLtrAfFjQLqKLSZNMJu5LZzGrZ+eHEiiM84Od5IAGeM0m3Z23/AP2v+ANJXV9v+Gv+p6Fb+NL6XxfpumS6RDDp2qWDXtrfvenc21VJjMfl4DDdn7+MAn2rb8OaleaxoNvf6hZRWUlwN6xRXBmGw/dbcUQ8jBxjjNeaeJtX8I3vg7QdLXx5oT6jp9xbxx3ttewptUDZK2N7bQYi45PUjviu5j+IfgWKJY4/GHh5UQBVUapBwB/wKqdtbd/6/O3yIV7K/b+v8zpqK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqko6Siub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqAOkorm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qgDpKK5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKoAPhx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iErpKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5ux/5Knrv/YF03/0ffV0lc3Y/wDJU9d/7Aum/wDo++oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAoqK5leC1llihe4eNCyxRkBpCB90ZIGT05IFc5p2pN4lneC41L7BJGMy6XAGiuFGSMuzgPg44KKvThmFG4HUUV43dP5ngfXfG8iH+37PWJVtrg/6yKOK5ESwKT0RlXBXoSxPXmvUtfsL3VvDl3Y6berp9zcxGNbh4jJ5eevyhlOcZHUY60fZuP7VjSorjfAkFlpV7qmiJ4e0vRdQsxE07aZCqRXcbBvLk4AOflcFWyQQeTnNdlTasSgooopDCiiigAooooAKKKKACiiigArm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76gDpKKKKACiiigAooooAKKKKACiiigAooooAKKxfEGtz6QbcR2p8mbPmXrozxW2MY3KgLc577V4OWHGat1pd1rfhq6OmeI/MuL+3McV8q+ZAit1KRoyg8ZwxYsM9e1LpdB1szpKK8j1C7Xwr4L8TaZpehafoGsWoto5bjR4QiTRTP5aTggAggb+GyVI6nrXQadZW3hf4pWejaFbpa2F/pEs9xBEML5sUiBZSP7zCRgW6tgZziqSu7f1tf8hX0v8A1vY7yiiikMKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8rpKACiiigAooooAKKKKACiisrXtJ0jU7Mt4ihiurCBGaS3uVDwnodzIRgkY4z0z60mBq0V5P/AGde6b4d8MeHb4zpYazrsoktpHJMVniWWO2J6gYVAV9Mr0rpfB23TvGHijQLFFi0yxe2ltoUACW5kjy0aAfdXKhsdtxqrf193+Yn/X3tfodnRXmerePfE9mPGc0VppMUPhd43Ct5srXMRTzCM5XYxUjnDAHIwetXp/HGr6XrGq22oWltexwaEdZto7ON0cAEgxMWY7zwPmAX/dpdL/1tf8irO9v63t+bR31MjmilaRYpEcxtscKwOxsA4PocEHHuK4XSfGurr4hj07WF0m5tpNK/td720eSLyIemzYd4c5/i3oCMkDjFQprXiHS/EOgaFa22nxnXbe6vZ7m5Z3eGUfOV2DaCF3qB83IBHy4BLs/6+f8Akybp/wBf13R6HWRp/iKK+1ufS5LG9sp44/OjNyihbiPO0umGJAB4IYKeRxzXFaf8QNflsdCv7yHTfIu9ZfRrqGKKQMZA7p5qMXwoymdhDHB+9W9LNr2nXGq6tqmn6an7kxWb299JK7ndiKPY0SBcs3J3NkkdgMLz/rb/AIK/4cfl1/4Nv0f/AAx1SXEEsJmjmjeJSwLqwKgqSDz7EEH6UltdQXtslxZzx3EEgyksThlYeoI4NcPfT3kjXHgvR00+RNP0pJb99SgaZbgSblEYUMvLbGJY5AyPlbPHKaH4s1fw18IfDraYdNijh0Nrv/S42ne4ZP8Alkkcbq68cmTDKvGRQ7JNv+t/8v60Czdkv62/z/rU9oorhV8Wa1D4s0RdQk0230HWbBp4W8h/OSZYw5iMhk2ngswO3kKRjvXS+GrjU7zw9a3WuNbtdzr5pFtA0SqrcqCrOxzjGeetOzW/9f1YSaaujVooopDCiiigAooooAKKKKAOb+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiErpKACiiigDzvwD4+8H2fw28NWt54s0OC4h0m1jlil1KFXjYQqCrAtkEEYINdB/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVVLUfGHw41aNE1HxR4bn8s7o3Opwh4jjG5GD5U+4INdjRQB5rJe/DaXVJbhvHWl/ZJrlbybTf7XtjbyXCkESkH585VTgMFJGSM1pX3i/wjeJcrH8T7G0850aI2+p2QNtt6hNynIbvv3e2K7iijpYOtzi9K8X+AtLWVv8AhOdGu7qcgz3VzqtuZJSBgZ2kKB7KABk8cmtD/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqufs/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RXolFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FVjXfiH4ey+fJpnjjRtGurhg0l1p2qWqM5BHLK25GPAGWUnHFd7RQBwI134cS6RfWGo+M9F1EajH5d5Pc6tB5k427edpULx0ChQDkgDNJoviDwDpF7Ley+P9L1K9kiWAXN7q1qXSJTkRrs2gDJznGT3JwK7+igOljm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvxH4+8Hz694Tkg8WaHIlvq0kkzJqUJEa/YbpdzENwNzKMnuwHeug/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qsfX/FPgzXFthH8S9O0z7PJ5g+x6lZMJG7bhKrg46jjrz1ArvKKAPOptZ8CXujmy1P4k2N9OtwtzDfS6taLNBIuNrIECoMY6bMHJznJq7onin4f6HFceV430W6ubqXzrq7uNVtzLO+Au5tpCjAAAAAAA6V3FFAHkl9b/AA+v/wDhIhN8U4QniPAvUXVbDAAG0BP3eQNo29zj35qvr1/4Ps47rXNP+I8d/qSaT/ZqW8erWC+ZH68Kp3Anfww5GBxxXsdFHS39dvyHfW/9d/0PDvCuv/DwL9l0TxzbJptyf+JjDe29jpwbABAGIImdicAn5ht3cg4NdVq2r+BNW8Wadr//AAsqxtLjTo3jght9UsvKw/38h1YkkAd+MDGOc+j0U27knj8dj8PYtKtLBPitGI7PUm1SJ/7V0/d55Ytk/u8EbmY4x/Ee2AOyvPHHgO++zifxpoW2CZZgo1WDDsvTd83QHB4xyBXXUUf1/X3D/r+vvPOtV1b4e6nrq6xD8QdO029MH2ad7LWLYC5hyTscNuHBJwwwwycEViWWlfC7TrJLSx+IsEUH9ntpsynXreTz4SScEvkrgsSNm0dsEcV7BRS6W/r+tWO7vf8Ar+tDyDxB4j+HuqaNpfg9fGVjcyWMttIL2S9jQJEhwxMy7YyxQMhVTn5uRjNd0PiN4HUADxj4fAHQf2pB/wDFV0tFO7e/qTb8Dm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SikM5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v4cf8AJLPCn/YFs/8A0QldJRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==" alt="" width="517" height="310" vspace="0" hspace="0" border="0" style="width:517px;height:310px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM1NAAAkpIAAgAAAAM1NAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMjoyNjoxOAAyMDIxOjA2OjI3IDEyOjI2OjE4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTI6MjY6MTguNTQwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAKUC3gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAorktN8cXur6Vaalp/gnxBNaXkKTwSebYLvR1DKcG5BGQRwRmrP/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXJXXji9srmygufBPiBJb6YwW6+bYHe4jeQji54+SNzk4HGOpFWf+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkoqjomqwa9oGn6vZpIlvqFrHdRLKAHVXUMAwBIzg84Jq9QAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQldJQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFABRRUN4sz2M62pCzmNhGT2bHH60m7K41q7GPdeNNDtdUk04XM91dQsFmjsbKa68g8cSGJGEfX+LFamnapY6vafatLu4ruDcU82Fwy7hwRkdweD6HIryr4IXE+l/C/UbMW8L+JLG9uH1C0u5jC7Sls7pGCsRlcYbac4rF8QeOb/AMTfA1vFWm20nhh5NWi8g2OpyF5CZQkhfaqDB5+XkHrwau2tvT8bEt2Tfr+Fz3mivOvGYj0e40mxHiHVVk1rU8/Y/tLg3H7sAosysrQRqQHO0nkkAHOK86l8T67e/s32eqtruoLqEGsrbpeQ3jpKY/O2YZlI3/Kf4s54PWktXb0/Gy/Ub0jf+ur/AEPoqoby6isbKa7uSwhgjaSQpGzsFAycKoJJ9gCa8Tu9V1WKf4u6VHq+p+TpVpFdWLfbpfNt5DCXOx924LuAO0HHbGDijRtb1Cfxz4bt5dXvZ4brwT9puoJLx3R5dn+sZC2N3vjJpSuo3Xa/4N/oUlrr/WqX6nsOgeINM8UaHb6xoVz9qsLnJim8tk3YJU8MARyD1FaNfPngO+v1+HPww0uG5uLbS9TvbqG+ktpmhZsGRkTzFIZckHoQeKuf8JtrI02306/vruPSf+Ewl0eXUhMyy/ZF+6pmHzA5O3fndx1zzVyj77iu9vxS/VGafucz/rf/ACZ7vUVzdQWcQkupViQusYZjjLMwVR9SSB+NeX/EHSL3wt4bsNf0jXtcvYtAvVlvbeTU5T59qXBZH2sN5QEEFskgYYtWZ8StLieHwdcPdaoqar4ogkeOTULgGNHBIVQX/d4AB+XG05xipirteqX32/z/AAKen3N/df8Ar5ntFFeLXmo+LdY+Jmv6NoF9DbDRIbR9Oa91WeFPKIDPIyKji53cqWc/LwRzzW/JLqel/FKK41mS9vdN1C8ENhc2OpSCK1k8rH2ee23BGBIZg+0nOM44wJXt5/1/X3bg9L+X9f1/kelUUVynxL1hND8CXl6+rTaUQ8arPBD5sjEuB5ajcvLfdzuGM5yMUho6uivC7HW9W/4Rf4q2DapfKuirvsT/AGjLLNanyi+BOT5hwy9z6jpTvB2v61beMPDMP9p398uo+DhezwXV08oluByGAYnDHGMjGe+TzR0v5J/em/0EtVfzt+KX6nrWr+KtI0LVNO0/VbiSC41SUQ2n+jSskkn93eqlVPsSK1Zpo7eCSaZgkcal3Y9FAGSa+eH1QXnh/wCGXiHW9ZmmvtQ8QCa8NzdHy42BdSFRjiMLwuFAHPOTXuPiX/SLO30teupTrA4/6ZDLSfmisPqRVcrS872/L/MlSvLytf8AP/I1oZUngjmiJKSKGUlSDgjI4PIp9cX8W9W1XQvhfqt/oEjw3cKx4ljGWiQyKHYfRSee1cdrmqX+nXnjbQ7HU9QOnWnhpdSguGv5Wltrg7z8sxbeA2AcbscYAwcVLejfr+Cv+RaTbSfX/NL9T2WiuO+GtvPceC9D1q91O/vLq80m3EwuLlpIy23O/aejnOC3U4Ga7GqlHlk49iU7q4UUUVIwooooAKwfEXjXQ/ClxaQa5NdQveuI7fyrCecSueiAxow3HsvU+lb1eX/GsTM3glbSWKG4Pia28qSaMuithsEqGUkZ7Aj6ihayS7tL72HRvyf4HTv8SfCkWj3+py6k8cGmsq3qPZzLNbFjgb4SnmKD6lcd66S1uYryzhurZ98M8ayRtgjcpGQcHnoa8e+Ifgk6H8P/AB34k1TU/wC0NY1azSOZ44PIhREYBVSPcxHGOSzE4rM8a+Ip7XQPI0zX72K70/wvDfJbW0z2yWrjaFlMiMPNLZx5bKy8ZyO6urPyt+Tb/L+tws7pLrf9F+v9PQ90muoLeWCOeVUe4fy4lJ5dtpbA/BSfwqUnAJrxTWca38QfhXc6pd3QN5ps887w3kkALC3VtwKMu3knOMZHByOKl8L6p4y8S+N9Xu4ry2t10nX2tZ4bnUpYwtmOBGLUIULNncJS24njpWji07ev4O39eRKknHm8l+Kb/rzPT/DninR/FlnPdaDdNcxW9w1tMXgkiKSLjcpV1ByMjtWlc3UFnEJLqVYkLrGGY4yzMFUfUkgfjXzhpviHVNC8EaqNIkEKX/jya0u5/PaDZCxGR5qgmLJAG8AkA8c1v+NdK1qHTvCNl4pvQ7N4shiiFlqk8jR2zAsqPKQjM69nI3Ywc5JpJX5bdbfjy/5/11p6X+f4X/y/rp7rRXmN61/ovxFtbq+nv9Q0K4uLe1sp7LVZT9ikKhRFPBu2yq5O7zDubnnsa9OpdLh1sFFFFIAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgCtqN/Bpeny3t2JjDCNz+RA8z49kQFj+ANcvZfFXwnqOnpf2NzqM9i7bRdpo14Yc5xzJ5W0c8cniurvTiwuM/8APJv5V47+z5aaxN8OdJeS7s5dEL3SvaC2Il3Fzgs5ch168BR1HWnHVu/SwS0imj1HRPFOj+IrrUbbSLppptMn+z3aPBJEYpPT51GenUZFa9fOurXV1Z6B8YLzTL26s7u11iGSKazuHidTkA8oQcYJ46V0MniPWNP+I/iw6ZfXd59l8KJew2b3LyxrcbR8wjJIBOBwAM596lP3U/K//kvMOzv82v8AyZL9T1G88V6Pp/iex8P3lzJFqWoKzWsRtpdkoUEtiQLsyAORuyOPUVsV4DbXMCeMPhDqN7rM11cajBcXFxLeXbSZlkhUfKGJ2AsdoVcLkYAzUtj4svZPiN4Xn03xHfahaalq97aTyyzMkVzGgBCrblmRQhIUOApbGSO50cbNR66r7nYTtbmXa/5v9P63PeaK8t8ARXOr+J/GEF1rmqyQaV4gBtU+3yNsULkxncTmMkkbOn9OYsfFl7J8RvC8+m+I77ULTUtXvbSeWWZkiuY0AIVbcsyKEJChwFLYyR3MR95pd7fjb/MHpfyv+F/8j2LQPFOkeJxenRbppzYXLWtyHgkiMcq9VIdQePbirEWt6fNr1xosVxu1C3gS4lh2N8sbEhTuxg5KngHNeAQXV3pXhf4i6zo9/d22q2XitjaJBMwWV2kRdjRg4kDAkYYH2xXTX2pamvj74g2bapqMccPhpbuOBb6ULbzbMloxu+Q5A+7ik3aKl5X/APJeYtx95xXe3/k1j2iivCPBWva1D4j+HwfV9Qvf7Y0C4lu47q6eVZpEBZW2scBu2RyR1JrU+E2peL/ErWHiK+vrb7NPNcw6nDLqUruzhj5aJbGPZCUx/C2WU5OTV8utvX8G1+hkpXV/T8Vc9jrJ8R+KNI8J6fHfa/cva20kywLIsEkoDt0B2KcZ6ZOBXDfEGa4T4ueBbNNW1Cys9S+1w3cNvfSQpMFjyoIVgM5Y/MMNyMHIGOC8V6nqF/8ACPxDZXt5NeW2m+LEsrG7mcySPEsq4BdslypJG45PHNKKu15//JJfqXNcqv5fo3+h9GdaK8L1HxR4j0ef4r2mk6jdzf2TFaz2ImlMzW3mJmVlLZwAMtjoMcAVrLfazH4s1DwzoOtzxW954YS/jvL66ef7NdM+0OHclgGB6A4GMgCi35X/AAb/AEC3f+tl+qPXqq6nqVto+l3Oo6g7Ja2sZlmdI2kKqBknaoJOB6CvD/FWrajYfCvVEE2u6Drel6rapcltamuAu8oN0czOS0bKc7W6E8itjVr68svE3jbQra/ur7R28LPft9puWn+zzsHGFZiSoZedo4GOAKmWkW15/grhCzkk/L8XY9W0jV7LXtHtdU0mbz7K7jEkMuxl3qehwwBH4irleC/DzU77Sta+G9jDqNyLLUvD8zXNvJMWiJQFlYIflUj1ABI65o8P+K765+JPhBrDxDfalYa1LqEVzNNM6JdrHnYy25Zli2kYBXaWwSQM1o4+/wAq8/wbX6ERlePM+lvxVz3WG6guJZ44JVke3cRyqpzsbaGwffDA/jUtfOun6lfeFvhp8RNc0K5uv7Uh1+5t0aS6llEcXmRqZNjMV3AH75UnpkkV6x8P7XXbaO8OrXdrNp1wsU2nxx6pNfyRqV+YtLKiswYjI64yQOAKlK6v5L8Vcp6O3m/wdjode17T/DWjTarrMskNlbjMsscEk2wepCKTj1OMCrVleQajYQXtm/mW9xGssT4I3KwyDg8jg968U8a6jc6xa/FNdX1C5gXRrRLextFuGjiEbxZ3MmdshcnALAkdsGjTtYu9QP2c6vd2+m6f4Mgv7BrO7aJTMowzkoRv2lQCrZXsRzU3XK2/J/Kzf5IWvMkvT53S/U9yorxm/wBX8Q3/AIR8OeKtTe7udPXSEn1S00zUXs7mFjg/alVGUSDAPyNx6CkTWPF/iT4k+IbfSL23tTo1zam3W71GW3RLYgM5NusbLLvGRucjbkYxV8r5uX1/B2/ry89Bc3u839f1/W2p7PRRRUlHN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJXSUAFFFFAHN/Dj/klnhT/ALAtn/6ISukrm/hx/wAks8Kf9gWz/wDRCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAZeqeF9A1u4jn1nQ9N1CaLiOS7tI5WT6FgSOlSal4f0bWLKOz1fSbG/tYm3RwXVskqIcYyFYEA4J/OtCijyApXGjaZdpapdadaTrZsGtlkgVhAQMApkfKQOOKqT+EPDVzZGzufD2lS2pmNwYJLKNkMp6vtK43HJ5681sUUAZln4Z0HT7u4urDRNOtbi5UpPNBaRo8qnqGIGWHsarJ4I8KR+X5fhjRl8pHjj26fENiNnco+XgHccjvk+tblFAGXD4X0C30h9Kg0PTYtOkbe9mlpGIWb1KAbSeB27VJ/wAI/ow0l9K/six/s6QkvZ/Zk8liTkkpjByeelaFFAGFfaTdkWulaXbabBoDQvDdQ7SjovG0RKo2bSNwIOMZBHTB07/TLDVbX7Nqdlb3sG4N5VxEsi7gcg4YEZBq1RQBRudD0m91C3v7zS7K4vLXi3uZbdGkh/3WIyv4U86VpzakmomwtTexqUS5MK+Yqk5IDYyAT1FW6KACq9/p1lqtm9pqlnb3ttJjfDcRLIjYORlWBB5qxRQBlyeGNAmW7WXQ9NkF6qrdBrSM+eF+6H4+YDAxnOMVHa+EPDdhe295Y+HtKtrm1XZBPDZRo8S88KwXKjk8D1Nc7430uw1jx14Ns9Wsba+tWluy0F1CsqEiHIJVgRwan103tp8T/CvkapdpZXS3MUunqyrAdkRIbAGSee5I4GAKaE2dJBoWkWtxJcWulWUM0svnSSR26Kzyf3yQMlvfrUE+u6NH4ih02aQHUMbYz9ncqhYZ2GXbtVmAztLAkDoa43Ubu/1y/wDGV3Bqd3ZN4cHk6fHBOyRiVYBKzyICBJksF2tkADgAnNSWGlXfinVdK12EXljp94tpqd4jyRGGeVYwUEajMgYHYGLFVwowCTkJa27afc9vwQ5aX76/ev8Ahz0N0WSNkkUOjDDKwyCPQ1kx+EvDcNjcWcPh/S47W6VVngWyjCShfuhlxhgO2elcD42hkuPCsevQX2o2c99rdsiPZX81vut3mSEA+WwBDINwznG84xmvSH0ixm0f+yru3F7ZeWI2ivWNx5ij++ZCxf6sSaLe7f5fgn+obO39b/8AAJNP06y0mxjstLs7eytYs+XBbRLGiZOThVAA5JNWa4n4SwxW3gQwW8aRQxanfpHHGoVUUXUgAAHQAdq7anLcXkFFFFIYUUUUAFZWreF/D+vzRy67oWm6nJGu1HvLOOZkHXALA4FatFAFK90bS9S0wabqOm2l3YgKBazwK8WF+78hGOMDHHFVx4V8PBVUaDpgVbc2qj7HHgQnrF0+5/s9K1aKA2KB0LSGhs4m0qyMdgwa0Q26YtiBgGMY+Qj2xSnQ9JOrnVjpdkdRKeWbw26edt/u78bse2avUUAZFt4R8N2djdWVp4f0qC1vMfaYIrKNY5/99QMN+NTv4f0aTSY9LfSbFtPiKmO0NshiQg5GExgYPTitCigCo+k6dJqEN/Jp9q95ACIrloVMkYPUK2MjOO1W6KKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7yukoAr3+n2eqWMlnqdpBeWsoxJBcRCRHGc8qQQeRVXSPDmieHxKNB0fT9ME2PN+xWqQ78ZxnaBnGT19a0qKAMq38LeH7RrxrXQtNha/BF2Y7ONftIJJIkwPnzk9c9aWy8L6Bpl2l1p2h6baXEcXkpNBaRo6x/3AwGQvt0rUooAoWWhaRpzbtP0qytG3s+YLdEO5vvHgdTjk96iXwxoCMjJoemqY5zcoRaRjbKesg44Y5+91rUooAz9O8P6No9xcXGkaRY2E10czyWtskTTHJOWKgFuSevrUa+GNARkZND01THOblCLSMbZT1kHHDHP3utalFAGe2gaO+oQXz6TYteW5Yw3BtkMkRY5ba2MjJJJx1qvN4R8N3F7c3lx4f0qW5u1KXE72UbPMp6h2K5YHA4PpWxRQBi2vg3wxY3Vtc2XhzSbee0GLeWKxiRoRknCELleWJ49T61ctdE0qy1G41Cy0yzt726/19zFbokk3+8wGW/Gr1FFwOC8a+DtY8QePvDGr2dvpdxp2kCcXMF7O6tMJV2MAoiYEAc8nnpx1rp7jwr4eu9Kg0y60HTJ9Pt23Q2klnG0UR55VCMA8noO9a1FHSw223czLLw3oem3k93p2i6faXNwu2aeC1RHlHozAZI+tOsPDuiaU0raZo9hZtMAJDb2qR7wCSAcAZ5JP1JrRooEcF8RPAlxrvgQ6B4Os9KsDJex3MgkJt4xtcOTiONssSB2HUnPaulsfDulppE1tc6Fpdv9vG+/toIVeGaQj5txKL5n1ZQT6VsUUdLf1/WgdbmLbeDfDFldW1zZ+HNIt57UYt5YrGJWhGScKQuV5Ynj1PrU0XhjQYGgaDRNNja2laaApaRgxSN951wOGPcjk1qUUAU49H0yGW7kh060jkvjm6dYFBuOMfOcfNxxzml0zSdN0WzFpo2n2un2wJYQ2sKxICep2qAKt0UAUbjRNKu74Xt3plnPdrGYhcS26tIEPVdxGce1N1HQNH1eKKLVtJsb6OEERpc2ySBMjBwGBxxx9K0KKAKVxoulXkcCXemWc6WzK0Cy26sIiv3SoI+UjtjpST6JpVzqsOp3OmWc1/bjEN3Jbo0sY9FcjI/A1eooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKAOb+HH/JLPCn/YFs//AEQldJXnfgHwD4PvPht4aurzwnoc9xNpNrJLLLpsLPIxhUlmJXJJJySa6D/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAM/xlK9j4y8Kak9pfT2lrLdee9nZS3Jj3Q7VysSsQCeM4q7rfhzVdW8W6LrNlq9pa2+ll2FtLp7SPL5i7Xy/mrj5eny8Hk56U/wD4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaFoKxW1jwTNf3+qPYar9istbjWPVLf7PvaQBdm6N9w8tinykkPwBgAjNdDPp/wDxI307T5BZj7OYIXVd3lDbtBAzzisf/hXHgj/oTfD/AP4K4P8A4mufs/APg9viTrNq3hPQzbx6TYSJEdNh2KzTXgZgNuASEUE99o9BR0sVfW5seMPB974h0Ow0rSNTtdLtrOeGb97YtcFjCytGBiVMDK89cjpin/Ytcs7+PV/E2tW97Z2EbslnpWjTKzSMNu8gSyu5ClgFUfxZ7VL/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE0XYtCn8L4LiDwWftVrcWrS6hezLHcwPC+x7mRlJRwGGVIPI712Fc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE027sDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQAeKP+Ri8Gf8AYak/9N95XSV534j8A+D4Ne8JxweE9DjS41aSOZU02ECRfsN021gF5G5VOD3UHtXQf8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AHw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUAFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZmn+IdM1TULixsp3a5tgGdHgePcpJAZCygOuQRuXIzxmgDTooooAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooA5v4cf8ks8Kf8AYFs//RCV0led+AfH3g+z+G3hq1vPFmhwXEOk2scsUupQq8bCFQVYFsggjBBroP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkrhL5rrxN481nSf7RvLG20WxgkhFncPCWnl3ne+0jeFCLhDlTk5B4xr/8ACx/BH/Q5eH//AAaQf/FVzOsa74Sutbm1TRPiP4d02e8tltL3fdwzCSNSxUp+9XbIN7AMdw55U0nfoNf1951XgjXLjxH4C0nV7lV+1XVqryADapfoT7AkVheFzc2HipbTxZHqEWu3aSzxTJqs89hcKG+ZY4yVRCqleDGDjkE8mlsvFvg3R9Ns9L0Px14YtdOtLQ26RvexSSBgAEYP5oGBzkFTn1FRad4r8L/2hb6h4i+IfhfULu1R0tza3MNvGm7G5tpmcliBjO7GM4Aq21zton7Nj0GoL23e6sZ4Irma0eRCqzwbd8ZI+8u4EZHuDXHat4h+FWvyRPrur+DtTeEERNeXNrMUB643E46DpV65+Ifg42Ukdh428NQT7CInlv4XRGxwSokUkewI+oqHsV1E+GV1d3nw90+bUbua9uS0yvcTtud8TOASfoPpWTfTXniTxP4pt49TvLGPw/BEloLWdox57xGQyOFIEgGVAVsrweOaq+FPEXh7wx4QbRz8SfCd3cRtI1tc+ZGipuYt86faCXwzHoy8YHvUeq6t4TvNRvLvTviV4dsDqlsltqSi6hfzQoIDxfvR5b4YjJ3jGOOM053bdv6YoWS1O38I6y/iLwZpGsTII5L6zindR0DMoJx7ZrYrk9P8cfD/AEvTbawsfF3h6K2tYlhiQapD8qqMAfe9BVj/AIWP4I/6HLw//wCDSD/4qqm05NrYmN1FJnSUVzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FVJR0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lc3Y/8lT13/sC6b/6PvqP+Fj+CP+hy8P8A/g0g/wDiq5+z8feD1+JOs3TeLNDFvJpNhGkp1KHYzLNeFlB3YJAdSR23D1FAHolFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAF7xPDq9x4bu4PDhhXUJE2RtNO0IUE/MQ4ViGxnBx1xXCXOvDTPDM2n6R/aum6tNq9rplyupX8t5JbmVlHmRvI7jBQkqRxnqMgit/VviB4auLMLovxA8L2NyHB8y5uobhCvdSglQ8+oYVjXepeA9R0m8iv/H2gvqN5PFcvfRahAnlyxEGMom84VSo4JJOTknOaFo9fL81+lwZteH55dJ8fal4XW5urqyTT4b+3a7neeSMs7o6mRyWYEqCMnjJxxgDsa890LxL4O0/UrzV9W8feG7/VrxEhknhvYYI1jTO1EQyuQMsxJLHJP0AtP4g+FMmtjWZNX8HNqgIIvmubUzggYB8zO7px16U+wdXb+v6ZY+KrXsPwz1q70zVLzTLi0tnnWW0ZVZtqn5SSCQD6rg8cEVH4jvri717wx4bjup7aHVFmnu5beVo5WjijB2K6kMuWdckEHAODzVHxp4n8J+KfCV7oll8QfDOn/bozDLPLdxT4QjB2qJUwfckj2qG/8Q+Fb6z0ic/EXwxFreksWhvEuYvJclSjK0XnZKkHpvzkA5o0t8wfT5lE+I9SN1/wiAvrkE+Izpf27zD5/wBm8j7Rjf137fk3/exznPNdT4TvJ7fxN4h8OS3E9zBpjQS2slxI0sixypnYzsSz4ZW5JJwea5k3XgT+xwkfxB0BdXGof2p/aJvoCDc9MmPzPubfk27s7eN2ea1fD/ifwTo8l/eXnjvw7ealqUqy3dwl/DGrFVCqqJ5jFVAHALE8k55prb+tdF+t/wCmJ76f1q/0t/SO+orm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqpGdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSV534j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSVieLFtF0KWfUZNW+zQjc8WkmYTOe2PI/ecH0IHrxVb/hY/gj/ocvD/AP4NIP8A4qs/VfiBoEwi/sT4g+EbMhj5v2ueO43j0XbcR7T7nNJq6GtDn7LxHdah4J8JWNrrc9y+uai1pNfAslxFEokdoyxAIkCoIy2Ac5I5wa6fwneT2/ibxD4cluJ7mDTGgltZLiRpZFjlTOxnYlnwytySTg81z0178P8A+w4LSx8e6Db31tftqUN62oW7YuWZmZigcZVtzAqCPlOMjrWh4f8AE/gnR5L+8vPHfh281LUpVlu7hL+GNWKqFVUTzGKqAOAWJ5JzzV3Wv9dv+D/TJtsv63f6W/pDdS+Jd5ZN4nePw25g8NSJ9rea9RDJEy7i8YUNk7cMFJGQeSDxV2T4g/2fqWp2+taZ9mis9J/teKSCfzmlgBIIZdo2vkdAWHvXFakNA1FfF8f/AAtXwlHH4nCq4xGTbqqhAAftPzHYOuBzzjHFR65reiWNxdeIP+FkeGLqRdD/ALK+yWsSO756OB57/wAZyRtb5cjnrUdP67P9bFaX/ruv0ud7pfji6n1+LSNY0NrOaayOoJPb3aTQpb9MuW2MGzgFVVgMjnHNULXxTfaZrGlaTDoclzeeIo7jUFuJbhIo0IGQjfeb5VMak7fTGeQOP0i88L6RIlk3jvwndQ6jb/Zp50nkEsECjOwSTXcu1T90RjbgtuA+Uiug1nXfDWo+N9H1+x+JHhS1i0uGWJLWSWKUyeYAGJcTrjhVwNvHPXPFu1/68/8AgfcSr21/rb/gmhY/Eq4urbR7u40JYLTUNSbSpmF6HeG5DMvyrsw8e5CNxKn/AGav/wBpXkOq6prGpeHb6z+y2rxW800tuySKGyFURyM5Z2wfmAAwB168BFBocOiafYL8WPCBax1p9YWUpH87s7PsI+1dNzt36Y9MnvdS8beCNSjto5PG/h9Y4rhJpF/tKE+ZsO4D7/HzBT36Y70tP67WX/BH18v8m/8AgFa8vri00+Twnplh/aV7Dp32jUpPtjWuxZN2SrqpYyMwcgDaOOWHFc74a8aXvhj4P6BcRaSt5DDo/wBsubm7u/s8YCn7iuUYPKeSFOM+taGqa14Sm8UvruifEjw7p891arZ3sct1BOk0aklSv71Sjjc2DyOeVNc1Z6T4RstLtrAfFjQLqKLSZNMJu5LZzGrZ+eHEiiM84Od5IAGeM0m3Z23/AP2v+ANJXV9v+Gv+p6Fb+NL6XxfpumS6RDDp2qWDXtrfvenc21VJjMfl4DDdn7+MAn2rb8OaleaxoNvf6hZRWUlwN6xRXBmGw/dbcUQ8jBxjjNeaeJtX8I3vg7QdLXx5oT6jp9xbxx3ttewptUDZK2N7bQYi45PUjviu5j+IfgWKJY4/GHh5UQBVUapBwB/wKqdtbd/6/O3yIV7K/b+v8zpqK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqko6Siub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqAOkorm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qgDpKK5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKoAPhx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iErpKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5ux/5Knrv/YF03/0ffV0lc3Y/wDJU9d/7Aum/wDo++oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAoqK5leC1llihe4eNCyxRkBpCB90ZIGT05IFc5p2pN4lneC41L7BJGMy6XAGiuFGSMuzgPg44KKvThmFG4HUUV43dP5ngfXfG8iH+37PWJVtrg/6yKOK5ESwKT0RlXBXoSxPXmvUtfsL3VvDl3Y6berp9zcxGNbh4jJ5eevyhlOcZHUY60fZuP7VjSorjfAkFlpV7qmiJ4e0vRdQsxE07aZCqRXcbBvLk4AOflcFWyQQeTnNdlTasSgooopDCiiigAooooAKKKKACiiigArm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76gDpKKKKACiiigAooooAKKKKACiiigAooooAKKxfEGtz6QbcR2p8mbPmXrozxW2MY3KgLc577V4OWHGat1pd1rfhq6OmeI/MuL+3McV8q+ZAit1KRoyg8ZwxYsM9e1LpdB1szpKK8j1C7Xwr4L8TaZpehafoGsWoto5bjR4QiTRTP5aTggAggb+GyVI6nrXQadZW3hf4pWejaFbpa2F/pEs9xBEML5sUiBZSP7zCRgW6tgZziqSu7f1tf8hX0v8A1vY7yiiikMKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8rpKACiiigAooooAKKKKACiisrXtJ0jU7Mt4ihiurCBGaS3uVDwnodzIRgkY4z0z60mBq0V5P/AGde6b4d8MeHb4zpYazrsoktpHJMVniWWO2J6gYVAV9Mr0rpfB23TvGHijQLFFi0yxe2ltoUACW5kjy0aAfdXKhsdtxqrf193+Yn/X3tfodnRXmerePfE9mPGc0VppMUPhd43Ct5srXMRTzCM5XYxUjnDAHIwetXp/HGr6XrGq22oWltexwaEdZto7ON0cAEgxMWY7zwPmAX/dpdL/1tf8irO9v63t+bR31MjmilaRYpEcxtscKwOxsA4PocEHHuK4XSfGurr4hj07WF0m5tpNK/td720eSLyIemzYd4c5/i3oCMkDjFQprXiHS/EOgaFa22nxnXbe6vZ7m5Z3eGUfOV2DaCF3qB83IBHy4BLs/6+f8Akybp/wBf13R6HWRp/iKK+1ufS5LG9sp44/OjNyihbiPO0umGJAB4IYKeRxzXFaf8QNflsdCv7yHTfIu9ZfRrqGKKQMZA7p5qMXwoymdhDHB+9W9LNr2nXGq6tqmn6an7kxWb299JK7ndiKPY0SBcs3J3NkkdgMLz/rb/AIK/4cfl1/4Nv0f/AAx1SXEEsJmjmjeJSwLqwKgqSDz7EEH6UltdQXtslxZzx3EEgyksThlYeoI4NcPfT3kjXHgvR00+RNP0pJb99SgaZbgSblEYUMvLbGJY5AyPlbPHKaH4s1fw18IfDraYdNijh0Nrv/S42ne4ZP8Alkkcbq68cmTDKvGRQ7JNv+t/8v60Czdkv62/z/rU9oorhV8Wa1D4s0RdQk0230HWbBp4W8h/OSZYw5iMhk2ngswO3kKRjvXS+GrjU7zw9a3WuNbtdzr5pFtA0SqrcqCrOxzjGeetOzW/9f1YSaaujVooopDCiiigAooooAKKKKAOb+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiErpKACiiigDzvwD4+8H2fw28NWt54s0OC4h0m1jlil1KFXjYQqCrAtkEEYINdB/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVVLUfGHw41aNE1HxR4bn8s7o3Opwh4jjG5GD5U+4INdjRQB5rJe/DaXVJbhvHWl/ZJrlbybTf7XtjbyXCkESkH585VTgMFJGSM1pX3i/wjeJcrH8T7G0850aI2+p2QNtt6hNynIbvv3e2K7iijpYOtzi9K8X+AtLWVv8AhOdGu7qcgz3VzqtuZJSBgZ2kKB7KABk8cmtD/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqufs/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RXolFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FVjXfiH4ey+fJpnjjRtGurhg0l1p2qWqM5BHLK25GPAGWUnHFd7RQBwI134cS6RfWGo+M9F1EajH5d5Pc6tB5k427edpULx0ChQDkgDNJoviDwDpF7Ley+P9L1K9kiWAXN7q1qXSJTkRrs2gDJznGT3JwK7+igOljm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvxH4+8Hz694Tkg8WaHIlvq0kkzJqUJEa/YbpdzENwNzKMnuwHeug/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qsfX/FPgzXFthH8S9O0z7PJ5g+x6lZMJG7bhKrg46jjrz1ArvKKAPOptZ8CXujmy1P4k2N9OtwtzDfS6taLNBIuNrIECoMY6bMHJznJq7onin4f6HFceV430W6ubqXzrq7uNVtzLO+Au5tpCjAAAAAAA6V3FFAHkl9b/AA+v/wDhIhN8U4QniPAvUXVbDAAG0BP3eQNo29zj35qvr1/4Ps47rXNP+I8d/qSaT/ZqW8erWC+ZH68Kp3Anfww5GBxxXsdFHS39dvyHfW/9d/0PDvCuv/DwL9l0TxzbJptyf+JjDe29jpwbABAGIImdicAn5ht3cg4NdVq2r+BNW8Wadr//AAsqxtLjTo3jght9UsvKw/38h1YkkAd+MDGOc+j0U27knj8dj8PYtKtLBPitGI7PUm1SJ/7V0/d55Ytk/u8EbmY4x/Ee2AOyvPHHgO++zifxpoW2CZZgo1WDDsvTd83QHB4xyBXXUUf1/X3D/r+vvPOtV1b4e6nrq6xD8QdO029MH2ad7LWLYC5hyTscNuHBJwwwwycEViWWlfC7TrJLSx+IsEUH9ntpsynXreTz4SScEvkrgsSNm0dsEcV7BRS6W/r+tWO7vf8Ar+tDyDxB4j+HuqaNpfg9fGVjcyWMttIL2S9jQJEhwxMy7YyxQMhVTn5uRjNd0PiN4HUADxj4fAHQf2pB/wDFV0tFO7e/qTb8Dm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SikM5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v4cf8AJLPCn/YFs/8A0QldJRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==" alt="" width="530" height="772" vspace="0" hspace="0" border="0" style="width:530px;height:772px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM1NAAAkpIAAgAAAAM1NAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMjoyNjoxOAAyMDIxOjA2OjI3IDEyOjI2OjE4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTI6MjY6MTguNTQwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAKUC3gMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAorktN8cXur6Vaalp/gnxBNaXkKTwSebYLvR1DKcG5BGQRwRmrP/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXJXXji9srmygufBPiBJb6YwW6+bYHe4jeQji54+SNzk4HGOpFWf+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkoqjomqwa9oGn6vZpIlvqFrHdRLKAHVXUMAwBIzg84Jq9QAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQldJQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFABRRUN4sz2M62pCzmNhGT2bHH60m7K41q7GPdeNNDtdUk04XM91dQsFmjsbKa68g8cSGJGEfX+LFamnapY6vafatLu4ruDcU82Fwy7hwRkdweD6HIryr4IXE+l/C/UbMW8L+JLG9uH1C0u5jC7Sls7pGCsRlcYbac4rF8QeOb/AMTfA1vFWm20nhh5NWi8g2OpyF5CZQkhfaqDB5+XkHrwau2tvT8bEt2Tfr+Fz3mivOvGYj0e40mxHiHVVk1rU8/Y/tLg3H7sAosysrQRqQHO0nkkAHOK86l8T67e/s32eqtruoLqEGsrbpeQ3jpKY/O2YZlI3/Kf4s54PWktXb0/Gy/Ub0jf+ur/AEPoqoby6isbKa7uSwhgjaSQpGzsFAycKoJJ9gCa8Tu9V1WKf4u6VHq+p+TpVpFdWLfbpfNt5DCXOx924LuAO0HHbGDijRtb1Cfxz4bt5dXvZ4brwT9puoJLx3R5dn+sZC2N3vjJpSuo3Xa/4N/oUlrr/WqX6nsOgeINM8UaHb6xoVz9qsLnJim8tk3YJU8MARyD1FaNfPngO+v1+HPww0uG5uLbS9TvbqG+ktpmhZsGRkTzFIZckHoQeKuf8JtrI02306/vruPSf+Ewl0eXUhMyy/ZF+6pmHzA5O3fndx1zzVyj77iu9vxS/VGafucz/rf/ACZ7vUVzdQWcQkupViQusYZjjLMwVR9SSB+NeX/EHSL3wt4bsNf0jXtcvYtAvVlvbeTU5T59qXBZH2sN5QEEFskgYYtWZ8StLieHwdcPdaoqar4ogkeOTULgGNHBIVQX/d4AB+XG05xipirteqX32/z/AAKen3N/df8Ar5ntFFeLXmo+LdY+Jmv6NoF9DbDRIbR9Oa91WeFPKIDPIyKji53cqWc/LwRzzW/JLqel/FKK41mS9vdN1C8ENhc2OpSCK1k8rH2ee23BGBIZg+0nOM44wJXt5/1/X3bg9L+X9f1/kelUUVynxL1hND8CXl6+rTaUQ8arPBD5sjEuB5ajcvLfdzuGM5yMUho6uivC7HW9W/4Rf4q2DapfKuirvsT/AGjLLNanyi+BOT5hwy9z6jpTvB2v61beMPDMP9p398uo+DhezwXV08oluByGAYnDHGMjGe+TzR0v5J/em/0EtVfzt+KX6nrWr+KtI0LVNO0/VbiSC41SUQ2n+jSskkn93eqlVPsSK1Zpo7eCSaZgkcal3Y9FAGSa+eH1QXnh/wCGXiHW9ZmmvtQ8QCa8NzdHy42BdSFRjiMLwuFAHPOTXuPiX/SLO30teupTrA4/6ZDLSfmisPqRVcrS872/L/MlSvLytf8AP/I1oZUngjmiJKSKGUlSDgjI4PIp9cX8W9W1XQvhfqt/oEjw3cKx4ljGWiQyKHYfRSee1cdrmqX+nXnjbQ7HU9QOnWnhpdSguGv5Wltrg7z8sxbeA2AcbscYAwcVLejfr+Cv+RaTbSfX/NL9T2WiuO+GtvPceC9D1q91O/vLq80m3EwuLlpIy23O/aejnOC3U4Ga7GqlHlk49iU7q4UUUVIwooooAKwfEXjXQ/ClxaQa5NdQveuI7fyrCecSueiAxow3HsvU+lb1eX/GsTM3glbSWKG4Pia28qSaMuithsEqGUkZ7Aj6ihayS7tL72HRvyf4HTv8SfCkWj3+py6k8cGmsq3qPZzLNbFjgb4SnmKD6lcd66S1uYryzhurZ98M8ayRtgjcpGQcHnoa8e+Ifgk6H8P/AB34k1TU/wC0NY1azSOZ44PIhREYBVSPcxHGOSzE4rM8a+Ip7XQPI0zX72K70/wvDfJbW0z2yWrjaFlMiMPNLZx5bKy8ZyO6urPyt+Tb/L+tws7pLrf9F+v9PQ90muoLeWCOeVUe4fy4lJ5dtpbA/BSfwqUnAJrxTWca38QfhXc6pd3QN5ps887w3kkALC3VtwKMu3knOMZHByOKl8L6p4y8S+N9Xu4ry2t10nX2tZ4bnUpYwtmOBGLUIULNncJS24njpWji07ev4O39eRKknHm8l+Kb/rzPT/DninR/FlnPdaDdNcxW9w1tMXgkiKSLjcpV1ByMjtWlc3UFnEJLqVYkLrGGY4yzMFUfUkgfjXzhpviHVNC8EaqNIkEKX/jya0u5/PaDZCxGR5qgmLJAG8AkA8c1v+NdK1qHTvCNl4pvQ7N4shiiFlqk8jR2zAsqPKQjM69nI3Ywc5JpJX5bdbfjy/5/11p6X+f4X/y/rp7rRXmN61/ovxFtbq+nv9Q0K4uLe1sp7LVZT9ikKhRFPBu2yq5O7zDubnnsa9OpdLh1sFFFFIAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgCtqN/Bpeny3t2JjDCNz+RA8z49kQFj+ANcvZfFXwnqOnpf2NzqM9i7bRdpo14Yc5xzJ5W0c8cniurvTiwuM/8APJv5V47+z5aaxN8OdJeS7s5dEL3SvaC2Il3Fzgs5ch168BR1HWnHVu/SwS0imj1HRPFOj+IrrUbbSLppptMn+z3aPBJEYpPT51GenUZFa9fOurXV1Z6B8YLzTL26s7u11iGSKazuHidTkA8oQcYJ46V0MniPWNP+I/iw6ZfXd59l8KJew2b3LyxrcbR8wjJIBOBwAM596lP3U/K//kvMOzv82v8AyZL9T1G88V6Pp/iex8P3lzJFqWoKzWsRtpdkoUEtiQLsyAORuyOPUVsV4DbXMCeMPhDqN7rM11cajBcXFxLeXbSZlkhUfKGJ2AsdoVcLkYAzUtj4svZPiN4Xn03xHfahaalq97aTyyzMkVzGgBCrblmRQhIUOApbGSO50cbNR66r7nYTtbmXa/5v9P63PeaK8t8ARXOr+J/GEF1rmqyQaV4gBtU+3yNsULkxncTmMkkbOn9OYsfFl7J8RvC8+m+I77ULTUtXvbSeWWZkiuY0AIVbcsyKEJChwFLYyR3MR95pd7fjb/MHpfyv+F/8j2LQPFOkeJxenRbppzYXLWtyHgkiMcq9VIdQePbirEWt6fNr1xosVxu1C3gS4lh2N8sbEhTuxg5KngHNeAQXV3pXhf4i6zo9/d22q2XitjaJBMwWV2kRdjRg4kDAkYYH2xXTX2pamvj74g2bapqMccPhpbuOBb6ULbzbMloxu+Q5A+7ik3aKl5X/APJeYtx95xXe3/k1j2iivCPBWva1D4j+HwfV9Qvf7Y0C4lu47q6eVZpEBZW2scBu2RyR1JrU+E2peL/ErWHiK+vrb7NPNcw6nDLqUruzhj5aJbGPZCUx/C2WU5OTV8utvX8G1+hkpXV/T8Vc9jrJ8R+KNI8J6fHfa/cva20kywLIsEkoDt0B2KcZ6ZOBXDfEGa4T4ueBbNNW1Cys9S+1w3cNvfSQpMFjyoIVgM5Y/MMNyMHIGOC8V6nqF/8ACPxDZXt5NeW2m+LEsrG7mcySPEsq4BdslypJG45PHNKKu15//JJfqXNcqv5fo3+h9GdaK8L1HxR4j0ef4r2mk6jdzf2TFaz2ImlMzW3mJmVlLZwAMtjoMcAVrLfazH4s1DwzoOtzxW954YS/jvL66ef7NdM+0OHclgGB6A4GMgCi35X/AAb/AEC3f+tl+qPXqq6nqVto+l3Oo6g7Ja2sZlmdI2kKqBknaoJOB6CvD/FWrajYfCvVEE2u6Drel6rapcltamuAu8oN0czOS0bKc7W6E8itjVr68svE3jbQra/ur7R28LPft9puWn+zzsHGFZiSoZedo4GOAKmWkW15/grhCzkk/L8XY9W0jV7LXtHtdU0mbz7K7jEkMuxl3qehwwBH4irleC/DzU77Sta+G9jDqNyLLUvD8zXNvJMWiJQFlYIflUj1ABI65o8P+K765+JPhBrDxDfalYa1LqEVzNNM6JdrHnYy25Zli2kYBXaWwSQM1o4+/wAq8/wbX6ERlePM+lvxVz3WG6guJZ44JVke3cRyqpzsbaGwffDA/jUtfOun6lfeFvhp8RNc0K5uv7Uh1+5t0aS6llEcXmRqZNjMV3AH75UnpkkV6x8P7XXbaO8OrXdrNp1wsU2nxx6pNfyRqV+YtLKiswYjI64yQOAKlK6v5L8Vcp6O3m/wdjode17T/DWjTarrMskNlbjMsscEk2wepCKTj1OMCrVleQajYQXtm/mW9xGssT4I3KwyDg8jg968U8a6jc6xa/FNdX1C5gXRrRLextFuGjiEbxZ3MmdshcnALAkdsGjTtYu9QP2c6vd2+m6f4Mgv7BrO7aJTMowzkoRv2lQCrZXsRzU3XK2/J/Kzf5IWvMkvT53S/U9yorxm/wBX8Q3/AIR8OeKtTe7udPXSEn1S00zUXs7mFjg/alVGUSDAPyNx6CkTWPF/iT4k+IbfSL23tTo1zam3W71GW3RLYgM5NusbLLvGRucjbkYxV8r5uX1/B2/ry89Bc3u839f1/W2p7PRRRUlHN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJXSUAFFFFAHN/Dj/klnhT/ALAtn/6ISukrm/hx/wAks8Kf9gWz/wDRCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAZeqeF9A1u4jn1nQ9N1CaLiOS7tI5WT6FgSOlSal4f0bWLKOz1fSbG/tYm3RwXVskqIcYyFYEA4J/OtCijyApXGjaZdpapdadaTrZsGtlkgVhAQMApkfKQOOKqT+EPDVzZGzufD2lS2pmNwYJLKNkMp6vtK43HJ5681sUUAZln4Z0HT7u4urDRNOtbi5UpPNBaRo8qnqGIGWHsarJ4I8KR+X5fhjRl8pHjj26fENiNnco+XgHccjvk+tblFAGXD4X0C30h9Kg0PTYtOkbe9mlpGIWb1KAbSeB27VJ/wAI/ow0l9K/six/s6QkvZ/Zk8liTkkpjByeelaFFAGFfaTdkWulaXbabBoDQvDdQ7SjovG0RKo2bSNwIOMZBHTB07/TLDVbX7Nqdlb3sG4N5VxEsi7gcg4YEZBq1RQBRudD0m91C3v7zS7K4vLXi3uZbdGkh/3WIyv4U86VpzakmomwtTexqUS5MK+Yqk5IDYyAT1FW6KACq9/p1lqtm9pqlnb3ttJjfDcRLIjYORlWBB5qxRQBlyeGNAmW7WXQ9NkF6qrdBrSM+eF+6H4+YDAxnOMVHa+EPDdhe295Y+HtKtrm1XZBPDZRo8S88KwXKjk8D1Nc7430uw1jx14Ns9Wsba+tWluy0F1CsqEiHIJVgRwan103tp8T/CvkapdpZXS3MUunqyrAdkRIbAGSee5I4GAKaE2dJBoWkWtxJcWulWUM0svnSSR26Kzyf3yQMlvfrUE+u6NH4ih02aQHUMbYz9ncqhYZ2GXbtVmAztLAkDoa43Ubu/1y/wDGV3Bqd3ZN4cHk6fHBOyRiVYBKzyICBJksF2tkADgAnNSWGlXfinVdK12EXljp94tpqd4jyRGGeVYwUEajMgYHYGLFVwowCTkJa27afc9vwQ5aX76/ev8Ahz0N0WSNkkUOjDDKwyCPQ1kx+EvDcNjcWcPh/S47W6VVngWyjCShfuhlxhgO2elcD42hkuPCsevQX2o2c99rdsiPZX81vut3mSEA+WwBDINwznG84xmvSH0ixm0f+yru3F7ZeWI2ivWNx5ij++ZCxf6sSaLe7f5fgn+obO39b/8AAJNP06y0mxjstLs7eytYs+XBbRLGiZOThVAA5JNWa4n4SwxW3gQwW8aRQxanfpHHGoVUUXUgAAHQAdq7anLcXkFFFFIYUUUUAFZWreF/D+vzRy67oWm6nJGu1HvLOOZkHXALA4FatFAFK90bS9S0wabqOm2l3YgKBazwK8WF+78hGOMDHHFVx4V8PBVUaDpgVbc2qj7HHgQnrF0+5/s9K1aKA2KB0LSGhs4m0qyMdgwa0Q26YtiBgGMY+Qj2xSnQ9JOrnVjpdkdRKeWbw26edt/u78bse2avUUAZFt4R8N2djdWVp4f0qC1vMfaYIrKNY5/99QMN+NTv4f0aTSY9LfSbFtPiKmO0NshiQg5GExgYPTitCigCo+k6dJqEN/Jp9q95ACIrloVMkYPUK2MjOO1W6KKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7yukoAr3+n2eqWMlnqdpBeWsoxJBcRCRHGc8qQQeRVXSPDmieHxKNB0fT9ME2PN+xWqQ78ZxnaBnGT19a0qKAMq38LeH7RrxrXQtNha/BF2Y7ONftIJJIkwPnzk9c9aWy8L6Bpl2l1p2h6baXEcXkpNBaRo6x/3AwGQvt0rUooAoWWhaRpzbtP0qytG3s+YLdEO5vvHgdTjk96iXwxoCMjJoemqY5zcoRaRjbKesg44Y5+91rUooAz9O8P6No9xcXGkaRY2E10czyWtskTTHJOWKgFuSevrUa+GNARkZND01THOblCLSMbZT1kHHDHP3utalFAGe2gaO+oQXz6TYteW5Yw3BtkMkRY5ba2MjJJJx1qvN4R8N3F7c3lx4f0qW5u1KXE72UbPMp6h2K5YHA4PpWxRQBi2vg3wxY3Vtc2XhzSbee0GLeWKxiRoRknCELleWJ49T61ctdE0qy1G41Cy0yzt726/19zFbokk3+8wGW/Gr1FFwOC8a+DtY8QePvDGr2dvpdxp2kCcXMF7O6tMJV2MAoiYEAc8nnpx1rp7jwr4eu9Kg0y60HTJ9Pt23Q2klnG0UR55VCMA8noO9a1FHSw223czLLw3oem3k93p2i6faXNwu2aeC1RHlHozAZI+tOsPDuiaU0raZo9hZtMAJDb2qR7wCSAcAZ5JP1JrRooEcF8RPAlxrvgQ6B4Os9KsDJex3MgkJt4xtcOTiONssSB2HUnPaulsfDulppE1tc6Fpdv9vG+/toIVeGaQj5txKL5n1ZQT6VsUUdLf1/WgdbmLbeDfDFldW1zZ+HNIt57UYt5YrGJWhGScKQuV5Ynj1PrU0XhjQYGgaDRNNja2laaApaRgxSN951wOGPcjk1qUUAU49H0yGW7kh060jkvjm6dYFBuOMfOcfNxxzml0zSdN0WzFpo2n2un2wJYQ2sKxICep2qAKt0UAUbjRNKu74Xt3plnPdrGYhcS26tIEPVdxGce1N1HQNH1eKKLVtJsb6OEERpc2ySBMjBwGBxxx9K0KKAKVxoulXkcCXemWc6WzK0Cy26sIiv3SoI+UjtjpST6JpVzqsOp3OmWc1/bjEN3Jbo0sY9FcjI/A1eooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKAOb+HH/JLPCn/YFs//AEQldJXnfgHwD4PvPht4aurzwnoc9xNpNrJLLLpsLPIxhUlmJXJJJySa6D/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAM/xlK9j4y8Kak9pfT2lrLdee9nZS3Jj3Q7VysSsQCeM4q7rfhzVdW8W6LrNlq9pa2+ll2FtLp7SPL5i7Xy/mrj5eny8Hk56U/wD4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaFoKxW1jwTNf3+qPYar9istbjWPVLf7PvaQBdm6N9w8tinykkPwBgAjNdDPp/wDxI307T5BZj7OYIXVd3lDbtBAzzisf/hXHgj/oTfD/AP4K4P8A4mufs/APg9viTrNq3hPQzbx6TYSJEdNh2KzTXgZgNuASEUE99o9BR0sVfW5seMPB974h0Ow0rSNTtdLtrOeGb97YtcFjCytGBiVMDK89cjpin/Ytcs7+PV/E2tW97Z2EbslnpWjTKzSMNu8gSyu5ClgFUfxZ7VL/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE0XYtCn8L4LiDwWftVrcWrS6hezLHcwPC+x7mRlJRwGGVIPI712Fc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE027sDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQAeKP+Ri8Gf8AYak/9N95XSV534j8A+D4Ne8JxweE9DjS41aSOZU02ECRfsN021gF5G5VOD3UHtXQf8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AHw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUAFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzdj/yVPXf+wLpv/o++rpK5ux/5Knrv/YF03/0ffUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZmn+IdM1TULixsp3a5tgGdHgePcpJAZCygOuQRuXIzxmgDTooooAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooA5v4cf8ks8Kf8AYFs//RCV0led+AfH3g+z+G3hq1vPFmhwXEOk2scsUupQq8bCFQVYFsggjBBroP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkorm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAOkrhL5rrxN481nSf7RvLG20WxgkhFncPCWnl3ne+0jeFCLhDlTk5B4xr/8ACx/BH/Q5eH//AAaQf/FVzOsa74Sutbm1TRPiP4d02e8tltL3fdwzCSNSxUp+9XbIN7AMdw55U0nfoNf1951XgjXLjxH4C0nV7lV+1XVqryADapfoT7AkVheFzc2HipbTxZHqEWu3aSzxTJqs89hcKG+ZY4yVRCqleDGDjkE8mlsvFvg3R9Ns9L0Px14YtdOtLQ26RvexSSBgAEYP5oGBzkFTn1FRad4r8L/2hb6h4i+IfhfULu1R0tza3MNvGm7G5tpmcliBjO7GM4Aq21zton7Nj0GoL23e6sZ4Irma0eRCqzwbd8ZI+8u4EZHuDXHat4h+FWvyRPrur+DtTeEERNeXNrMUB643E46DpV65+Ifg42Ukdh428NQT7CInlv4XRGxwSokUkewI+oqHsV1E+GV1d3nw90+bUbua9uS0yvcTtud8TOASfoPpWTfTXniTxP4pt49TvLGPw/BEloLWdox57xGQyOFIEgGVAVsrweOaq+FPEXh7wx4QbRz8SfCd3cRtI1tc+ZGipuYt86faCXwzHoy8YHvUeq6t4TvNRvLvTviV4dsDqlsltqSi6hfzQoIDxfvR5b4YjJ3jGOOM053bdv6YoWS1O38I6y/iLwZpGsTII5L6zindR0DMoJx7ZrYrk9P8cfD/AEvTbawsfF3h6K2tYlhiQapD8qqMAfe9BVj/AIWP4I/6HLw//wCDSD/4qqm05NrYmN1FJnSUVzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FVJR0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lc3Y/8lT13/sC6b/6PvqP+Fj+CP+hy8P8A/g0g/wDiq5+z8feD1+JOs3TeLNDFvJpNhGkp1KHYzLNeFlB3YJAdSR23D1FAHolFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAF7xPDq9x4bu4PDhhXUJE2RtNO0IUE/MQ4ViGxnBx1xXCXOvDTPDM2n6R/aum6tNq9rplyupX8t5JbmVlHmRvI7jBQkqRxnqMgit/VviB4auLMLovxA8L2NyHB8y5uobhCvdSglQ8+oYVjXepeA9R0m8iv/H2gvqN5PFcvfRahAnlyxEGMom84VSo4JJOTknOaFo9fL81+lwZteH55dJ8fal4XW5urqyTT4b+3a7neeSMs7o6mRyWYEqCMnjJxxgDsa890LxL4O0/UrzV9W8feG7/VrxEhknhvYYI1jTO1EQyuQMsxJLHJP0AtP4g+FMmtjWZNX8HNqgIIvmubUzggYB8zO7px16U+wdXb+v6ZY+KrXsPwz1q70zVLzTLi0tnnWW0ZVZtqn5SSCQD6rg8cEVH4jvri717wx4bjup7aHVFmnu5beVo5WjijB2K6kMuWdckEHAODzVHxp4n8J+KfCV7oll8QfDOn/bozDLPLdxT4QjB2qJUwfckj2qG/8Q+Fb6z0ic/EXwxFreksWhvEuYvJclSjK0XnZKkHpvzkA5o0t8wfT5lE+I9SN1/wiAvrkE+Izpf27zD5/wBm8j7Rjf137fk3/exznPNdT4TvJ7fxN4h8OS3E9zBpjQS2slxI0sixypnYzsSz4ZW5JJwea5k3XgT+xwkfxB0BdXGof2p/aJvoCDc9MmPzPubfk27s7eN2ea1fD/ifwTo8l/eXnjvw7ealqUqy3dwl/DGrFVCqqJ5jFVAHALE8k55prb+tdF+t/wCmJ76f1q/0t/SO+orm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqpGdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAdJRXN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FUAHij/kYvBn/Yak/9N95XSV534j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSVieLFtF0KWfUZNW+zQjc8WkmYTOe2PI/ecH0IHrxVb/hY/gj/ocvD/AP4NIP8A4qs/VfiBoEwi/sT4g+EbMhj5v2ueO43j0XbcR7T7nNJq6GtDn7LxHdah4J8JWNrrc9y+uai1pNfAslxFEokdoyxAIkCoIy2Ac5I5wa6fwneT2/ibxD4cluJ7mDTGgltZLiRpZFjlTOxnYlnwytySTg81z0178P8A+w4LSx8e6Db31tftqUN62oW7YuWZmZigcZVtzAqCPlOMjrWh4f8AE/gnR5L+8vPHfh281LUpVlu7hL+GNWKqFVUTzGKqAOAWJ5JzzV3Wv9dv+D/TJtsv63f6W/pDdS+Jd5ZN4nePw25g8NSJ9rea9RDJEy7i8YUNk7cMFJGQeSDxV2T4g/2fqWp2+taZ9mis9J/teKSCfzmlgBIIZdo2vkdAWHvXFakNA1FfF8f/AAtXwlHH4nCq4xGTbqqhAAftPzHYOuBzzjHFR65reiWNxdeIP+FkeGLqRdD/ALK+yWsSO756OB57/wAZyRtb5cjnrUdP67P9bFaX/ruv0ud7pfji6n1+LSNY0NrOaayOoJPb3aTQpb9MuW2MGzgFVVgMjnHNULXxTfaZrGlaTDoclzeeIo7jUFuJbhIo0IGQjfeb5VMak7fTGeQOP0i88L6RIlk3jvwndQ6jb/Zp50nkEsECjOwSTXcu1T90RjbgtuA+Uiug1nXfDWo+N9H1+x+JHhS1i0uGWJLWSWKUyeYAGJcTrjhVwNvHPXPFu1/68/8AgfcSr21/rb/gmhY/Eq4urbR7u40JYLTUNSbSpmF6HeG5DMvyrsw8e5CNxKn/AGav/wBpXkOq6prGpeHb6z+y2rxW800tuySKGyFURyM5Z2wfmAAwB168BFBocOiafYL8WPCBax1p9YWUpH87s7PsI+1dNzt36Y9MnvdS8beCNSjto5PG/h9Y4rhJpF/tKE+ZsO4D7/HzBT36Y70tP67WX/BH18v8m/8AgFa8vri00+Twnplh/aV7Dp32jUpPtjWuxZN2SrqpYyMwcgDaOOWHFc74a8aXvhj4P6BcRaSt5DDo/wBsubm7u/s8YCn7iuUYPKeSFOM+taGqa14Sm8UvruifEjw7p891arZ3sct1BOk0aklSv71Sjjc2DyOeVNc1Z6T4RstLtrAfFjQLqKLSZNMJu5LZzGrZ+eHEiiM84Od5IAGeM0m3Z23/AP2v+ANJXV9v+Gv+p6Fb+NL6XxfpumS6RDDp2qWDXtrfvenc21VJjMfl4DDdn7+MAn2rb8OaleaxoNvf6hZRWUlwN6xRXBmGw/dbcUQ8jBxjjNeaeJtX8I3vg7QdLXx5oT6jp9xbxx3ttewptUDZK2N7bQYi45PUjviu5j+IfgWKJY4/GHh5UQBVUapBwB/wKqdtbd/6/O3yIV7K/b+v8zpqK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqko6Siub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqAOkorm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qgDpKK5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKoAPhx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iErpKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5ux/5Knrv/YF03/0ffV0lc3Y/wDJU9d/7Aum/wDo++oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAoqK5leC1llihe4eNCyxRkBpCB90ZIGT05IFc5p2pN4lneC41L7BJGMy6XAGiuFGSMuzgPg44KKvThmFG4HUUV43dP5ngfXfG8iH+37PWJVtrg/6yKOK5ESwKT0RlXBXoSxPXmvUtfsL3VvDl3Y6berp9zcxGNbh4jJ5eevyhlOcZHUY60fZuP7VjSorjfAkFlpV7qmiJ4e0vRdQsxE07aZCqRXcbBvLk4AOflcFWyQQeTnNdlTasSgooopDCiiigAooooAKKKKACiiigArm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76gDpKKKKACiiigAooooAKKKKACiiigAooooAKKxfEGtz6QbcR2p8mbPmXrozxW2MY3KgLc577V4OWHGat1pd1rfhq6OmeI/MuL+3McV8q+ZAit1KRoyg8ZwxYsM9e1LpdB1szpKK8j1C7Xwr4L8TaZpehafoGsWoto5bjR4QiTRTP5aTggAggb+GyVI6nrXQadZW3hf4pWejaFbpa2F/pEs9xBEML5sUiBZSP7zCRgW6tgZziqSu7f1tf8hX0v8A1vY7yiiikMKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8rpKACiiigAooooAKKKKACiisrXtJ0jU7Mt4ihiurCBGaS3uVDwnodzIRgkY4z0z60mBq0V5P/AGde6b4d8MeHb4zpYazrsoktpHJMVniWWO2J6gYVAV9Mr0rpfB23TvGHijQLFFi0yxe2ltoUACW5kjy0aAfdXKhsdtxqrf193+Yn/X3tfodnRXmerePfE9mPGc0VppMUPhd43Ct5srXMRTzCM5XYxUjnDAHIwetXp/HGr6XrGq22oWltexwaEdZto7ON0cAEgxMWY7zwPmAX/dpdL/1tf8irO9v63t+bR31MjmilaRYpEcxtscKwOxsA4PocEHHuK4XSfGurr4hj07WF0m5tpNK/td720eSLyIemzYd4c5/i3oCMkDjFQprXiHS/EOgaFa22nxnXbe6vZ7m5Z3eGUfOV2DaCF3qB83IBHy4BLs/6+f8Akybp/wBf13R6HWRp/iKK+1ufS5LG9sp44/OjNyihbiPO0umGJAB4IYKeRxzXFaf8QNflsdCv7yHTfIu9ZfRrqGKKQMZA7p5qMXwoymdhDHB+9W9LNr2nXGq6tqmn6an7kxWb299JK7ndiKPY0SBcs3J3NkkdgMLz/rb/AIK/4cfl1/4Nv0f/AAx1SXEEsJmjmjeJSwLqwKgqSDz7EEH6UltdQXtslxZzx3EEgyksThlYeoI4NcPfT3kjXHgvR00+RNP0pJb99SgaZbgSblEYUMvLbGJY5AyPlbPHKaH4s1fw18IfDraYdNijh0Nrv/S42ne4ZP8Alkkcbq68cmTDKvGRQ7JNv+t/8v60Czdkv62/z/rU9oorhV8Wa1D4s0RdQk0230HWbBp4W8h/OSZYw5iMhk2ngswO3kKRjvXS+GrjU7zw9a3WuNbtdzr5pFtA0SqrcqCrOxzjGeetOzW/9f1YSaaujVooopDCiiigAooooAKKKKAOb+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiErpKACiiigDzvwD4+8H2fw28NWt54s0OC4h0m1jlil1KFXjYQqCrAtkEEYINdB/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVVLUfGHw41aNE1HxR4bn8s7o3Opwh4jjG5GD5U+4INdjRQB5rJe/DaXVJbhvHWl/ZJrlbybTf7XtjbyXCkESkH585VTgMFJGSM1pX3i/wjeJcrH8T7G0850aI2+p2QNtt6hNynIbvv3e2K7iijpYOtzi9K8X+AtLWVv8AhOdGu7qcgz3VzqtuZJSBgZ2kKB7KABk8cmtD/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqufs/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RXolFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQBzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVXSUUAc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FVjXfiH4ey+fJpnjjRtGurhg0l1p2qWqM5BHLK25GPAGWUnHFd7RQBwI134cS6RfWGo+M9F1EajH5d5Pc6tB5k427edpULx0ChQDkgDNJoviDwDpF7Ley+P9L1K9kiWAXN7q1qXSJTkRrs2gDJznGT3JwK7+igOljm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDzvxH4+8Hz694Tkg8WaHIlvq0kkzJqUJEa/YbpdzENwNzKMnuwHeug/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v/AIWP4I/6HLw//wCDSD/4qsfX/FPgzXFthH8S9O0z7PJ5g+x6lZMJG7bhKrg46jjrz1ArvKKAPOptZ8CXujmy1P4k2N9OtwtzDfS6taLNBIuNrIECoMY6bMHJznJq7onin4f6HFceV430W6ubqXzrq7uNVtzLO+Au5tpCjAAAAAAA6V3FFAHkl9b/AA+v/wDhIhN8U4QniPAvUXVbDAAG0BP3eQNo29zj35qvr1/4Ps47rXNP+I8d/qSaT/ZqW8erWC+ZH68Kp3Anfww5GBxxXsdFHS39dvyHfW/9d/0PDvCuv/DwL9l0TxzbJptyf+JjDe29jpwbABAGIImdicAn5ht3cg4NdVq2r+BNW8Wadr//AAsqxtLjTo3jght9UsvKw/38h1YkkAd+MDGOc+j0U27knj8dj8PYtKtLBPitGI7PUm1SJ/7V0/d55Ytk/u8EbmY4x/Ee2AOyvPHHgO++zifxpoW2CZZgo1WDDsvTd83QHB4xyBXXUUf1/X3D/r+vvPOtV1b4e6nrq6xD8QdO029MH2ad7LWLYC5hyTscNuHBJwwwwycEViWWlfC7TrJLSx+IsEUH9ntpsynXreTz4SScEvkrgsSNm0dsEcV7BRS6W/r+tWO7vf8Ar+tDyDxB4j+HuqaNpfg9fGVjcyWMttIL2S9jQJEhwxMy7YyxQMhVTn5uRjNd0PiN4HUADxj4fAHQf2pB/wDFV0tFO7e/qTb8Dm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SikM5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq6SigDm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOb/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qukooA5v4cf8AJLPCn/YFs/8A0QldJRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==" alt="" width="516" height="217" vspace="0" hspace="0" border="0" style="width:516px;height:217px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The most appropriate MedDRA term to describe a certain adverse event is listed. Synonyms or related conditions are not listed, but should be taken into account as well. Adverse event term representation is based on MedDRA version 12.0.<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.<br /><em><u>Postmarketing experience with frequency unknown</u></em><br />&bull; Nervous system disorders<br />o Cerebral haemorrhage<br />o Leukoencephalopathy (see section 4.4)<br />o Acute toxic leukoencephalopathy (see section 4.4)<br />o Reversible posterior leukoencephalopathy syndrome (RPLS) (see section 4.4)<br />&bull; Respiratory, thoracic and mediastinal disorders<br />o Pulmonary haemorrhage<br />&bull; Renal and urinary disorder<br />o Haemorrhagic cystitis<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o SFDA call center : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High doses of Fludara given intravenously have been associated with leukoencephalopathy, acute toxic leukoencephalopathy, or reversible posterior leukoencephalopathy syndrome (RPLS). Symptoms may include headache, nausea and vomiting, seizures, visual disturbances such as vision loss, altered sensorium, and focal neurological deficits. Additional effects may include optic neuritis, and papillitis, confusion, somnolence, agitation, paraparesis/ quadriparesis, muscle spasticity, incontinence, irreversible central nervous system toxicity characterised by delayed blindness, coma,<br />and death. High doses are also associated with severe thrombocytopenia and neutropenia due to bone marrow suppression.<br />There is no known specific antidote for Fludara overdosage. Treatment consists of drug discontinuation and supportive therapy.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, purine analogues<br />ATC code: L01B B05<br /><em><u>Mechanism of action</u></em><br />Fludara contains fludarabine phosphate, a water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine 9-&beta;-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase.<br />Fludarabine phosphate is rapidly dephosphorylated to 2F-ara-A which is taken up by cells and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2F-ara-ATP. This metabolite has been shown to inhibit ribonucleotide reductase, DNA polymerase &alpha;/&delta; and &epsilon;, DNA primase and DNA ligase thereby inhibiting DNA synthesis. Furthermore, partial inhibition of RNA polymerase II and consequent reduction in protein synthesis occur.<br />While some aspects of the mechanism of action of 2F-ara-ATP are as yet unclear, it is assumed that effects on DNA, RNA and protein synthesis all contribute to inhibition of cell growth with inhibition of DNA synthesis being the dominant factor. In addition, in vitro studies have shown that exposure of CLL lymphocytes to 2F-ara-A triggers extensive DNA fragmentation and cell death characteristic of apoptosis.<br /><em><u>Clinical efficacy and safety</u></em><br />A phase III trial in patients with previously untreated B-chronic lymphocytic leukaemia comparing treatment with Fludara vs. chlorambucil (40mg/m2 q4 weeks) in 195 and 199 patients respectively showed the following outcome: statistically significant higher overall response rates and complete response rates after 1st line treatment with Fludara compared to chlorambucil (61.1% vs. 37.6% and 14.9% vs. 3.4%, respectively); statistically significant longer duration of response (19 vs. 12.2 months) and time to progression (17 vs. 13.2 months) for the patients in the Fludara group. The median survival of the two patient groups was 56.1 months for Fludara and 55.1 months for chlorambucil, a non-significant difference was also shown with performance status. The proportion of patients reported to have toxicities were comparable between Fludara patients (89.7%) and chlorambucil patients (89.9%). While the difference in the overall incidence of haematological toxicities was not significant between the two treatment groups, significantly greater proportions of Fludara patients experienced white blood cell (p=0.0054) and lymphocyte (p=0.0240) toxicities than chlorambucil patients. The proportions of patients who experienced nausea, vomiting and diarrhoea were significantly lower for Fludara patients (p&lt;0.0001, p&lt;0.0001, and p=0.0489, respectively) than chlorambucil patients. Toxicities of the liver were also reported for significantly (p=0.0487) less proportions of patients in the Fludara group than in the chlorambucil group. Patients who initially respond to Fludara have a chance of responding again to Fludara monotherapy.<br />A randomised trial of Fludara vs. cyclophosphamide, adriamycin and prednisone (CAP) in 208 patients with CLL Binet stage B or C revealed the following results in the subgroup of 103 previously treated patients: the overall response rate and the complete response rate were higher with Fludara compared to CAP (45% vs. 26% and 13% vs. 6%, respectively); response duration and overall</p><p>survival were similar with Fludara and CAP. Within the stipulated treatment period of 6 months the number of deaths was 9 (Fludara) vs. 4 (CAP).<br />Post-hoc analyses using only data of up to 6 months after start of treatment revealed a difference between survival curves of Fludara and CAP in favour of CAP in the subgroup of pretreated Binet stage C patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Plasma and urinary pharmacokinetics of fludarabine (2F-ara-A)</u></em><br />The pharmacokinetics of fludarabine (2F-ara-A) have been studied after intravenous administration by rapid bolus injection and short-term infusion as well as following continuous infusion and after peroral dosing of fludarabine phosphate (Fludara, 2F-ara-AMP).<br />No clear correlation was found between 2F-ara-A pharmacokinetics and treatment efficacy in cancer patients.<br />However, occurrence of neutropenia and haematocrit changes indicated that the cytotoxicity of fludarabine phosphate depresses the haematopoiesis in a dose-dependent manner.<br />Distribution and metabolism<br />2F-ara-AMP is a water-soluble prodrug of fludarabine (2F-ara-A), which is rapidly and quantitatively dephosphorylated in the human organism to the nucleoside fludarabine (2F-ara-A).<br />Another metabolite, 2F-ara-hypoxanthine, which represents the major metabolite in the dog, was observed in humans only to a minor extent.<br />After single dose infusion of 25 mg 2F-ara-AMP per m&sup2; to CLL patients for 30 minutes 2F-ara-A reached mean maximum concentrations in the plasma of 3.5 - 3.7 &mu;M at the end of the infusion. Corresponding 2F-ara-A levels after the fifth dose showed a moderate accumulation with mean maximum levels of 4.4 -4.8 &mu;M at the end of infusion. During a 5-day treatment schedule 2F-ara-A plasma trough levels increased by a factor of about 2. An accumulation of 2F-ara-A over several treatment cycles can be excluded. Postmaximum levels decayed in three disposition phases with an initial half-life of approximately 5 minutes, an intermediate half-life of 1 - 2 hours and a terminal half-life of approximately 20 hours.<br />An interstudy comparison of 2F-ara-A pharmacokinetics resulted in a mean total plasma clearance (CL) of 79 &plusmn; 40 ml/min/m&sup2; (2.2 &plusmn; 1.2 ml/min/kg) and a mean volume of distribution (Vss) of 83 &plusmn; 55 l/m&sup2; (2.4 &plusmn; 1.6 l/kg). Data showed a high interindividual variability. After intravenous and peroral administration of fludarabine phosphate, plasma levels of 2F-ara-A and areas under the plasma level time curves increased linearly with the dose, whereas half-lives, plasma clearance and volumes of distribution remained constant independent of the dose indicating a dose linear behaviour.<br />After peroral fludarabine phosphate doses, maximum 2F-ara-A plasma levels reached approximately 20 - 30 % of corresponding intravenous levels at the end of infusion and occurred 1 &ndash; 2 hours postdose. The mean systemic 2F-ara-A availability was in the range of 50 - 65 % following single and repeated doses and was similar after ingestion of a solution or immediate release tablet formulation. After peroral dose of 2F-ara-AMP with concomitant food intake a slight increase (&lt;10 %) of systemic availability (AUC), a slight decrease of maximum plasma levels (Cmax ) of 2F-ara-A and a delayed time of occurrence of Cmax was observed; terminal half-lives were unaffected.</p><p><em><u>Elimination</u></em><br />2F-ara-A elimination is largely by renal excretion. 40 to 60 % of the administered intravenous dose was excreted in the urine. Mass balance studies in laboratory animals with &sup3;H-2F-ara-AMP showed a complete recovery of radio-labelled substances in the urine.<br />Characteristics in patients<br />Individuals with impaired renal function exhibited a reduced total body clearance, indicating the need for a dose reduction. In vitro investigations with human plasma proteins revealed no pronounced tendency of 2F-ara-A protein binding.<br /><em><u>Cellular pharmacokinetics of fludarabine triphosphate</u></em><br />2F-ara-A is actively transported into leukaemic cells, whereupon it is rephosphorylated to the monophosphate and subsequently to the di- and triphosphate. The triphosphate 2F-ara-ATP is the major intracellular metabolite and the only metabolite known to have cytotoxic activity. Maximum 2F-ara-ATP levels in leukaemic lymphocytes of CLL patients were observed at a median of 4 hours and exhibited a considerable variation with a median peak concentration of approximately 20 &mu;M. 2F-ara-ATP levels in leukaemic cells were always considerably higher than maximum 2F-ara-A levels in the plasma indicating an accumulation at the target sites. In-vitro incubation of leukaemic lymphocytes showed a linear relationship between extracellular 2F-ara-A exposure (product of 2F-ara-A concentration and duration of incubation) and intracellular 2F-ara-ATP enrichment. 2F-ara-ATP elimination from target cells showed median half-life values of 15 and 23 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Systemic toxicity</u></em><br />In acute toxicity studies, single doses of fludarabine phosphate produced severe intoxication symptoms or death at dosages about two orders of magnitude above the therapeutic dose. As expected for a cytotoxic compound, the bone marrow, lymphoid organs, gastrointestinal mucosa, kidneys and male gonads were affected. In patients, severe side effects were observed closer to the recommended therapeutic dose (factor 3 to 4) and included severe neurotoxicity partly with lethal outcome (see section 4.9).<br />Systemic toxicity studies following repeated administration of fludarabine phosphate showed also the expected effects on rapidly proliferating tissues above a threshold dose. The severity of morphological manifestations increased with dose levels and duration of dosing and the observed changes were generally considered to be reversible. In principle, the available experience from the therapeutic use of Fludara points to a comparable toxicological profile in humans, although additional undesirable effects such as neurotoxicity were observed in patients (see section 4.8).<br /><em><u>Embryotoxicity</u></em><br />The results from intravenous animal embryotoxicity studies in rats and rabbits indicated an embryolethal and teratogenic potential of fludarabine phosphate as manifested in skeletal malformations, foetal weight loss and post implantation loss. In view of the small safety margin between the teratogenic doses in animals and the human therapeutic dose as well as in analogy to other antimetabolites which are assumed to interfere with the process of differentiation, the therapeutic use of Fludara is associated with a relevant risk of teratogenic effects in humans (see section 4.6).</p><p><em><u>Genotoxic potential, tumorigenicity</u></em><br />Fludarabine phosphate has been shown to cause DNA-damage in a sister chromatid exchange test, to induce chromosomal aberrations in an in vitro cytogenetic assay and to increase the rate of micronuclei in the mouse micronucleus test in vivo, but was negative in gene mutation assays and in the dominant lethal test in male mice. Thus, the mutagenic potential was demonstrated in somatic cells but could not be shown in germ cells.<br />The known activity of fludarabine phosphate at the DNA-level and the mutagenicity test results form the basis for the suspicion of a tumorigenic potential. No animal studies which directly address the question of tumorigenicity have been conducted, because the suspicion of an increased risk of second tumours due to Fludara therapy can exclusively be verified by epidemiological data.<br /><em><u>Local tolerance</u></em><br />According to the results from animal experiments following intravenous administration of fludarabine phosphate, no remarkable local irritation has to be expected at the injection site. Even in case of misplaced injections, no relevant local irritation was observed after paravenous, intraarterial, and intramuscular administration of an aqueous solution containing 7.5 mg fludarabine phosphate/ml.<br />The similarity in nature of the observed lesions in the gastrointestinal tract after intravenous or intragastric dosing in animal experiments supports the assumption that the fludarabine phosphate induced enteritis is a systemic effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Cellulose, microcrystalline<br />Lactose, monohydrate<br />Silica, colloidal anhydrous<br />Croscarmellose sodium<br />Magnesium stearate<br />Film-coat: Hypromellose<br />Talc<br />Titanium dioxide (E171)<br />Ferric oxide pigment, yellow (E172)<br />Ferric oxide pigment, red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package to protect from moisture.<br />This medicinal product does not require any special temperature storage conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blisters of 5 tablets each, comprising polyamide/aluminium/polypropylene thermoformable foil with a lidding foil of aluminium. The blisters are packed in a polyethylene tablet container with a child-resistant polypropylene screw cap.<br />Pack sizes: 15 or 20 film-coated tablets per tablet container.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Handling and disposal<br />Fludara should not be handled by pregnant staff.<br />Procedures for proper handling should be followed according to local requirements for cytotoxic drugs. Waste material may be disposed of by incineration.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GENZYME EUROPE B.V
Paasheuvelweg 25,
1105 BP
Amsterdam
Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 October 2010
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>